| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
\n\n## FEATURES \n\n- Easier start-up and programming with Start-Up Genie\n- Wide range of standard and permanent magnet motors with power up to 600 hp\n- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)\n- Remote commissioning and monitoring with USB connectivity and software\n- Two wire multi-pump connection for faster installation\n- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation\n- System redundancy with multi-master control in case of drive failure\n- BACnet and Modbus as a standard for seamless BMS integration\n- Submersible and above ground applications\n- Wide range of voltage and enclosure options\n- True 208 V coverage\n- Dedicated single phase input\n- Remote commissioning and monitoring with USB connectivity and software\n- In-panel or handheld keypad with backlit display\n- Alarm Log for last 5 alarms and maintenance events\n- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference\n- I/O expansion cards, factory installed or field configured", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00003/document_with_boxes.png", "raw_response_path": "sample_00003/raw_response.md", "source_image_path": "sample_00003/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00004", "dataset_index": 4, "document_markdown_path": "sample_00004/document.md", "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , Feral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00004/document_with_boxes.png", "raw_response_path": "sample_00004/raw_response.md", "source_image_path": "sample_00004/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00005", "dataset_index": 5, "document_markdown_path": "sample_00005/document.md", "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI). \n\nPrecautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\nRadiopharmaceutical \n\nRadiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-\\[^{123}\\mathrm{I}\\]Iodo-α-methyl-L-tyrosine (IMT). \n- \\[ \\mathrm{Methyl-}^{11}\\mathrm{C} \\]-L-methionine (MET). \n- \\(O-(2-[^{18}\\mathrm{F}]\\mathrm{Fluoroethyl})-L\\)-tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\nRadiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \\(\\sim 20\\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00005/document_with_boxes.png", "raw_response_path": "sample_00005/raw_response.md", "source_image_path": "sample_00005/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00006", "dataset_index": 6, "document_markdown_path": "sample_00006/document.md", "document_markdown_text": "1) (X) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 2) 1) 1) 1) 1) 1) 1) 1) 1) 1) 3) 1) 1) 1) 1) 1) 1) 1) 1) 1) 4) 1) 1) 1) 1) 1) 1) 1) 1) 1) 5) 1) 1) 1) 1) 1) 1) 1) 1) 6) 1) 1) 1) 1) 1) 1) 1) 1) 1) 7) 1) 1) 1) 1) 1) 1) 1) 1) 1) 8) 1) 1) 1) 1) 1) 1) 1) 1) 1) 9) 1) 1) 1) 1) 1) 1) 1) 1) 1) 10) 1) 1) 1) 1) 1) 1) 1) 1) 1) 11) 1) 1) 1) 1) 1) 1) 1) 1) 1) 12) 1) 1) 1) 1) 1) 1) 1) 1) 1) 13) 1) 1) 1) 1) 1) 1) 1) 1) 1) 14) 1) 1) 1) 1) 1) 1) 1) 1) 1) 15) 1) 1) 1) 1) 1) 1) 1) 1) 1) 16) 1) 1) 1) 1) 1) 1) 1) 1) 1) 17) 1) 1) 1) 1) 1) 1) 1) 1) 1) 18) 1) 1) 1) 1) 1) 1) 1) 1) 1) 19) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 20) 1) 1) 1) 1) 1) 1) 1) 1) 1) 21) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 22) 1) 1) 1) 1) 1) 1) 1) 1) 1) 23) 1) 1) 1) 1) 1) 1) 1) 1) 1) 24) 1) 1) 1) 1) 1) 1) 1) 1) 1) 25) 1) 1) 1) 1) 1) 1) 1) 1) 1) 26) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 27) 1) 1) 1) 1) 1) 1) 1) 1) 1) 28) 1) 1) 1) 1) 1) 1) 1) 1) 1) 29) 1) 1) 1) 1) 1) 1) 1) 1) 30) 1) 1) 1) 1) 1) 1) 1) 1) 1) 31) 1) 1) 1) 1) 1) 1) 1) 1) 1) 32) 1) 1) 1) 1) 1) 1) 1) 1) 1) 33) 1) 1) 1) 1) 1) 1) 1) 1) 1) 34) 1) 1) 1) 1) 1) 1) 1) 1) 1) 35) 1) 1) 1) 1) 1) 1) 1) 1) 1) 36) 1) 1) 1) 1) 1) 1) 1) 1) 1) 37) 1) 1) 1) 1) 1) 1) 1) 1) 1) 38) 1) 1) 1) 1) 1) 1) 1) 1) 1) 39) 1) 1) 1) 1) 1) 1) 1) 1) 1) 40) 1) 1) 1) 1) 1) 1) 1) 1) 1) 41) 1) 1) 1) 1) 1) 1) 1) 1) 1) 42) 1) 1) 1) 1) 1) 1) 1) 1) 1) 43) 1) 1) 1) 1) 1) 1) 1) 1) 1) 44) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 45) 1) 1) 1) 1) 1) 1) 1) 1) 1) 46) 1) 1) 1) 1) 1) 1) 1) 1) 1) 47) 1) 1) 1) 1) 1) 1) 1) 1) 1) 48) 1) 1) 1) 1) 1) 1) 1) 1) 1) 49) 1) 1) 1) 1) 1) 1) 1) 1) 1) 50) 1) 1) 1) 1) 1) 1) 1) 1) 1) 51) 1) 1) 1) 1) 1) 1) 1) 1) 1) 52) 1) 1) 1) 1) 1) 1) 1) 1) 1) 53) 1) 1) 1) 1) 1) 1) 1) 1) 1) 54) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 55) 1) 1) 1) 1) 1) 1) 1) 1) 1) 56) 1) 1) 1) 1) 1) 1) 1) 1) 1) 57) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 58) 1) 1) 1) 1) 1) 1) 1) 1) 1) 59) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 60) 1) 1) 1) 1) 1) 1) 1) 1) 1) 61) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 62) 1) 1) 1) 1) 1) 1) 1) 1) 1) 63) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 64) 1) 1) 1) 1) 1) 1) 1) 1) 1) 65) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 66) 1) 1) 1) 1) 1) 1) 1) 1) 1) 67) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 68) 1) 1) 1) 1) 1) 1) 1) 1) 1) 69) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 70) 1) 1) 1) 1) 1) 1) 1) 1) 1) 71) 1) 1) 1) 1) 1) 1) 1) 1) 1) 72) 1) 1) 1) 1) 1) 1) 1) 1) 1) 73) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 74) 1) 1) 1) 1) 1) 1) 1) 1) 1) 75) 1) 1) 1) 1) 1) 1) 1) 1) 1) 76) 1) 1) 1) 1) 1) 1) 1) 1) 1) 77) 1) 1) 1) 1) 1) 1) 1) 1) 1) 78) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 79) 1) 1) 1) 1) 1) 1) 1) 1) 1) 80) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 81) 1) 1) 1) 1) 1) 1) 1) 1) 1) 82) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 83) 1) 1) 1) 1) 1) 1) 1) 1) 1) 84) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 85) 1) 1) 1) 1) 1) 1) 1) 1) 1) 86) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 87) 1) 1) 1) 1) 1) 1) 1) 1) 1) 88) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 89) 1) 1) 1) 1) 1) 1) 1) 1) 1) 90) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 91) 1) 1) 1) 1) 1) 1) 1) 1) 92) 1) 1) 1) 1) 1) 1) 1) 1) 1) 93) 1) 1) 1) 1) 1) 1) 1) 1) 1) 94) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 95) 1) 1) 1) 1) 1) 1) 1) 1) 1) 96) 1) 1) 1) 1) 1) 1) 1) 1) 1) 97) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 98) 1) 1) 1) 1) 1) 1) 1) 1) 1) 99) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 100) 1) 1) 1) 1) 1) 1) 1) 1) 1) 101) 1) 1) 1) 1) 1) 1) 1) 1) 1) 102) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 103) 1) 1) 1) 1) 1) 1) 1) 1) 1) 104) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 105) 1) 1) 1) 1) 1) 1) 1) 1) 1) 106) 1) 1) 1) 1) 1) 1) 1) 1) 1) 107) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 108) 1) 1) 1) 1) 1) 1) 1) 1) 1) 109) 1) 1) 1) 1) 1) 1) 1) 1) 1) 110) 1) 1) 1) 1) 1) 1) 1) 1) 1) 111) 1) 1) 1) 1) 1) 1) 1) 1) 1) 112) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 113) 1) 1) 1) 1) 1) 1) 1) 1) 1) 114) 1) 1) 1) 1) 1) 1) 1) 1) 115) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 116) 1) 1) 1) 1) 1) 1) 1) 1) 1) 117) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 118) 1) 1) 1) 1) 1) 1) 1) 1) 1) 119) 1) 1) 1) 1) 1) 1) 1) 1) 120) 1) 1) 1) 1) 1) 1) 1) 1) 1) 121) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 122) 1) 1) 1) 1) 1) 1) 1) 1) 1) 123) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 124) 1) 1) 1) 1) 1) 1) 1) 1) 1) 125) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 126) 1) 1) 1) 1) 1) 1) 1) 1) 1) 127) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 128) 1) 1) 1) 1) 1) 1) 1) 1) 1) 129) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 130) 1) 1) 1) 1) 1) 1) 1) 1) 1) 131) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 132) 1) 1) 1) 1) 1) 1) 1) 1) 1) 133) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 134) 1) 1", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00006/document_with_boxes.png", "raw_response_path": "sample_00006/raw_response.md", "source_image_path": "sample_00006/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00007", "dataset_index": 7, "document_markdown_path": "sample_00007/document.md", "document_markdown_text": "2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00007/document_with_boxes.png", "raw_response_path": "sample_00007/raw_response.md", "source_image_path": "sample_00007/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00008", "dataset_index": 8, "document_markdown_path": "sample_00008/document.md", "document_markdown_text": "The parametric equations for a projectile with constant gravity g: \n\n\\[x = v_0 t \\cos \\theta + x_0\\]\n\n\\[y = -\\frac{1}{2} gt^2 + v_0 t \\sin \\theta + y_0\\]\n\nex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: \n\n1. \\(\\vec{r}(t)\\) \n\n2. the maximum altitude attained \n\n3. the range of the shell \n\n4. the speed on impact \n\n5. the horizontal distance when \\(y = 2240\\) ft.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00008/document_with_boxes.png", "raw_response_path": "sample_00008/raw_response.md", "source_image_path": "sample_00008/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00009", "dataset_index": 9, "document_markdown_path": "sample_00009/document.md", "document_markdown_text": "purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at 140 kV, which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is <10 s). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. \n\n- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15–30 min aiming to collect 50–200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\n## IMT Single Photon Emission Tomography \n\n- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. \n\n- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \\(^{123}\\mathrm{I}\\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. \n\nTABLE 2.2. Acquisition parameters for IMT-SPECT \n\n- Rotational radius: smallest possible with appropriate patient safeguard\n- Matrix: \\(128 \\times 128\\)\n- Angular sampling: \\(\\leq 3^\\circ\\) (360° rotation)\n- Zoom: acquisition pixel size should be \\(1/3-1/2\\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size\n- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort\n- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30–50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00009/document_with_boxes.png", "raw_response_path": "sample_00009/raw_response.md", "source_image_path": "sample_00009/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00010", "dataset_index": 10, "document_markdown_path": "sample_00010/document.md", "document_markdown_text": "Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \\(10^{6}\\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used? \n\na. \\(y = -4.9t^2\\) b. \\(y = -4.9t^2 - 5x10^6t\\) c. \\(5x10^6t = 4\\) d. \\(5x10^6t = 40\\)", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00010/document_with_boxes.png", "raw_response_path": "sample_00010/raw_response.md", "source_image_path": "sample_00010/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00011", "dataset_index": 11, "document_markdown_path": "sample_00011/document.md", "document_markdown_text": "0 \n\n\n\n# Bio \n\n**Bio** \n\nBrett received his B.S. in Chemical Engineering from the University of Massachusetts Amherst in 2009. There he worked in the lab of Dr. Neil Forbes developing microfluidic devices to study the interactions between bacteria and in vitro tumor models. He earned his Ph.D. in Chemical Engineering from the California Institute of Technology in 2016 where he worked with Dr. Dave Tirrell and Dr. Dianne Newman. His thesis focused on the development and application of a method for time- and cell-selective proteomic analysis in bacteria. He used this approach to study protein synthesis by the opportunistic pathogen Pseudomonas aeruginosa under dormancy and biofilm growth conditions. Brett joined the Bogyo lab at Stanford in the fall of 2016. His current focus is on the roles of serine hydrolases in the physiology of pathogenic bacteria. \n\n# HONORS AND AWARDS \n\n• A. P. Giannini Postdoctoral Fellowship, A. P. Giannini Foundation (2018) \n\n• Microbiology and Immunology Postdoctoral Fellowship, Stanford School of Medicine (2018) \n\n• Dean's Fellowship, Stanford School of Medicine (2017) \n\n# PROFESSIONAL EDUCATION \n\n• Bachelor of Science, University of Massachusetts Amherst (2009) \n\n• Doctor of Philosophy, California Institute of Technology (2016) \n\n# STANFORD ADVISORS \n\n• Matthew Bogyo, Postdoctoral Faculty Sponsor \n\n# Research & Scholarship \n\n**LAB AFFILIATIONS** \n\n• Matthew Bogyo, Bogyo Lab (9/1/2016) \n\n# Publications \n\n## PUBLICATIONS \n\n• Activity-based protein profiling in bacteria: Applications for identification of therapeutic targets and characterization of microbial communities. Current opinion in chemical biology \n\nKeller, L. J., Babin, B. M., Lakemeyer, M., Bogyo, M. \n\n2019; 54: 45-53 \n\n• Leveraging Peptide Substrate Libraries to Design Inhibitors of Bacterial L Proteinase ACS CHEMICAL BIOLOGY", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00011/document_with_boxes.png", "raw_response_path": "sample_00011/raw_response.md", "source_image_path": "sample_00011/source.png", "figures": [{"figure_id": "sample_00011_fig01", "image_path": "sample_00011/figures/sample_00011_fig01.png", "description": "", "image": "sample_00011/figures/sample_00011_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00011_fig01\", \"image_path\": \"sample_00011/figures/sample_00011_fig01.png\", \"description\": \"\"}"]}
-{"sample_id": "sample_00012", "dataset_index": 12, "document_markdown_path": "sample_00012/document.md", "document_markdown_text": "4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4: \n\n", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00012/document_with_boxes.png", "raw_response_path": "sample_00012/raw_response.md", "source_image_path": "sample_00012/source.png", "figures": [{"figure_id": "sample_00012_fig01", "image_path": "sample_00012/figures/sample_00012_fig01.png", "description": "", "image": "sample_00012/figures/sample_00012_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00012_fig01\", \"image_path\": \"sample_00012/figures/sample_00012_fig01.png\", \"description\": \"\"}"]}
-{"sample_id": "sample_00013", "dataset_index": 13, "document_markdown_path": "sample_00013/document.md", "document_markdown_text": "2019; 14 (11): 2453-62 \n\n• The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology Bergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019 \n\n• Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY Garland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M. 2019; 14 (1): 76-87 \n\n• Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio Babin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5) \n\n• SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Babin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A. 2016; 113 (5): E597-E605 \n\n• In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY Hatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J. 2014; 16 (8): 2568-2590 \n\n• State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY Ngo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A. 2012; 7 (8): 1326-1330 \n\n• Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE Solorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A. 2010; 143 (2): 183-190 \n\n• A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP Walsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S. 2009; 9 (4): 545-554", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00013/document_with_boxes.png", "raw_response_path": "sample_00013/raw_response.md", "source_image_path": "sample_00013/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00014", "dataset_index": 14, "document_markdown_path": "sample_00014/document.md", "document_markdown_text": "18 \n\nSoftware functionality: SepINRIA has different functionality which can be loaded from a single main window: \n\n- Lesion Segmentation Edition: Manual or semi-automatic segmentation of MS lesions (e.g. a segmentation realized by an expert). Segmentations can be saved and visualized in 2D or 3D. Lesion number and lesion volume can be computed and print. \n\n- Automatic Lesion Segmentation: Automatic segmentation of MS lesions from four MRI sequences (Dual Spin Echo T2-PD, T1, T2-FLAIR). \n\n- Images or Segmentation Comparison: Quantitative comparisons of two images registered to assess evolution and comparison between a segmentation (e.g. automatic segmentation) and a segmentation of reference (segmentation of an expert): by computation of the difference image or by visualizing them in the same window (side to side or image fusion). \n\n- Brain Atrophy Evaluation: Manual and automatic evaluation of the brain atrophy. Linear measurements computation of the brain, lateral ventricle and third ventricle width are available in the manual mode. And evolution of the BPF in function of the exam dates can be perform in the automatic mode. \n\n### 4.2 Structure based on C++ \n\nThis section describes concisely dependencies of the software and also its structure by providing a simplify UML scheme of the code architecture. \n\n#### 4.2.1 Software dependencies \n\nSepINRIA is based on several C++ libraries (C.f. Figure 4.2). ITK \\(^2\\) and MIPS \\(^3\\) contain both image processing tools. The first one can be downloaded on Internet and is especially used for image conversion. Whereas the second one is inner to the Asclepios team (algorithms presented in chapter 3 can be found in this library). \n\n\n\n| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \\(Age\\pm \\mathrm {SD}\\)(year) | \\(54.0\\pm 13.1\\) | \\(54.0\\pm 13.2\\) |
| Females (n \\((\\%)\\) | \\(144\\)(84.2) | \\(128\\)(78.5) |
| RA duration±SD (year) | \\(0.3\\pm 0.4\\) | \\(0.3\\pm 0.4\\) |
| Weight±SD (kg) | \\(54.4\\pm 9.7\\) | \\(56.1\\pm 12.3\\) |
| Previous DMARD use (n \\((\\%)\\) | \\(74\\)(43.3) | \\(87\\)(53.4) |
| 1 DMARD | \\(57\\)(33.3) | \\(69\\)(42.3) |
| 2 DMARDs | \\(17\\)(9.9) | \\(18\\)(11.0) |
| Corticosteroid use at baseline (n \\((\\%)\\) | \\(58\\)(33.9) | \\(49\\)(30.1) |
| RF positive (n \\((\\%)\\) | \\(146\\)(85.4) | \\(136\\)(83.4) |
| Mean titre±SD (IU/ml) | \\(154.5\\pm 202.3\\) | \\(163.7\\pm 362.8\\) |
| Anti-CCP positive (n \\((\\%)\\) | \\(145\\)(84.8) | \\(136\\)(83.4) |
| Mean titre±SD (U/ml) | \\(386.2\\pm 694.2\\) | \\(241.3\\pm 367.2\\) |
| ESR (mm/h) | \\(59.9\\pm 30.1\\) | \\(61.8\\pm 29.0\\) |
| CRP (mg/dl) | \\(2.9\\pm 3.0\\) | \\(3.1\\pm 3.3\\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \\(11.5\\pm 4.7\\) | \\(11.8\\pm 5.3\\) |
| 0-66 | \\(16.5\\pm 6.2\\) | \\(17.3\\pm 7.7\\) |
| Tender joint count (n±SD) | | |
| 0-28 | \\(13.2\\pm 5.8\\) | \\(13.2\\pm 6.1\\) |
| 0-68 | \\(20.7\\pm 9.4\\) | \\(21.1\\pm 10.2\\) |
| mTSS | \\(13.6\\pm 22.3\\) | \\(13.6\\pm 17.4\\) |
| Erosion score | \\(7.5\\pm 11.6\\) | \\(7.3\\pm 9.2\\) |
| Joint space narrowing score | \\(6.2\\pm 11.4\\) | \\(6.2\\pm 9.4\\) |
| DAS28-ESR | \\(6.6\\pm 0.9\\) | \\(6.6\\pm 1.0\\) |
| DAS28-CRP | \\(5.8\\pm 1.0\\) | \\(5.9\\pm 1.0\\) |
| HAQ-DI score | \\(1.1\\pm 0.7\\) | \\(1.3\\pm 0.8\\) |
| SDAI score | \\(40.7\\pm 12.0\\) | \\(41.4\\pm 13.8\\) |
| CDAI score | \\(37.8\\pm 10.9\\) | \\(38.3\\pm 12.4\\) |
Physician's global assessment of
disease activity±SD (mm) | \\(65.8\\pm 18.4\\) | \\(66.2\\pm 18.8\\) |
Patient's global assessment of disease
activity±SD (mm) | \\(64.1\\pm 24.8\\) | \\(66.4\\pm 23.7\\) |
\n\n*Data are mean±SD unless otherwise indicated.\n\nCCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.\n\nto 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.\n\nA significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).\n\n# Factors associated with the absence of radiographic progression or with clinical remission\n\nDisease activity or function baseline variables generally were associated with the absence of radiographic progression ( \\(\\Delta \\mathrm {mTSS}\\leq 0.5\\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00018/document_with_boxes.png", "raw_response_path": "sample_00018/raw_response.md", "source_image_path": "sample_00018/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00019", "dataset_index": 19, "document_markdown_path": "sample_00019/document.md", "document_markdown_text": "1 unit\n\n**CPE 101. Fundamentals of Computer Science. 4 units** \nTerm Typically Offered: F, W, SP \nPrerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor. \n\nBasic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101. \n\n**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.** \n\n1 unit \n\nTerm Typically Offered: TBD \nConcurrent: CPE/CSC 101. \n\nFacilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105. \n\nCPE 108. Accelerated Introduction to Computer Science. 4 units \n\nTerm Typically Offered: TBD \nPrerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor. \n\nAccelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108. \n\nCPE 123. Introduction to Computing. 4 units \nTerm Typically Offered: F \nPrerequisite: Basic computer literacy. \n\nUse of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123. \n\nCPE 133. Digital Design. 4 units \nTerm Typically Offered: F, W, SP \nPrerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101. \n\nNumber systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133. \n\nCPE 200. Special Problems for Undergraduates. 1- 2 units \nTerm Typically Offered: F, W, SP \nPrerequisite: Consent of instructor. \n\nIndividual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter. \n\nCPE 202. Data Structures. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor. \n\nIntroduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103. \n\nCPE 203. Project-Based Object-Oriented Programming and Design. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor. \n\nObject-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102. \n\nCPE 233. Computer Design and Assembly Language Programming. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/EE 133. \n\nDesign and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233. \n\nCPE 290. Selected Topics. 1- 4 units \nTerm Typically Offered: TBD \nPrerequisite: Open to undergraduate students and consent of instructor. \n\nDirected group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00019/document_with_boxes.png", "raw_response_path": "sample_00019/raw_response.md", "source_image_path": "sample_00019/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00020", "dataset_index": 20, "document_markdown_path": "sample_00020/document.md", "document_markdown_text": "1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00020/document_with_boxes.png", "raw_response_path": "sample_00020/raw_response.md", "source_image_path": "sample_00020/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00021", "dataset_index": 21, "document_markdown_path": "sample_00021/document.md", "document_markdown_text": "Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00021/document_with_boxes.png", "raw_response_path": "sample_00021/raw_response.md", "source_image_path": "sample_00021/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00022", "dataset_index": 22, "document_markdown_path": "sample_00022/document.md", "document_markdown_text": "0.3-0.7 \n\nof anti- TNF- \\(\\alpha\\) and MTX combination therapy in patients with early RA and high disease activity. \n\n## Author affiliations \n\nDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan \n\nAcknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. \n\nContributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. \n\nFunding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). \n\nCompeting interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. \n\npatients other to distribute, remix, adapt, build upon this work non- commercially, \n\nand license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/ \n\n## REFERENCES \n\n1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \\(\\alpha\\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00022/document_with_boxes.png", "raw_response_path": "sample_00022/raw_response.md", "source_image_path": "sample_00022/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00023", "dataset_index": 23, "document_markdown_path": "sample_00023/document.md", "document_markdown_text": "0.5cm 0cm 0cm 0cm 0cm \n\n## Adding Time Limit for Degree Completion for Students who Stop Out- \n\nS. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00023/document_with_boxes.png", "raw_response_path": "sample_00023/raw_response.md", "source_image_path": "sample_00023/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00024", "dataset_index": 24, "document_markdown_path": "sample_00024/document.md", "document_markdown_text": "Local transportation for the participating teams shall be the responsibility of the participating institutions.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00024/document_with_boxes.png", "raw_response_path": "sample_00024/raw_response.md", "source_image_path": "sample_00024/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00025", "dataset_index": 25, "document_markdown_path": "sample_00025/document.md", "document_markdown_text": "5B-10\n\n| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00025/document_with_boxes.png", "raw_response_path": "sample_00025/raw_response.md", "source_image_path": "sample_00025/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00026", "dataset_index": 26, "document_markdown_path": "sample_00026/document.md", "document_markdown_text": "1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: \n\n## Friday \n\nCourse preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting. \n\n## Saturday \n\nCourse preparation. Course review and practice by participants. Women's race - race start time to be determined.\\* Men's race - race start time to be determined.\\* Post- competition recognition ceremony. \n\n\\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00026/document_with_boxes.png", "raw_response_path": "sample_00026/raw_response.md", "source_image_path": "sample_00026/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00027", "dataset_index": 27, "document_markdown_path": "sample_00027/document.md", "document_markdown_text": "5B-6\n\n\n\n* As of July 9, 2015, IRS Notice 2015-49 prohibits sponsors from adopting lump sum windows for participants who currently receive annuity payments.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00027/document_with_boxes.png", "raw_response_path": "sample_00027/raw_response.md", "source_image_path": "sample_00027/source.png", "figures": [{"figure_id": "sample_00027_fig01", "image_path": "sample_00027/figures/sample_00027_fig01.png", "description": "", "image": "sample_00027/figures/sample_00027_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00027_fig01\", \"image_path\": \"sample_00027/figures/sample_00027_fig01.png\", \"description\": \"\"}"]}
-{"sample_id": "sample_00028", "dataset_index": 28, "document_markdown_path": "sample_00028/document.md", "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00028/document_with_boxes.png", "raw_response_path": "sample_00028/raw_response.md", "source_image_path": "sample_00028/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00029", "dataset_index": 29, "document_markdown_path": "sample_00029/document.md", "document_markdown_text": "5B-15", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00029/document_with_boxes.png", "raw_response_path": "sample_00029/raw_response.md", "source_image_path": "sample_00029/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00030", "dataset_index": 30, "document_markdown_path": "sample_00030/document.md", "document_markdown_text": "145 (Fig. 6B), which over-express EGFR (Fig. 6C). \n\n\n \n\n| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
\n\nPrinciples of Organizations and Communities\n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14° F - 113° F (-10° C - 45° C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50° C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical - input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
\n\n## AQUAVAR® IPC VARIABLE SPEED CONTROLLER \n\n## FEATURES \n\n- Easier start-up and programming with Start-Up Genie \n\n- Wide range of standard and permanent magnet motors with power up to 600 hp \n\n- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC) \n\n- Remote commissioning and monitoring with USB connectivity and software \n\n- Two wire multi-pump connection for faster installation \n\n- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation \n\n- System redundancy with multi-master control in case of drive failure \n\n- BACnet and Modbus as a standard for seamless BMS integration \n\n- Submersible and above ground applications \n\n- Wide range of voltage and enclosure options \n\n- True 208 V coverage \n\n- Dedicated single phase input \n\n- Remote commissioning and monitoring with USB connectivity and software \n\n- In-panel or handheld keypad with backlit display \n\n- Alarm Log for last 5 alarms and maintenance events \n\n- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference \n\n- I/O expansion cards, factory installed or field configured", "figures": [{"figure_id": "sample_00003_fig01", "image_path": "sample_00003/figures/sample_00003_fig01.png", "description": "", "image": "sample_00003/figures/sample_00003_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00003_fig01\", \"image_path\": \"sample_00003/figures/sample_00003_fig01.png\", \"description\": \"\"}"], "document_markdown_path": "sample_00003/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00003/raw_response.md"}
+{"sample_id": "sample_00004", "dataset_index": 4, "source_image_path": "sample_00004/source.png", "document_with_boxes_image_path": "sample_00004/document_with_boxes.png", "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open A ccess \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , Feral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of \n\nimmune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00004/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00004/raw_response.md"}
+{"sample_id": "sample_00005", "dataset_index": 5, "source_image_path": "sample_00005/source.png", "document_with_boxes_image_path": "sample_00005/document_with_boxes.png", "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \\(\\sim 1\\) h for SPECT. \n\n## Precautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oxymetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\n## Radiopharmaceutical \n\n## Radiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-\\[^{123}\\mathrm{I}\\]Iodo-\\(\\alpha\\) -methyl-L-tyrosine (IMT). \n- [Methyl-\\(^{11}\\mathrm{C}\\)]-L-methionine (MET). \n- \\(O-(2-[^{18}\\mathrm{F}]\\) Fluoroethyl)-L-tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\n## Radiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 \\(\\mu \\mathrm{Sv}\\) for Germanium- based transmission, \\(\\sim 20 \\mu \\mathrm{Sv}\\) for low- dose high- speed CT, and between 220 and 450 \\(\\mu \\mathrm{Sv}\\) for high- quality CT.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00005/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00005/raw_response.md"}
+{"sample_id": "sample_00006", "dataset_index": 6, "source_image_path": "sample_00006/source.png", "document_with_boxes_image_path": "sample_00006/document_with_boxes.png", "document_markdown_text": "1) (X) 1) (X) 1) (X) 1) (X) 1) (X) 1) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00006/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00006/raw_response.md"}
+{"sample_id": "sample_00007", "dataset_index": 7, "source_image_path": "sample_00007/source.png", "document_with_boxes_image_path": "sample_00007/document_with_boxes.png", "document_markdown_text": "2011, XLVl, 394 p., Hardcover ISBN: 978-90-481-8664-8", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00007/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00007/raw_response.md"}
+{"sample_id": "sample_00008", "dataset_index": 8, "source_image_path": "sample_00008/source.png", "document_with_boxes_image_path": "sample_00008/document_with_boxes.png", "document_markdown_text": "The parametric equations for a projectile with constant gravity g: \n\n\\[ x = v_0 t \\cos \\theta + x_0 \\]\n\n\\[ y = -\\frac{1}{2} gt^2 + v_0 t \\sin \\theta + y_0 \\]\n\nex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: \n\n1. \\(\\vec{r}(t)\\) \n\n2. the maximum altitude attained \n\n3. the range of the shell \n\n4. the speed on impact \n\n5. the horizontal distance when \\(y = 2240\\) ft.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00008/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00008/raw_response.md"}
+{"sample_id": "sample_00009", "dataset_index": 9, "source_image_path": "sample_00009/source.png", "document_with_boxes_image_path": "sample_00009/document_with_boxes.png", "document_markdown_text": "2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\npurpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \\(140\\mathrm{kV}\\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \\(< 10\\mathrm{~s}\\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. \n\nEmission scan. As semiquantitative estimates of tumor- to- background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3- D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15- 30 min aiming to collect 50- 200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\n## IMT Single Photon Emission Tomography \n\n- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. \n\n- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \\(^{123}\\mathrm{I}\\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. \n\n# TABLE 2.2. Acquisition parameters for IMT-SPECT \n\n- Rotational radius: smallest possible with appropriate patient safeguard- Matrix: \\(128 \\times 128\\) - Angular sampling: \\(\\leq 3^{\\circ}\\) (360° rotation)- Zoom: acquisition pixel size should be \\(1 / 3 - 1 / 2\\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30-50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00009/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00009/raw_response.md"}
+{"sample_id": "sample_00010", "dataset_index": 10, "source_image_path": "sample_00010/source.png", "document_with_boxes_image_path": "sample_00010/document_with_boxes.png", "document_markdown_text": "Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \\(10^{6}\\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used? \n\na. \\(y = -4.9t^2\\) b. \\(y = -4.9t^2 - 5\\times 10^6 t\\) c. \\(5\\times 10^6 t = 4\\) d. \\(5\\times 10^6 t = 40\\)", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00010/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00010/raw_response.md"}
+{"sample_id": "sample_00011", "dataset_index": 11, "source_image_path": "sample_00011/source.png", "document_with_boxes_image_path": "sample_00011/document_with_boxes.png", "document_markdown_text": "0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 12.9 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 13.9 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 14.9 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 15.9 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 16.9 17.0 17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8 17.9 18.0 18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9 19.0 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 21.0 21.1 21.2 21.3 21.4 21.5 21.6 21.7 21.8 21.9 22.0 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 23.0 23.1 23.2 23.3 23.4 23.5 23.6 23.7 23.8 23.9 24.0 24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 24.9 25.0 25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8 25.9 26.0 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8 26.9 27.0 27.1 27.2 27.3 27.4 27.5 27.6 27.7 27.8 27.9 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 28.9 29.0 29.1 29.2 29.3 29.4 29.5 29.6 29.7 29.8 29.9 30.0 30.1 30.2 30.3 30.4 30.5 30.6 30.7 30.8 30.9 31.0 31.1 31.2 31.3 31.4 31.5 31.6 31.7 31.8 31.9 32.0 32.1 32.2 32.3 32.4 32.5 32.6 32.7 32.8 32.9 33.0 33.1 33.2 33.3 33.4 33.5 33.6 33.7 33.8 33.9 34.0 34.1 34.2 34.3 34.4 34.5 34.6 34.7 34.8 34.9 35.0 35.1 35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 36.0 36.1 36.2 36.3 36.4 36.5 36.6 36.7 36.8 36.9 37.0 37.1 37.2 37.3 37.4 37.5 37.6 37.7 37.8 37.9 38.0 38.1 38.2 38.3 38.4 38.5 38.6 38.7 38.8 38.9 39.0 39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 39.9 40.0 40.1 40.2 40.3 40.4 40.5 40.6 40.7 40.8 40.9 41.0 41.1 41.2 41.3 41.4 41.5 41.6 41.7 41.8 41.9 42.0 42.1 42.2 42.3 42.4 42.5 42.6 42.7 42.8 42.9 43.0 43.1 43.2 43.3 43.4 43.5 43.6 43.7 43.8 43.9 44.0 44.1 44.2 44.3 44.4 44.5 44.6 44.7 44.8 44.9 45.0 45.1 45.2 45.3 45.4 45.5 45.6 45.7 45.8 45.9 46.0 46.1 46.2 46.3 46.4 46.5 46.6 46.7 46.8 46.9 47.0 47.1 47.2 47.3 47.4 47.5 47.6 47.7 47.8 47.9 48.0 48.1 48.2 48.3 48.4 48.5 48.6 48.7 48.8 48.9 49.0 49.1 49.2 49.3 49.4 49.5 49.6 49.7 49.8 49.9 50.0 50.1 50.2 50.3 50.4 50.5 50.6 50.7 50.8 50.9 51.0 51.1 51.2 51.3 51.4 51.5 51.6 51.7 51.8 51.9 52.0 52.1 52.2 52.3 52.4 52.5 52.6 52.7 52.8 52.9 53.0 53.1 53.2 53.3 53.4 53.5 53.6 53.7 53.8 53.9 54.0 54.1 54.2 54.3 54.4 54.5 54.6 54.7 54.8 54.9 55.0 55.1 55.2 55.3 55.4 55.5 55.6 55.7 55.8 55.9 56.0 56.1 56.2 56.3 56.4 56.5 56.6 56.7 56.8 56.9 57.0 57.1 57.2 57.3 57.4 57.5 57.6 57.7 57.8 57.9 58.0 58.1 58.2 58.3 58.4 58.5 58.6 58.7 58.8 58.9 59.0 59.1 59.2 59.3 59.4 59.5 59.6 59.7 59.8 59.9 60.0 60.1 60.2 60.3 60.4 60.5 60.6 60.7 60.8 60.9 61.0 61.1 61.2 61.3 61.4 61.5 61.6 61.7 61.8 61.9 62.0 62.1 62.2 62.3 62.4 62.5 62.6 62.7 62.8 62.9 63.0 63.1 63.2 63.3 63.4 63.5 63.6 63.7 63.8 63.9 64.0 64.1 64.2 64.3 64.4 64.5 64.6 64.7 64.8 64.9 65.0 65.1 65.2 65.3 65.4 65.5 65.6 65.7 65.8 65.9 66.0 66.1 66.2 66.3 66.4 66.5 66.6 66.7 66.8 66.9 67.0 67.1 67.2 67.3 67.4 67.5 67.6 67.7 67.8 67.9 68.0 68.1 68.2 68.3 68.4 68.5 68.6 68.7 68.8 68.9 69.0 69.1 69.2 69.3 69.4 69.5 69.6 69.7 69.8 69.9 70.0 70.1 70.2 70.3 70.4 70.5 70.6 70.7 70.8 70.9 71.0 71.1 71.2 71.3 71.4 71.5 71.6 71.7 71.8 71.9 72.0 72.1 72.2 72.3 72.4 72.5 72.6 72.7 72.8 72.9 73.0 73.1 73.2 73.3 73.4 73.5 73.6 73.7 73.8 73.9 74.0 74.1 74.2 74.3 74.4 74.5 74.6 74.7 74.8 74.9 75.0 75.1 75.2 75.3 75.4 75.5 75.6 75.7 75.8 75.9 76.0 76.1 76.2 76.3 76.4 76.5 76.6 76.7 76.8 76.9 77.0 77.1 77.2 77.3 77.4 77.5 77.6 77.7 77.8 77.9 78.0 78.1 78.2 78.3 78.4 78.5 78.6 78.7 78.8 78.9 79.0 79.1 79.2 79.3 79.4 79.5 79.6 79.7 79.8 79.9 80.0 80.1 80.2 80.3 80.4 80.5 80.6 80.7 80.8 80.9 81.0 81.1 81.2 81.3 81.4 81.5 81.6 81.7 81.8 81.9 82.0 82.1 82.2 82.3 82.4 82.5 82.6 82.7 82.8 82.9 83.0 83.1 83.2 83.3 83.4 83.5 83.6 83.7 83.8 83.9 84.0 84.1 84.2 84.3 84.4 84.5 84.6 84.7 84.8 84.9 85.0 85.1 85.2 85.3 85.4 85.5 85.6 85.7 85.8 85.9 86.0 86.1 86.2 86.3 86.4 86.5 86.6 86.7 86.8 86.9 87.0 87.1 87.2 87.3 87.4 87.5 87.6 87.7 87.8 87.9 88.0 88.1 88.2 88.3 88.4 88.5 88.6 88.7 88.8 88.9 89.0 89.1 89.2 89.3 89.4 89.5 89.6 89.7 89.8 89.9 90.0 90.1 90.2 90.3 90.4 90.5 90.6 90.7 90.8 90.9 91.0 91.1 91.2 91.3 91.4 91.5 91.6 91.7 91.8 91.9 92.0 92.1 92.2 92.3 92.4 92.5 92.6 92.7 92.8 92.9 93.0 93.1 93.2 93.3 93.4 93.5 93.6 93.7 93.8 93.9 94.0 94.1 94.2 94.3 94.4 94.5 94.6 94.7 94.8 94.9 95.0 95.1 95.2 95.3 95.4 95.5 95.6 95.7 95.8 95.9 96.0 96.1 96.2 96.3 96.4 96.5 96.6 96.7 96.8 96.9 97.0 97.1 97.2 97.3 97.4 97.5 97.6 97.7 97.8 97.9 98.0 98.1 98.2 98.3 98.4 98.5 98.6 98.7 98.8 98.9 99.0 99.1 99.2 99.3 99.4 99.5 99.6 99.7 99.8 99.9 100.0 100.1 100.2 100.3 100.4 100.5 100.6 100.7 100.8 100.9 101.0 101.1 101.2 101.3 101.4 101.5 101.6 101.7 101.8 101.9 102.0 102.1 102.2 102.3 102.4 102.5 102.6", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00011/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00011/raw_response.md"}
+{"sample_id": "sample_00012", "dataset_index": 12, "source_image_path": "sample_00012/source.png", "document_with_boxes_image_path": "sample_00012/document_with_boxes.png", "document_markdown_text": "4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.8.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.9.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.12.1.1.1.1.1.1.1.1.1.1.1.1.1.1.13.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.14.1.1.1.1.1.1.1.1.1.1.1.1.1.1.15.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.16.1.1.1.1.1.1.1.1.1.1.1.1.1.1.17.1.1.1.1.1.1.1.1.1.1.1.1.1.1.18.1.1.1.1.1.1.1.1.1.1.1.1.1.1.19.1.1.1.1.1.1.1.1.1.1.1.1.1.20.1.1.1.1.1.1.1.1.1.1.1.1.1.21.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.22.1.1.1.1.1.1.1.1.1.1.1.1.1.1.23.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.24.1.1.1.1.1.1.1.1.1.1.1.1.1.1.25.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.26.1.1.1.1.1.1.1.1.1.1.1.1.1.1.27.1.1.1.1.1.1.1.1.1.1.1.1.1.1.28.1.1.1.1.1.1.1.1.1.1.1.1.1.1.29.1.1.1.1.1.1.1.1.1.1.1.1.1.1.30.1.1.1.1.1.1.1.1.1.1.1.1.1.1.31.1.1.1.1.1.1.1.1.1.1.1.1.1.32.1.1.1.1.1.1.1.1.1.1.1.1.1.1.33.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.34.1.1.1.1.1.1.1.1.1.1.1.1.1.1.35.1.1.1.1.1.1.1.1.1.1.1.1.1.1.36.1.1.1.1.1.1.1.1.1.1.1.1.1.1.37.1.1.1.1.1.1.1.1.1.1.1.1.1.1.38.1.1.1.1.1.1.1.1.1.1.1.1.1.1.39.1.1.1.1.1.1.1.1.1.1.1.1.1.1.40.1.1.1.1.1.1.1.1.1.1.1.1.1.1.41.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.42.1.1.1.1.1.1.1.1.1.1.1.1.1.1.43.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.45.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.46.1.1.1.1.1.1.1.1.1.1.1.1.1.1.47.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.48.1.1.1.1.1.1.1.1.1.1.1.1.1.1.49.1.1.1.1.1.1.1.1.1.1.1.1.1.1.50.1.1.1.1.1.1.1.1.1.1.1.1.1.1.51.1.1.1.1.1.1.1.1.1.1.1.1.1.1.52.1.1.1.1.1.1.1.1.1.1.1.1.1.1.53.1.1.1.1.1.1.1.1.1.1.1.1.1.1.54.1.1.1.1.1.1.1.1.1.1.1.1.1.1.55.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.56.1.1.1.1.1.1.1.1.1.1.1.1.1.1.57.1.1.1.1.1.1.1.1.1.1.1.1.1.1.58.1.1.1.1.1.1.1.1.1.1.1.1.1.1.59.1.1.1.1.1.1.1.1.1.1.1.1.1.1.60.1.1.1.1.1.1.1.1.1.1.1.1.1.1.61.1.1.1.1.1.1.1.1.1.1.1.1.1.1.62.1.1.1.1.1.1.1.1.1.1.1.1.1.1.63.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.64.1.1.1.1.1.1.1.1.1.1.1.1.1.1.65.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.66.1.1.1.1.1.1.1.1.1.1.1.1.1.1.67.1.1.1.1.1.1.1.1.1.1.1.1.1.1.68.1.1.1.1.1.1.1.1.1.1.1.1.1.1.69.1.1.1.1.1.1.1.1.1.1.1.1.1.1.70.1.1.1.1.1.1.1.1.1.1.1.1.1.1.71.1.1.1.1.1.1.1.1.1.1.1.1.1.1.72.1.1.1.1.1.1.1.1.1.1.1.1.1.1.73.1.1.1.1.1.1.1.1.1.1.1.1.1.1.74.1.1.1.1.1.1.1.1.1.1.1.1.1.1.75.1.1.1.1.1.1.1.1.1.1.1.1.1.1.76.1.1.1.1.1.1.1.1.1.1.1.1.1.1.77.1.1.1.1.1.1.1.1.1.1.1.1.1.1.78.1.1.1.1.1.1.1.1.1.1.1.1.1.1.79.1.1.1.1.1.1.1.1.1.1.1.1.1.1.80.1.1.1.1.1.1.1.1.1.1.1.1.1.1.81.1.1.1.1.1.1.1.1.1.1.1.1.1.1.82.1.1.1.1.1.1.1.1.1.1.1.1.1.1.83.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.84.1.1.1.1.1.1.1.1.1.1.1.1.1.1.85.1.1.1.1.1.1.1.1.1.1.1.1.1.1.86.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.87.1.1.1.1.1.1.1.1.1.1.1.1.1.1.88.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.89.1.1.1.1.1.1.1.1.1.1.1.1.1.1.90.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.91.1.1.1.1.1.1.1.1.1.1.1.1.1.1.92.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.93.1.1.1.1.1.1.1.1.1.1.1.1.1.1.94.1.1.1.1.1.1.1.1.1.1.1.1.1.1.95.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.96.1.1.1.1.1.1.1.1.1.1.1.1.1.1.97.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.98.1.1.1.1.1.1.1.1.1.1.1.1.1.1.99.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.100.1.1.1.1.1.1.1.1.1.1.1.1.1.1.101.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.102.1.1.1.1.1.1.1.1.1.1.1.1.1.1.103.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.104.1.1.1.1.1.1.1.1.1.1.1.1.1.1.105.1.1.1.1.1.1.1.1.1.1.1.1.1.1.106.1.1.1.1.1.1.1.1.1.1.1.1.1.1.107.1.1.1.1.1.1.1.1.1.1.1.1.1.1.108.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.109.1.1.1.1.1.1.1.1.1.1.1.1.1.1.110.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.111.1.1.1.1.1.1.1.1.1.1.1.1.1.1.112.1.1.1.1.1.1.1.1.1.1.1.1.1.1.113.1.1.1.1.1.1.1.1.1.1.1.1.1.1.114.1.1.1.1.1.1.1.1.1.1.1.1.1.1.115.1.1.1.1.1.1.1.1.1.1.1.1.1.1.116.1.1.1.1.1.1.1.1.1.1.1.1.1.1.117.1.1.1.1.1.1.1.1.1.1.1.1.1.1.118.1.1.1.1.1.1.1.1.1.1.1.1.1.1.119.1.1.1.1.1.1.1.1.1.1.1.1.1.1.120.1.1.1.1.1.1.1.1.1.1.1.1.1.1.121.1.1.1.1.1.1.1.1.1.1.1.1.1.1.122.1.1.1.1.1.1.1.1.1.1.1.1.1.1.123.1.1.1.1.1.1.1.1.1.1.1.1.1.1.124.1.1.1.1.1.1.1.1.1.1.1.1.1.1.125.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.126.1.1.1.1.1.1.1.1.1.1.1.1.1.1.127.1.1.1.1.1.1.1.1.1.1.1.1.1.1.128.1.1.1.1.1.1.1.1.1.1.1.1.1.1.129.1.1.1.1.1.1.1.1.1.1.1.1.1.1.130.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.131.1.1.1.1.1.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00012/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00012/raw_response.md"}
+{"sample_id": "sample_00013", "dataset_index": 13, "source_image_path": "sample_00013/source.png", "document_with_boxes_image_path": "sample_00013/document_with_boxes.png", "document_markdown_text": "2019; 14 (11): 2453-62 \n\n- The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology \n\nBergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019 \n\n- Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY \n\nGarland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M. \n\n2019; 14 (1): 76- 87 \n\n- Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio \n\nBabin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5) \n\n- SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA \n\nBabin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A. \n\n2016; 113 (5): E597- E605 \n\n- In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY \n\nHatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J. \n\n2014; 16 (8): 2568- 2590 \n\n- State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY \n\nNgo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A. \n\n2012; 7 (8): 1326- 1330 \n\n- Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE \n\nSolorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A. \n\n2010; 143 (2): 183- 190 \n\n- A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP \n\nWalsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S. \n\n2009; 9 (4): 545- 554", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00013/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00013/raw_response.md"}
+{"sample_id": "sample_00014", "dataset_index": 14, "source_image_path": "sample_00014/source.png", "document_with_boxes_image_path": "sample_00014/document_with_boxes.png", "document_markdown_text": "4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. \n\nSoftware functionality: SepINRIA has different functionality which can be loaded from a single main window: \n\n- Lesion Segmentation Edition: Manual or semi-automatic segmentation of MS lesions (e.g. a segmentation realized by an expert). Segmentations can be saved and visualized in 2D or 3D. Lesion number and lesion volume can be computed and print. \n\n- Automatic Lesion Segmentation: Automatic segmentation of MS lesions from four MRI sequences (Dual Spin Echo T2-PD, T1, T2-FLAIR). \n\n- Images or Segmentation Comparison: Quantitative comparisons of two images registered to assess evolution and comparison between a segmentation (e.g. automatic segmentation) and a segmentation of reference (segmentation of an expert): by computation of the difference image or by visualizing them in the same window (side to side or image fusion). \n\n- Brain Atrophy Evaluation: Manual and automatic evaluation of the brain atrophy. Linear measurements computation of the brain, lateral ventricle and third ventricle width are available in the manual mode. And evolution of the BPF in function of the exam dates can be perform in the automatic mode. \n\n### 4.2 Structure based on C++ \n\nThis section describes concisely dependencies of the software and also its structure by providing a simplify UML scheme of the code architecture. \n\n#### 4.2.1 Software dependencies \n\nSepINRIA is based on several C++ libraries (C.f. Figure 4.2). ITK \\(^{2}\\) and MIPS \\(^{3}\\) contain both image processing tools. The first one can be downloaded on Internet and is especially used for image conversion. Whereas the second one is inner to the Asclepios team (algorithms presented in chapter 3 can be found in this library). \n\n\n\nNature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | |
| | | | | | | Patterson |
", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00021/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00021/raw_response.md"}
+{"sample_id": "sample_00022", "dataset_index": 22, "source_image_path": "sample_00022/source.png", "document_with_boxes_image_path": "sample_00022/document_with_boxes.png", "document_markdown_text": "0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00022/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00022/raw_response.md"}
+{"sample_id": "sample_00023", "dataset_index": 23, "source_image_path": "sample_00023/source.png", "document_with_boxes_image_path": "sample_00023/document_with_boxes.png", "document_markdown_text": "2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2: 2.0 2.0 2.0 2.0 2.0 2.0 2.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.10 3.10 3.10 3.10 3.10 3.10 3.11 3.11 3.11 3.11 3.11 3.11 3.12 3.12 3.12 3.12 3.12 3.12 3.13 3.13 3.13 3.13 3.13 3.14 3.14 3.14 3.14 3.14 3.14 3.15 3.15 3.15 3.15 3.15 3.15 3.16 3.16 3.16 3.16 3.16 3.16 3.17 3.17 3.17 3.17 3.17 3.17 3.18 3.18 3.18 3.18 3.18 3.18 3.19 3.19 3.19 3.19 3.19 3.19 3.20 3.20 3.20 3.20 3.20 3.20 3.21 3.21 3.21 3.21 3.21 3.21 3.22 3.22 3.22 3.22 3.22 3.22 3.23 3.23 3.23 3.23 3.23 3.23 3.24 3.24 3.24 3.24 3.24 3.24 3.25 3.25 3.25 3.25 3.25 3.25 3.26 3.26 3.26 3.26 3.26 3.26 3.27 3.27 3.27 3.27 3.27 3.27 3.28 3.28 3.28 3.28 3.28 3.28 3.29 3.29 3.29 3.29 3.29 3.29 3.30 3.30 3.30 3.30 3.30 3.30 3.31 3.31 3.31 3.31 3.31 3.31 3.32 3.32 3.32 3.32 3.32 3.32 3.33 3.33 3.33 3.33 3.33 3.33 3.34 3.34 3.34 3.34 3.34 3.34 3.35 3.35 3.35 3.35 3.35 3.35 3.36 3.36 3.36 3.36 3.36 3.36 3.37 3.37 3.37 3.37 3.37 3.37 3.38 3.38 3.38 3.38 3.38 3.38 3.39 3.39 3.39 3.39 3.39 3.39 3.40 3.40 3.40 3.40 3.40 3.40 3.41 3.41 3.41 3.41 3.41 3.41 3.42 3.42 3.42 3.42 3.42 3.42 3.43 3.43 3.43 3.43 3.43 3.43 3.44 3.44 3.44 3.44 3.44 3.44 3.45 3.45 3.45 3.45 3.45 3.45 3.46 3.46 3.46 3.46 3.46 3.46 3.47 3.47 3.47 3.47 3.47 3.47 3.48 3.48 3.48 3.48 3.48 3.48 3.49 3.49 3.49 3.49 3.49 3.49 3.50 3.50 3.50 3.50 3.50 3.50 3.51 3.51 3.51 3.51 3.51 3.51 3.52 3.52 3.52 3.52 3.52 3.52 3.53 3.53 3.53 3.53 3.53 3.53 3.54 3.54 3.54 3.54 3.54 3.54 3.55 3.55 3.55 3.55 3.55 3.55 3.56 3.56 3.56 3.56 3.56 3.56 3.57 3.57 3.57 3.57 3.57 3.57 3.58 3.58 3.58 3.58 3.58 3.58 3.59 3.59 3.59 3.59 3.59 3.59 3.60 3.60 3.60 3.60 3.60 3.60 3.61 3.61 3.61 3.61 3.61 3.61 3.62 3.62 3.62 3.62 3.62 3.62 3.63 3.63 3.63 3.63 3.63 3.63 3.64 3.64 3.64 3.64 3.64 3.64 3.65 3.65 3.65 3.65 3.65 3.65 3.66 3.66 3.66 3.66 3.66 3.66 3.67 3.67 3.67 3.67 3.67 3.67 3.68 3.68 3.68 3.68 3.68 3.68 3.69 3.69 3.69 3.69 3.69 3.69 3.70 3.70 3.70 3.70 3.70 3.70 3.71 3.71 3.71 3.71 3.71 3.71 3.72 3.72 3.72 3.72 3.72 3.72 3.73 3.73 3.73 3.73 3.73 3.73 3.74 3.74 3.74 3.74 3.74 3.74 3.75 3.75 3.75 3.75 3.75 3.75 3.76 3.76 3.76 3.76 3.76 3.76 3.77 3.77 3.77 3.77 3.77 3.77 3.78 3.78 3.78 3.78 3.78 3.78 3.79 3.79 3.79 3.79 3.79 3.79 3.80 3.80 3.80 3.80 3.80 3.80 3.81 3.81 3.81 3.81 3.81 3.81 3.82 3.82 3.82 3.82 3.82 3.82 3.83 3.83 3.83 3.83 3.83 3.83 3.84 3.84 3.84 3.84 3.84 3.84 3.85 3.85 3.85 3.85 3.85 3.85 3.86 3.86 3.86 3.86 3.86 3.86 3.87 3.87 3.87 3.87 3.87 3.87 3.88 3.88 3.88 3.88 3.88 3.88 3.89 3.89 3.89 3.89 3.89 3.89 3.90 3.90 3.90 3.90 3.90 3.90 3.91 3.91 3.91 3.91 3.91 3.91 3.92 3.92 3.92 3.92 3.92 3.92 3.93 3.93 3.93 3.93 3.93 3.93 3.94 3.94 3.94 3.94 3.94 3.94 3.95 3.95 3.95 3.95 3.95 3.95 3.96 3.96 3.96 3.96 3.96 3.96 3.97 3.97 3.97 3.97 3.97 3.97 3.98 3.98 3.98 3.98 3.98 3.98 3.99 3.99 3.99 3.99 3.99 3.99 3.100 3.100 3.100 3.100 3.100 3.100 3.101 3.101 3.101 3.101 3.101 3.101 3.102 3.102 3.102 3.102 3.102 3.102 3.103 3.103 3.103 3.103 3.103 3.103 3.104 3.104 3.104 3.104 3.104 3.104 3.105 3.105 3.105 3.105 3.105 3.105 3.106 3.106 3.106 3.106 3.106 3.106 3.107 3.107 3.107 3.107 3.107 3.107 3.108 3.108 3.108 3.108 3.108 3.108 3.109 3.109 3.109 3.109 3.109 3.109 3.110 3.110 3.110 3.110 3.110 3.110 3.111 3.111 3.111 3.111 3.111 3.111 3.112 3.112 3.112 3.112 3.112 3.112 3.113 3.113 3.113 3.113 3.113 3.113 3.114 3.114 3.114 3.114 3.114 3.114 3.115 3.115 3.115 3.115 3.115 3.115 3.116 3.116 3.116 3.116 3.116 3.116 3.117 3.117 3.117 3.117 3.117 3.117 3.118 3.118 3.118 3.118 3.118 3.118 3.119 3.119 3.119 3.119 3.119 3.119 3.120 3.120 3.120 3.120 3.120 3.120 3.121 3.121 3.121 3.121 3.121 3.121 3.122 3.122 3.122 3.122 3.122 3.122 3.123 3.123 3.123 3.123 3.123 3.123 3.124 3.124 3.124 3.124 3.124 3.124 3.125 3.125 3.125 3.125 3.125 3.125 3.126 3.126 3.126 3.126 3.126 3.126 3.127 3.127 3.127 3.127 3.127 3.127 3.128 3.128 3.128 3.128 3.128 3.128 3.129 3.129 3.129 3.129 3.129 3.129 3.130 3.130 3.130 3.130 3.130 3.130 3.131 3.131 3.131 3.131 3.131 3.131 3.132 3.132 3.132 3.132 3.132 3.132 3.133 3.133 3.133 3.133 3.133 3.133 3.134 3.134 3.134 3.134 3.134 3.134 3.135 3.135 3.135 3.135 3.135 3.135 3.136 3.136 3.136 3.136 3.136 3.136 3.137 3.137 3.137 3.137 3.137 3.137 3.138 3.138 3.138 3.138 3.138 3.138 3.139 3.139 3.139 3.139 3.139 3.139 3.140 3.140 3.140 3.140 3.140 3.140 3.141 3.141 3.141 3.141 3.141 3.141 3.142 3.142 3.142 3.142 3.142 3.142 3.143 3.143 3.143 3.143 3.143 3.143 3.144 3.144 3.144 3.144 3.144 3.144 3.145 3.145 3.145 3.145 3.145 3.145 3.146 3.146 3.146 3.146 3.146 3.146 3.147 3.147 3.147 3.147 3.147 3.147 3.148 3.148 3.148 3.148 3.148 3.148 3.149 3.149 3.149 3.149 3.149 3.149 3.150 3.150 3.150 3.150 3.150 3.150 3.151 3.151 3.151 3.151 3.151 3.151 3.152 3.152 3.152 3.152 3.152 3.152 3.153 3.153 3.153 3.153 3.153 3.153 3.154 3.154 3.154 3.154 3.154 3.154 3.155 3.155 3.155 3.155 3.155 3.155 3.156 3.156 3.156 3.156 3.156 3.156 3.157 3.157 3.157 3.157 3.157 3.157 3.158 3.158 3.158 3.158 3.158 3.158 3.159 3.159 3.159 3.159 3.159 3.159 3.160 3.160 3.160 3.160 3.160 3.160 3.161 3.161 3.161 3.161 3.161 3.161 3.162 3.162 3.162 3.162 3.162 3.162 3.163 3.163 3.163 3.163 3.163 3.163 3.164 3.164 3.164 3.164 3.164 3.164 3.165 3.165 3.165 3.165 3.165 3.165 3.166 3.166 3.166 3.166 3.166 3.166 3.167 3", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00023/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00023/raw_response.md"}
+{"sample_id": "sample_00024", "dataset_index": 24, "source_image_path": "sample_00024/source.png", "document_with_boxes_image_path": "sample_00024/document_with_boxes.png", "document_markdown_text": "Local transportation for the participating teams shall be the responsibility of the participating institutions.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00024/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00024/raw_response.md"}
+{"sample_id": "sample_00025", "dataset_index": 25, "source_image_path": "sample_00025/source.png", "document_with_boxes_image_path": "sample_00025/document_with_boxes.png", "document_markdown_text": "2015 ASC 715 report) valuation report) \n\nService Cost (cost of benefits earned) \n\nExpense/Minimum Required Contribution \n\nProjected Benefit Obligation (PBO) \n\nAccumulated Benefit Obligation (ABO)/Funding Target \n\nAssets \n\nBalance Sheet Liability \n\nAOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment) \n\nCash into Plan \n\nCash out of Plan \n\nLiability by Group: \n\nActives \n\nRetired \n\nTerminated Vested \n\nTotal \n\nPBGC Premiums \n\nDemographics: \n\nActives \n\nRetired \n\nTerminated Vested \n\nTotal \n\nDiscount Rate/Effective Rate \n\nAccounting (based on June 30, 2015 ASC 715 report) \n\nN/A - plan frozen \n\n\\(\\)63,881\\$ \n\n\\(\\)15,498,295\\$ \n\n\\(\\)15,498,295\\$ \n\n\\(\\)11,888,246\\$ \n\n\\(\\)3,610,049\\$ \n\n\\(\\)7,690,218\\$ \n\n\\(\\)548,000 (cash basis) \n\n\\(\\)628,690+$99,236 (expenses) \n\n\\(\\)4,326,586\\$ \n\n6,791,034 \n\n4,380,675 \n\n\\(\\)15,498,295\\$ \n\n152 \n\n472 \n\n4.30% (BOY)/4.25% (EOY) \n\nFunding (based on July 1, 2015 \n\nvaluation report) \n\n\\(\\)0\\$ \n\nN/A \n\nN/A \n\n\\(\\)321,000 (accrual basis) \n\n\\(\\)628,690+$99,236 (expenses) \n\n\\(\\)3,046,932\\$ \n\n5,791,017 \n\n3,038,118 \n\n\\(\\)11,876,067\\$ \n\n152 \n\n472 \n\n6.28%", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00025/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00025/raw_response.md"}
+{"sample_id": "sample_00026", "dataset_index": 26, "source_image_path": "sample_00026/source.png", "document_with_boxes_image_path": "sample_00026/document_with_boxes.png", "document_markdown_text": "1. Course preparation. 2. Course walk-through with NCAA site representative. 3. Course review and practice by participants. 4. Packet pick-up. 5. Mandatory coaches meeting. \n\n## Friday \n\nCourse preparation. Course walk-through with NCAA site representative. Course review and practice by participants. Packet pick-up. Mandatory coaches meeting. \n\n## Saturday \n\nCourse preparation. Course review and practice by participants. Women's race - race start time to be determined.* Men's race - race start time to be determined.* Post-competition recognition ceremony. \n\n*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00026/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00026/raw_response.md"}
+{"sample_id": "sample_00027", "dataset_index": 27, "source_image_path": "sample_00027/source.png", "document_with_boxes_image_path": "sample_00027/document_with_boxes.png", "document_markdown_text": "5B-6\n\n\n\n* As of July 9, 2015, IRS Notice 2015-49 prohibits sponsors from adopting lump sum windows for participants who currently receive annuity payments.", "figures": [{"figure_id": "sample_00027_fig01", "image_path": "sample_00027/figures/sample_00027_fig01.png", "description": "", "image": "sample_00027/figures/sample_00027_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00027_fig01\", \"image_path\": \"sample_00027/figures/sample_00027_fig01.png\", \"description\": \"\"}"], "document_markdown_path": "sample_00027/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00027/raw_response.md"}
+{"sample_id": "sample_00028", "dataset_index": 28, "source_image_path": "sample_00028/source.png", "document_with_boxes_image_path": "sample_00028/document_with_boxes.png", "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\nYES NO NO with Exception \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00028/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00028/raw_response.md"}
+{"sample_id": "sample_00029", "dataset_index": 29, "source_image_path": "sample_00029/source.png", "document_with_boxes_image_path": "sample_00029/document_with_boxes.png", "document_markdown_text": "0.00(continued)Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases \n\n# Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program \n\n- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases", "figures": [], "figures_metadata": [], "document_markdown_path": "sample_00029/document.md", "document_final_markdown_path": "", "document_final_markdown_text": "", "raw_response_path": "sample_00029/raw_response.md"}
+{"sample_id": "sample_00030", "dataset_index": 30, "source_image_path": "sample_00030/source.png", "document_with_boxes_image_path": "sample_00030/document_with_boxes.png", "document_markdown_text": "145 (Fig. 6B), which over-express EGFR (Fig. 6C). \n\n\n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
\n\n## FEATURES \n\n- Easier start-up and programming with Start-Up Genie\n- Wide range of standard and permanent magnet motors with power up to 600 hp\n- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)\n- Remote commissioning and monitoring with USB connectivity and software\n- Two wire multi-pump connection for faster installation\n- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation\n- System redundancy with multi-master control in case of drive failure\n- BACnet and Modbus as a standard for seamless BMS integration\n- Submersible and above ground applications\n- Wide range of voltage and enclosure options\n- True 208 V coverage\n- Dedicated single phase input\n- Remote commissioning and monitoring with USB connectivity and software\n- In-panel or handheld keypad with backlit display\n- Alarm Log for last 5 alarms and maintenance events\n- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference\n- I/O expansion cards, factory installed or field configured",
+ "document_markdown_text": "To build and operate an efficient water system, you need both the right products and experts who know the application. Aquavar® IPC and Hydrovar® controllers have been designed by Xylem's engineers with these things in mind. The Aquavar® IPC or Hydrovar® variable speed controller provide built in pump protection controls and monitoring to help you optimize pump operations and increase energy savings up to 70% (vs. fixed speed) while reducing installation time. \n\n\n \n\n## SPECIFICATIONS \n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14° F - 113° F (-10° C - 45° C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50° C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical - input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
\n\n## AQUAVAR® IPC VARIABLE SPEED CONTROLLER \n\n## FEATURES \n\n- Easier start-up and programming with Start-Up Genie \n\n- Wide range of standard and permanent magnet motors with power up to 600 hp \n\n- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC) \n\n- Remote commissioning and monitoring with USB connectivity and software \n\n- Two wire multi-pump connection for faster installation \n\n- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation \n\n- System redundancy with multi-master control in case of drive failure \n\n- BACnet and Modbus as a standard for seamless BMS integration \n\n- Submersible and above ground applications \n\n- Wide range of voltage and enclosure options \n\n- True 208 V coverage \n\n- Dedicated single phase input \n\n- Remote commissioning and monitoring with USB connectivity and software \n\n- In-panel or handheld keypad with backlit display \n\n- Alarm Log for last 5 alarms and maintenance events \n\n- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference \n\n- I/O expansion cards, factory installed or field configured",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
- "figures": []
+ "figures": [
+ {
+ "figure_id": "sample_00003_fig01",
+ "label": "image",
+ "image_path": "sample_00003/figures/sample_00003_fig01.png",
+ "document_relative_path": "figures/sample_00003_fig01.png",
+ "bounding_box_pixels": {
+ "x1": 68,
+ "y1": 391,
+ "x2": 516,
+ "y2": 852
+ },
+ "description": ""
+ }
+ ]
},
{
"sample_id": "sample_00004",
@@ -90,7 +170,7 @@
"raw_response_path": "sample_00004/raw_response.md",
"source_image_path": "sample_00004/source.png",
"document_with_boxes_path": "sample_00004/document_with_boxes.png",
- "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , Feral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive",
+ "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open A ccess \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , Feral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of \n\nimmune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -102,7 +182,7 @@
"raw_response_path": "sample_00005/raw_response.md",
"source_image_path": "sample_00005/source.png",
"document_with_boxes_path": "sample_00005/document_with_boxes.png",
- "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI). \n\nPrecautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\nRadiopharmaceutical \n\nRadiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-\\[^{123}\\mathrm{I}\\]Iodo-α-methyl-L-tyrosine (IMT). \n- \\[ \\mathrm{Methyl-}^{11}\\mathrm{C} \\]-L-methionine (MET). \n- \\(O-(2-[^{18}\\mathrm{F}]\\mathrm{Fluoroethyl})-L\\)-tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\nRadiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \\(\\sim 20\\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.",
+ "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \\(\\sim 1\\) h for SPECT. \n\n## Precautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oxymetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\n## Radiopharmaceutical \n\n## Radiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-\\[^{123}\\mathrm{I}\\]Iodo-\\(\\alpha\\) -methyl-L-tyrosine (IMT). \n- [Methyl-\\(^{11}\\mathrm{C}\\)]-L-methionine (MET). \n- \\(O-(2-[^{18}\\mathrm{F}]\\) Fluoroethyl)-L-tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\n## Radiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 \\(\\mu \\mathrm{Sv}\\) for Germanium- based transmission, \\(\\sim 20 \\mu \\mathrm{Sv}\\) for low- dose high- speed CT, and between 220 and 450 \\(\\mu \\mathrm{Sv}\\) for high- quality CT.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -114,7 +194,7 @@
"raw_response_path": "sample_00006/raw_response.md",
"source_image_path": "sample_00006/source.png",
"document_with_boxes_path": "sample_00006/document_with_boxes.png",
- "document_markdown_text": "1) (X) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 2) 1) 1) 1) 1) 1) 1) 1) 1) 1) 3) 1) 1) 1) 1) 1) 1) 1) 1) 1) 4) 1) 1) 1) 1) 1) 1) 1) 1) 1) 5) 1) 1) 1) 1) 1) 1) 1) 1) 6) 1) 1) 1) 1) 1) 1) 1) 1) 1) 7) 1) 1) 1) 1) 1) 1) 1) 1) 1) 8) 1) 1) 1) 1) 1) 1) 1) 1) 1) 9) 1) 1) 1) 1) 1) 1) 1) 1) 1) 10) 1) 1) 1) 1) 1) 1) 1) 1) 1) 11) 1) 1) 1) 1) 1) 1) 1) 1) 1) 12) 1) 1) 1) 1) 1) 1) 1) 1) 1) 13) 1) 1) 1) 1) 1) 1) 1) 1) 1) 14) 1) 1) 1) 1) 1) 1) 1) 1) 1) 15) 1) 1) 1) 1) 1) 1) 1) 1) 1) 16) 1) 1) 1) 1) 1) 1) 1) 1) 1) 17) 1) 1) 1) 1) 1) 1) 1) 1) 1) 18) 1) 1) 1) 1) 1) 1) 1) 1) 1) 19) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 20) 1) 1) 1) 1) 1) 1) 1) 1) 1) 21) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 22) 1) 1) 1) 1) 1) 1) 1) 1) 1) 23) 1) 1) 1) 1) 1) 1) 1) 1) 1) 24) 1) 1) 1) 1) 1) 1) 1) 1) 1) 25) 1) 1) 1) 1) 1) 1) 1) 1) 1) 26) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 27) 1) 1) 1) 1) 1) 1) 1) 1) 1) 28) 1) 1) 1) 1) 1) 1) 1) 1) 1) 29) 1) 1) 1) 1) 1) 1) 1) 1) 30) 1) 1) 1) 1) 1) 1) 1) 1) 1) 31) 1) 1) 1) 1) 1) 1) 1) 1) 1) 32) 1) 1) 1) 1) 1) 1) 1) 1) 1) 33) 1) 1) 1) 1) 1) 1) 1) 1) 1) 34) 1) 1) 1) 1) 1) 1) 1) 1) 1) 35) 1) 1) 1) 1) 1) 1) 1) 1) 1) 36) 1) 1) 1) 1) 1) 1) 1) 1) 1) 37) 1) 1) 1) 1) 1) 1) 1) 1) 1) 38) 1) 1) 1) 1) 1) 1) 1) 1) 1) 39) 1) 1) 1) 1) 1) 1) 1) 1) 1) 40) 1) 1) 1) 1) 1) 1) 1) 1) 1) 41) 1) 1) 1) 1) 1) 1) 1) 1) 1) 42) 1) 1) 1) 1) 1) 1) 1) 1) 1) 43) 1) 1) 1) 1) 1) 1) 1) 1) 1) 44) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 45) 1) 1) 1) 1) 1) 1) 1) 1) 1) 46) 1) 1) 1) 1) 1) 1) 1) 1) 1) 47) 1) 1) 1) 1) 1) 1) 1) 1) 1) 48) 1) 1) 1) 1) 1) 1) 1) 1) 1) 49) 1) 1) 1) 1) 1) 1) 1) 1) 1) 50) 1) 1) 1) 1) 1) 1) 1) 1) 1) 51) 1) 1) 1) 1) 1) 1) 1) 1) 1) 52) 1) 1) 1) 1) 1) 1) 1) 1) 1) 53) 1) 1) 1) 1) 1) 1) 1) 1) 1) 54) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 55) 1) 1) 1) 1) 1) 1) 1) 1) 1) 56) 1) 1) 1) 1) 1) 1) 1) 1) 1) 57) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 58) 1) 1) 1) 1) 1) 1) 1) 1) 1) 59) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 60) 1) 1) 1) 1) 1) 1) 1) 1) 1) 61) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 62) 1) 1) 1) 1) 1) 1) 1) 1) 1) 63) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 64) 1) 1) 1) 1) 1) 1) 1) 1) 1) 65) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 66) 1) 1) 1) 1) 1) 1) 1) 1) 1) 67) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 68) 1) 1) 1) 1) 1) 1) 1) 1) 1) 69) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 70) 1) 1) 1) 1) 1) 1) 1) 1) 1) 71) 1) 1) 1) 1) 1) 1) 1) 1) 1) 72) 1) 1) 1) 1) 1) 1) 1) 1) 1) 73) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 74) 1) 1) 1) 1) 1) 1) 1) 1) 1) 75) 1) 1) 1) 1) 1) 1) 1) 1) 1) 76) 1) 1) 1) 1) 1) 1) 1) 1) 1) 77) 1) 1) 1) 1) 1) 1) 1) 1) 1) 78) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 79) 1) 1) 1) 1) 1) 1) 1) 1) 1) 80) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 81) 1) 1) 1) 1) 1) 1) 1) 1) 1) 82) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 83) 1) 1) 1) 1) 1) 1) 1) 1) 1) 84) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 85) 1) 1) 1) 1) 1) 1) 1) 1) 1) 86) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 87) 1) 1) 1) 1) 1) 1) 1) 1) 1) 88) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 89) 1) 1) 1) 1) 1) 1) 1) 1) 1) 90) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 91) 1) 1) 1) 1) 1) 1) 1) 1) 92) 1) 1) 1) 1) 1) 1) 1) 1) 1) 93) 1) 1) 1) 1) 1) 1) 1) 1) 1) 94) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 95) 1) 1) 1) 1) 1) 1) 1) 1) 1) 96) 1) 1) 1) 1) 1) 1) 1) 1) 1) 97) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 98) 1) 1) 1) 1) 1) 1) 1) 1) 1) 99) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 100) 1) 1) 1) 1) 1) 1) 1) 1) 1) 101) 1) 1) 1) 1) 1) 1) 1) 1) 1) 102) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 103) 1) 1) 1) 1) 1) 1) 1) 1) 1) 104) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 105) 1) 1) 1) 1) 1) 1) 1) 1) 1) 106) 1) 1) 1) 1) 1) 1) 1) 1) 1) 107) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 108) 1) 1) 1) 1) 1) 1) 1) 1) 1) 109) 1) 1) 1) 1) 1) 1) 1) 1) 1) 110) 1) 1) 1) 1) 1) 1) 1) 1) 1) 111) 1) 1) 1) 1) 1) 1) 1) 1) 1) 112) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 113) 1) 1) 1) 1) 1) 1) 1) 1) 1) 114) 1) 1) 1) 1) 1) 1) 1) 1) 115) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 116) 1) 1) 1) 1) 1) 1) 1) 1) 1) 117) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 118) 1) 1) 1) 1) 1) 1) 1) 1) 1) 119) 1) 1) 1) 1) 1) 1) 1) 1) 120) 1) 1) 1) 1) 1) 1) 1) 1) 1) 121) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 122) 1) 1) 1) 1) 1) 1) 1) 1) 1) 123) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 124) 1) 1) 1) 1) 1) 1) 1) 1) 1) 125) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 126) 1) 1) 1) 1) 1) 1) 1) 1) 1) 127) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 128) 1) 1) 1) 1) 1) 1) 1) 1) 1) 129) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 130) 1) 1) 1) 1) 1) 1) 1) 1) 1) 131) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 132) 1) 1) 1) 1) 1) 1) 1) 1) 1) 133) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 134) 1) 1",
+ "document_markdown_text": "1) (X) 1) (X) 1) (X) 1) (X) 1) (X) 1) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -126,7 +206,7 @@
"raw_response_path": "sample_00007/raw_response.md",
"source_image_path": "sample_00007/source.png",
"document_with_boxes_path": "sample_00007/document_with_boxes.png",
- "document_markdown_text": "2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8",
+ "document_markdown_text": "2011, XLVl, 394 p., Hardcover ISBN: 978-90-481-8664-8",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -138,7 +218,7 @@
"raw_response_path": "sample_00008/raw_response.md",
"source_image_path": "sample_00008/source.png",
"document_with_boxes_path": "sample_00008/document_with_boxes.png",
- "document_markdown_text": "The parametric equations for a projectile with constant gravity g: \n\n\\[x = v_0 t \\cos \\theta + x_0\\]\n\n\\[y = -\\frac{1}{2} gt^2 + v_0 t \\sin \\theta + y_0\\]\n\nex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: \n\n1. \\(\\vec{r}(t)\\) \n\n2. the maximum altitude attained \n\n3. the range of the shell \n\n4. the speed on impact \n\n5. the horizontal distance when \\(y = 2240\\) ft.",
+ "document_markdown_text": "The parametric equations for a projectile with constant gravity g: \n\n\\[ x = v_0 t \\cos \\theta + x_0 \\]\n\n\\[ y = -\\frac{1}{2} gt^2 + v_0 t \\sin \\theta + y_0 \\]\n\nex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: \n\n1. \\(\\vec{r}(t)\\) \n\n2. the maximum altitude attained \n\n3. the range of the shell \n\n4. the speed on impact \n\n5. the horizontal distance when \\(y = 2240\\) ft.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -150,7 +230,7 @@
"raw_response_path": "sample_00009/raw_response.md",
"source_image_path": "sample_00009/source.png",
"document_with_boxes_path": "sample_00009/document_with_boxes.png",
- "document_markdown_text": "purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at 140 kV, which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is <10 s). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. \n\n- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15–30 min aiming to collect 50–200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\n## IMT Single Photon Emission Tomography \n\n- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. \n\n- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \\(^{123}\\mathrm{I}\\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. \n\nTABLE 2.2. Acquisition parameters for IMT-SPECT \n\n- Rotational radius: smallest possible with appropriate patient safeguard\n- Matrix: \\(128 \\times 128\\)\n- Angular sampling: \\(\\leq 3^\\circ\\) (360° rotation)\n- Zoom: acquisition pixel size should be \\(1/3-1/2\\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size\n- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort\n- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30–50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)",
+ "document_markdown_text": "2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\npurpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \\(140\\mathrm{kV}\\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \\(< 10\\mathrm{~s}\\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. \n\nEmission scan. As semiquantitative estimates of tumor- to- background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3- D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15- 30 min aiming to collect 50- 200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\n## IMT Single Photon Emission Tomography \n\n- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. \n\n- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \\(^{123}\\mathrm{I}\\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. \n\n# TABLE 2.2. Acquisition parameters for IMT-SPECT \n\n- Rotational radius: smallest possible with appropriate patient safeguard- Matrix: \\(128 \\times 128\\) - Angular sampling: \\(\\leq 3^{\\circ}\\) (360° rotation)- Zoom: acquisition pixel size should be \\(1 / 3 - 1 / 2\\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30-50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -162,7 +242,7 @@
"raw_response_path": "sample_00010/raw_response.md",
"source_image_path": "sample_00010/source.png",
"document_with_boxes_path": "sample_00010/document_with_boxes.png",
- "document_markdown_text": "Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \\(10^{6}\\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used? \n\na. \\(y = -4.9t^2\\) b. \\(y = -4.9t^2 - 5x10^6t\\) c. \\(5x10^6t = 4\\) d. \\(5x10^6t = 40\\)",
+ "document_markdown_text": "Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \\(10^{6}\\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used? \n\na. \\(y = -4.9t^2\\) b. \\(y = -4.9t^2 - 5\\times 10^6 t\\) c. \\(5\\times 10^6 t = 4\\) d. \\(5\\times 10^6 t = 40\\)",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -174,24 +254,10 @@
"raw_response_path": "sample_00011/raw_response.md",
"source_image_path": "sample_00011/source.png",
"document_with_boxes_path": "sample_00011/document_with_boxes.png",
- "document_markdown_text": "0 \n\n\n\n# Bio \n\n**Bio** \n\nBrett received his B.S. in Chemical Engineering from the University of Massachusetts Amherst in 2009. There he worked in the lab of Dr. Neil Forbes developing microfluidic devices to study the interactions between bacteria and in vitro tumor models. He earned his Ph.D. in Chemical Engineering from the California Institute of Technology in 2016 where he worked with Dr. Dave Tirrell and Dr. Dianne Newman. His thesis focused on the development and application of a method for time- and cell-selective proteomic analysis in bacteria. He used this approach to study protein synthesis by the opportunistic pathogen Pseudomonas aeruginosa under dormancy and biofilm growth conditions. Brett joined the Bogyo lab at Stanford in the fall of 2016. His current focus is on the roles of serine hydrolases in the physiology of pathogenic bacteria. \n\n# HONORS AND AWARDS \n\n• A. P. Giannini Postdoctoral Fellowship, A. P. Giannini Foundation (2018) \n\n• Microbiology and Immunology Postdoctoral Fellowship, Stanford School of Medicine (2018) \n\n• Dean's Fellowship, Stanford School of Medicine (2017) \n\n# PROFESSIONAL EDUCATION \n\n• Bachelor of Science, University of Massachusetts Amherst (2009) \n\n• Doctor of Philosophy, California Institute of Technology (2016) \n\n# STANFORD ADVISORS \n\n• Matthew Bogyo, Postdoctoral Faculty Sponsor \n\n# Research & Scholarship \n\n**LAB AFFILIATIONS** \n\n• Matthew Bogyo, Bogyo Lab (9/1/2016) \n\n# Publications \n\n## PUBLICATIONS \n\n• Activity-based protein profiling in bacteria: Applications for identification of therapeutic targets and characterization of microbial communities. Current opinion in chemical biology \n\nKeller, L. J., Babin, B. M., Lakemeyer, M., Bogyo, M. \n\n2019; 54: 45-53 \n\n• Leveraging Peptide Substrate Libraries to Design Inhibitors of Bacterial L Proteinase ACS CHEMICAL BIOLOGY",
+ "document_markdown_text": "0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 12.9 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 13.9 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 14.9 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 15.9 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 16.9 17.0 17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8 17.9 18.0 18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9 19.0 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 21.0 21.1 21.2 21.3 21.4 21.5 21.6 21.7 21.8 21.9 22.0 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 23.0 23.1 23.2 23.3 23.4 23.5 23.6 23.7 23.8 23.9 24.0 24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 24.9 25.0 25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8 25.9 26.0 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8 26.9 27.0 27.1 27.2 27.3 27.4 27.5 27.6 27.7 27.8 27.9 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 28.9 29.0 29.1 29.2 29.3 29.4 29.5 29.6 29.7 29.8 29.9 30.0 30.1 30.2 30.3 30.4 30.5 30.6 30.7 30.8 30.9 31.0 31.1 31.2 31.3 31.4 31.5 31.6 31.7 31.8 31.9 32.0 32.1 32.2 32.3 32.4 32.5 32.6 32.7 32.8 32.9 33.0 33.1 33.2 33.3 33.4 33.5 33.6 33.7 33.8 33.9 34.0 34.1 34.2 34.3 34.4 34.5 34.6 34.7 34.8 34.9 35.0 35.1 35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 36.0 36.1 36.2 36.3 36.4 36.5 36.6 36.7 36.8 36.9 37.0 37.1 37.2 37.3 37.4 37.5 37.6 37.7 37.8 37.9 38.0 38.1 38.2 38.3 38.4 38.5 38.6 38.7 38.8 38.9 39.0 39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 39.9 40.0 40.1 40.2 40.3 40.4 40.5 40.6 40.7 40.8 40.9 41.0 41.1 41.2 41.3 41.4 41.5 41.6 41.7 41.8 41.9 42.0 42.1 42.2 42.3 42.4 42.5 42.6 42.7 42.8 42.9 43.0 43.1 43.2 43.3 43.4 43.5 43.6 43.7 43.8 43.9 44.0 44.1 44.2 44.3 44.4 44.5 44.6 44.7 44.8 44.9 45.0 45.1 45.2 45.3 45.4 45.5 45.6 45.7 45.8 45.9 46.0 46.1 46.2 46.3 46.4 46.5 46.6 46.7 46.8 46.9 47.0 47.1 47.2 47.3 47.4 47.5 47.6 47.7 47.8 47.9 48.0 48.1 48.2 48.3 48.4 48.5 48.6 48.7 48.8 48.9 49.0 49.1 49.2 49.3 49.4 49.5 49.6 49.7 49.8 49.9 50.0 50.1 50.2 50.3 50.4 50.5 50.6 50.7 50.8 50.9 51.0 51.1 51.2 51.3 51.4 51.5 51.6 51.7 51.8 51.9 52.0 52.1 52.2 52.3 52.4 52.5 52.6 52.7 52.8 52.9 53.0 53.1 53.2 53.3 53.4 53.5 53.6 53.7 53.8 53.9 54.0 54.1 54.2 54.3 54.4 54.5 54.6 54.7 54.8 54.9 55.0 55.1 55.2 55.3 55.4 55.5 55.6 55.7 55.8 55.9 56.0 56.1 56.2 56.3 56.4 56.5 56.6 56.7 56.8 56.9 57.0 57.1 57.2 57.3 57.4 57.5 57.6 57.7 57.8 57.9 58.0 58.1 58.2 58.3 58.4 58.5 58.6 58.7 58.8 58.9 59.0 59.1 59.2 59.3 59.4 59.5 59.6 59.7 59.8 59.9 60.0 60.1 60.2 60.3 60.4 60.5 60.6 60.7 60.8 60.9 61.0 61.1 61.2 61.3 61.4 61.5 61.6 61.7 61.8 61.9 62.0 62.1 62.2 62.3 62.4 62.5 62.6 62.7 62.8 62.9 63.0 63.1 63.2 63.3 63.4 63.5 63.6 63.7 63.8 63.9 64.0 64.1 64.2 64.3 64.4 64.5 64.6 64.7 64.8 64.9 65.0 65.1 65.2 65.3 65.4 65.5 65.6 65.7 65.8 65.9 66.0 66.1 66.2 66.3 66.4 66.5 66.6 66.7 66.8 66.9 67.0 67.1 67.2 67.3 67.4 67.5 67.6 67.7 67.8 67.9 68.0 68.1 68.2 68.3 68.4 68.5 68.6 68.7 68.8 68.9 69.0 69.1 69.2 69.3 69.4 69.5 69.6 69.7 69.8 69.9 70.0 70.1 70.2 70.3 70.4 70.5 70.6 70.7 70.8 70.9 71.0 71.1 71.2 71.3 71.4 71.5 71.6 71.7 71.8 71.9 72.0 72.1 72.2 72.3 72.4 72.5 72.6 72.7 72.8 72.9 73.0 73.1 73.2 73.3 73.4 73.5 73.6 73.7 73.8 73.9 74.0 74.1 74.2 74.3 74.4 74.5 74.6 74.7 74.8 74.9 75.0 75.1 75.2 75.3 75.4 75.5 75.6 75.7 75.8 75.9 76.0 76.1 76.2 76.3 76.4 76.5 76.6 76.7 76.8 76.9 77.0 77.1 77.2 77.3 77.4 77.5 77.6 77.7 77.8 77.9 78.0 78.1 78.2 78.3 78.4 78.5 78.6 78.7 78.8 78.9 79.0 79.1 79.2 79.3 79.4 79.5 79.6 79.7 79.8 79.9 80.0 80.1 80.2 80.3 80.4 80.5 80.6 80.7 80.8 80.9 81.0 81.1 81.2 81.3 81.4 81.5 81.6 81.7 81.8 81.9 82.0 82.1 82.2 82.3 82.4 82.5 82.6 82.7 82.8 82.9 83.0 83.1 83.2 83.3 83.4 83.5 83.6 83.7 83.8 83.9 84.0 84.1 84.2 84.3 84.4 84.5 84.6 84.7 84.8 84.9 85.0 85.1 85.2 85.3 85.4 85.5 85.6 85.7 85.8 85.9 86.0 86.1 86.2 86.3 86.4 86.5 86.6 86.7 86.8 86.9 87.0 87.1 87.2 87.3 87.4 87.5 87.6 87.7 87.8 87.9 88.0 88.1 88.2 88.3 88.4 88.5 88.6 88.7 88.8 88.9 89.0 89.1 89.2 89.3 89.4 89.5 89.6 89.7 89.8 89.9 90.0 90.1 90.2 90.3 90.4 90.5 90.6 90.7 90.8 90.9 91.0 91.1 91.2 91.3 91.4 91.5 91.6 91.7 91.8 91.9 92.0 92.1 92.2 92.3 92.4 92.5 92.6 92.7 92.8 92.9 93.0 93.1 93.2 93.3 93.4 93.5 93.6 93.7 93.8 93.9 94.0 94.1 94.2 94.3 94.4 94.5 94.6 94.7 94.8 94.9 95.0 95.1 95.2 95.3 95.4 95.5 95.6 95.7 95.8 95.9 96.0 96.1 96.2 96.3 96.4 96.5 96.6 96.7 96.8 96.9 97.0 97.1 97.2 97.3 97.4 97.5 97.6 97.7 97.8 97.9 98.0 98.1 98.2 98.3 98.4 98.5 98.6 98.7 98.8 98.9 99.0 99.1 99.2 99.3 99.4 99.5 99.6 99.7 99.8 99.9 100.0 100.1 100.2 100.3 100.4 100.5 100.6 100.7 100.8 100.9 101.0 101.1 101.2 101.3 101.4 101.5 101.6 101.7 101.8 101.9 102.0 102.1 102.2 102.3 102.4 102.5 102.6",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
- "figures": [
- {
- "figure_id": "sample_00011_fig01",
- "label": "image",
- "image_path": "sample_00011/figures/sample_00011_fig01.png",
- "document_relative_path": "figures/sample_00011_fig01.png",
- "bounding_box_pixels": {
- "x1": 72,
- "y1": 227,
- "x2": 276,
- "y2": 429
- },
- "description": ""
- }
- ]
+ "figures": []
},
{
"sample_id": "sample_00012",
@@ -200,24 +266,10 @@
"raw_response_path": "sample_00012/raw_response.md",
"source_image_path": "sample_00012/source.png",
"document_with_boxes_path": "sample_00012/document_with_boxes.png",
- "document_markdown_text": "4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4: \n\n",
+ "document_markdown_text": "4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.8.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.9.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.12.1.1.1.1.1.1.1.1.1.1.1.1.1.1.13.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.14.1.1.1.1.1.1.1.1.1.1.1.1.1.1.15.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.16.1.1.1.1.1.1.1.1.1.1.1.1.1.1.17.1.1.1.1.1.1.1.1.1.1.1.1.1.1.18.1.1.1.1.1.1.1.1.1.1.1.1.1.1.19.1.1.1.1.1.1.1.1.1.1.1.1.1.20.1.1.1.1.1.1.1.1.1.1.1.1.1.21.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.22.1.1.1.1.1.1.1.1.1.1.1.1.1.1.23.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.24.1.1.1.1.1.1.1.1.1.1.1.1.1.1.25.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.26.1.1.1.1.1.1.1.1.1.1.1.1.1.1.27.1.1.1.1.1.1.1.1.1.1.1.1.1.1.28.1.1.1.1.1.1.1.1.1.1.1.1.1.1.29.1.1.1.1.1.1.1.1.1.1.1.1.1.1.30.1.1.1.1.1.1.1.1.1.1.1.1.1.1.31.1.1.1.1.1.1.1.1.1.1.1.1.1.32.1.1.1.1.1.1.1.1.1.1.1.1.1.1.33.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.34.1.1.1.1.1.1.1.1.1.1.1.1.1.1.35.1.1.1.1.1.1.1.1.1.1.1.1.1.1.36.1.1.1.1.1.1.1.1.1.1.1.1.1.1.37.1.1.1.1.1.1.1.1.1.1.1.1.1.1.38.1.1.1.1.1.1.1.1.1.1.1.1.1.1.39.1.1.1.1.1.1.1.1.1.1.1.1.1.1.40.1.1.1.1.1.1.1.1.1.1.1.1.1.1.41.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.42.1.1.1.1.1.1.1.1.1.1.1.1.1.1.43.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.45.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.46.1.1.1.1.1.1.1.1.1.1.1.1.1.1.47.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.48.1.1.1.1.1.1.1.1.1.1.1.1.1.1.49.1.1.1.1.1.1.1.1.1.1.1.1.1.1.50.1.1.1.1.1.1.1.1.1.1.1.1.1.1.51.1.1.1.1.1.1.1.1.1.1.1.1.1.1.52.1.1.1.1.1.1.1.1.1.1.1.1.1.1.53.1.1.1.1.1.1.1.1.1.1.1.1.1.1.54.1.1.1.1.1.1.1.1.1.1.1.1.1.1.55.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.56.1.1.1.1.1.1.1.1.1.1.1.1.1.1.57.1.1.1.1.1.1.1.1.1.1.1.1.1.1.58.1.1.1.1.1.1.1.1.1.1.1.1.1.1.59.1.1.1.1.1.1.1.1.1.1.1.1.1.1.60.1.1.1.1.1.1.1.1.1.1.1.1.1.1.61.1.1.1.1.1.1.1.1.1.1.1.1.1.1.62.1.1.1.1.1.1.1.1.1.1.1.1.1.1.63.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.64.1.1.1.1.1.1.1.1.1.1.1.1.1.1.65.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.66.1.1.1.1.1.1.1.1.1.1.1.1.1.1.67.1.1.1.1.1.1.1.1.1.1.1.1.1.1.68.1.1.1.1.1.1.1.1.1.1.1.1.1.1.69.1.1.1.1.1.1.1.1.1.1.1.1.1.1.70.1.1.1.1.1.1.1.1.1.1.1.1.1.1.71.1.1.1.1.1.1.1.1.1.1.1.1.1.1.72.1.1.1.1.1.1.1.1.1.1.1.1.1.1.73.1.1.1.1.1.1.1.1.1.1.1.1.1.1.74.1.1.1.1.1.1.1.1.1.1.1.1.1.1.75.1.1.1.1.1.1.1.1.1.1.1.1.1.1.76.1.1.1.1.1.1.1.1.1.1.1.1.1.1.77.1.1.1.1.1.1.1.1.1.1.1.1.1.1.78.1.1.1.1.1.1.1.1.1.1.1.1.1.1.79.1.1.1.1.1.1.1.1.1.1.1.1.1.1.80.1.1.1.1.1.1.1.1.1.1.1.1.1.1.81.1.1.1.1.1.1.1.1.1.1.1.1.1.1.82.1.1.1.1.1.1.1.1.1.1.1.1.1.1.83.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.84.1.1.1.1.1.1.1.1.1.1.1.1.1.1.85.1.1.1.1.1.1.1.1.1.1.1.1.1.1.86.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.87.1.1.1.1.1.1.1.1.1.1.1.1.1.1.88.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.89.1.1.1.1.1.1.1.1.1.1.1.1.1.1.90.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.91.1.1.1.1.1.1.1.1.1.1.1.1.1.1.92.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.93.1.1.1.1.1.1.1.1.1.1.1.1.1.1.94.1.1.1.1.1.1.1.1.1.1.1.1.1.1.95.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.96.1.1.1.1.1.1.1.1.1.1.1.1.1.1.97.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.98.1.1.1.1.1.1.1.1.1.1.1.1.1.1.99.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.100.1.1.1.1.1.1.1.1.1.1.1.1.1.1.101.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.102.1.1.1.1.1.1.1.1.1.1.1.1.1.1.103.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.104.1.1.1.1.1.1.1.1.1.1.1.1.1.1.105.1.1.1.1.1.1.1.1.1.1.1.1.1.1.106.1.1.1.1.1.1.1.1.1.1.1.1.1.1.107.1.1.1.1.1.1.1.1.1.1.1.1.1.1.108.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.109.1.1.1.1.1.1.1.1.1.1.1.1.1.1.110.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.111.1.1.1.1.1.1.1.1.1.1.1.1.1.1.112.1.1.1.1.1.1.1.1.1.1.1.1.1.1.113.1.1.1.1.1.1.1.1.1.1.1.1.1.1.114.1.1.1.1.1.1.1.1.1.1.1.1.1.1.115.1.1.1.1.1.1.1.1.1.1.1.1.1.1.116.1.1.1.1.1.1.1.1.1.1.1.1.1.1.117.1.1.1.1.1.1.1.1.1.1.1.1.1.1.118.1.1.1.1.1.1.1.1.1.1.1.1.1.1.119.1.1.1.1.1.1.1.1.1.1.1.1.1.1.120.1.1.1.1.1.1.1.1.1.1.1.1.1.1.121.1.1.1.1.1.1.1.1.1.1.1.1.1.1.122.1.1.1.1.1.1.1.1.1.1.1.1.1.1.123.1.1.1.1.1.1.1.1.1.1.1.1.1.1.124.1.1.1.1.1.1.1.1.1.1.1.1.1.1.125.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.126.1.1.1.1.1.1.1.1.1.1.1.1.1.1.127.1.1.1.1.1.1.1.1.1.1.1.1.1.1.128.1.1.1.1.1.1.1.1.1.1.1.1.1.1.129.1.1.1.1.1.1.1.1.1.1.1.1.1.1.130.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.131.1.1.1.1.1.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
- "figures": [
- {
- "figure_id": "sample_00012_fig01",
- "label": "image",
- "image_path": "sample_00012/figures/sample_00012_fig01.png",
- "document_relative_path": "figures/sample_00012_fig01.png",
- "bounding_box_pixels": {
- "x1": 448,
- "y1": 359,
- "x2": 944,
- "y2": 1481
- },
- "description": ""
- }
- ]
+ "figures": []
},
{
"sample_id": "sample_00013",
@@ -226,7 +278,7 @@
"raw_response_path": "sample_00013/raw_response.md",
"source_image_path": "sample_00013/source.png",
"document_with_boxes_path": "sample_00013/document_with_boxes.png",
- "document_markdown_text": "2019; 14 (11): 2453-62 \n\n• The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology Bergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019 \n\n• Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY Garland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M. 2019; 14 (1): 76-87 \n\n• Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio Babin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5) \n\n• SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Babin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A. 2016; 113 (5): E597-E605 \n\n• In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY Hatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J. 2014; 16 (8): 2568-2590 \n\n• State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY Ngo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A. 2012; 7 (8): 1326-1330 \n\n• Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE Solorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A. 2010; 143 (2): 183-190 \n\n• A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP Walsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S. 2009; 9 (4): 545-554",
+ "document_markdown_text": "2019; 14 (11): 2453-62 \n\n- The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology \n\nBergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019 \n\n- Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY \n\nGarland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M. \n\n2019; 14 (1): 76- 87 \n\n- Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio \n\nBabin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5) \n\n- SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA \n\nBabin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A. \n\n2016; 113 (5): E597- E605 \n\n- In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY \n\nHatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J. \n\n2014; 16 (8): 2568- 2590 \n\n- State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY \n\nNgo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A. \n\n2012; 7 (8): 1326- 1330 \n\n- Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE \n\nSolorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A. \n\n2010; 143 (2): 183- 190 \n\n- A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP \n\nWalsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S. \n\n2009; 9 (4): 545- 554",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -238,7 +290,7 @@
"raw_response_path": "sample_00014/raw_response.md",
"source_image_path": "sample_00014/source.png",
"document_with_boxes_path": "sample_00014/document_with_boxes.png",
- "document_markdown_text": "18 \n\nSoftware functionality: SepINRIA has different functionality which can be loaded from a single main window: \n\n- Lesion Segmentation Edition: Manual or semi-automatic segmentation of MS lesions (e.g. a segmentation realized by an expert). Segmentations can be saved and visualized in 2D or 3D. Lesion number and lesion volume can be computed and print. \n\n- Automatic Lesion Segmentation: Automatic segmentation of MS lesions from four MRI sequences (Dual Spin Echo T2-PD, T1, T2-FLAIR). \n\n- Images or Segmentation Comparison: Quantitative comparisons of two images registered to assess evolution and comparison between a segmentation (e.g. automatic segmentation) and a segmentation of reference (segmentation of an expert): by computation of the difference image or by visualizing them in the same window (side to side or image fusion). \n\n- Brain Atrophy Evaluation: Manual and automatic evaluation of the brain atrophy. Linear measurements computation of the brain, lateral ventricle and third ventricle width are available in the manual mode. And evolution of the BPF in function of the exam dates can be perform in the automatic mode. \n\n### 4.2 Structure based on C++ \n\nThis section describes concisely dependencies of the software and also its structure by providing a simplify UML scheme of the code architecture. \n\n#### 4.2.1 Software dependencies \n\nSepINRIA is based on several C++ libraries (C.f. Figure 4.2). ITK \\(^2\\) and MIPS \\(^3\\) contain both image processing tools. The first one can be downloaded on Internet and is especially used for image conversion. Whereas the second one is inner to the Asclepios team (algorithms presented in chapter 3 can be found in this library). \n\n\n\n| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \\(Age\\pm \\mathrm {SD}\\)(year) | \\(54.0\\pm 13.1\\) | \\(54.0\\pm 13.2\\) |
| Females (n \\((\\%)\\) | \\(144\\)(84.2) | \\(128\\)(78.5) |
| RA duration±SD (year) | \\(0.3\\pm 0.4\\) | \\(0.3\\pm 0.4\\) |
| Weight±SD (kg) | \\(54.4\\pm 9.7\\) | \\(56.1\\pm 12.3\\) |
| Previous DMARD use (n \\((\\%)\\) | \\(74\\)(43.3) | \\(87\\)(53.4) |
| 1 DMARD | \\(57\\)(33.3) | \\(69\\)(42.3) |
| 2 DMARDs | \\(17\\)(9.9) | \\(18\\)(11.0) |
| Corticosteroid use at baseline (n \\((\\%)\\) | \\(58\\)(33.9) | \\(49\\)(30.1) |
| RF positive (n \\((\\%)\\) | \\(146\\)(85.4) | \\(136\\)(83.4) |
| Mean titre±SD (IU/ml) | \\(154.5\\pm 202.3\\) | \\(163.7\\pm 362.8\\) |
| Anti-CCP positive (n \\((\\%)\\) | \\(145\\)(84.8) | \\(136\\)(83.4) |
| Mean titre±SD (U/ml) | \\(386.2\\pm 694.2\\) | \\(241.3\\pm 367.2\\) |
| ESR (mm/h) | \\(59.9\\pm 30.1\\) | \\(61.8\\pm 29.0\\) |
| CRP (mg/dl) | \\(2.9\\pm 3.0\\) | \\(3.1\\pm 3.3\\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \\(11.5\\pm 4.7\\) | \\(11.8\\pm 5.3\\) |
| 0-66 | \\(16.5\\pm 6.2\\) | \\(17.3\\pm 7.7\\) |
| Tender joint count (n±SD) | | |
| 0-28 | \\(13.2\\pm 5.8\\) | \\(13.2\\pm 6.1\\) |
| 0-68 | \\(20.7\\pm 9.4\\) | \\(21.1\\pm 10.2\\) |
| mTSS | \\(13.6\\pm 22.3\\) | \\(13.6\\pm 17.4\\) |
| Erosion score | \\(7.5\\pm 11.6\\) | \\(7.3\\pm 9.2\\) |
| Joint space narrowing score | \\(6.2\\pm 11.4\\) | \\(6.2\\pm 9.4\\) |
| DAS28-ESR | \\(6.6\\pm 0.9\\) | \\(6.6\\pm 1.0\\) |
| DAS28-CRP | \\(5.8\\pm 1.0\\) | \\(5.9\\pm 1.0\\) |
| HAQ-DI score | \\(1.1\\pm 0.7\\) | \\(1.3\\pm 0.8\\) |
| SDAI score | \\(40.7\\pm 12.0\\) | \\(41.4\\pm 13.8\\) |
| CDAI score | \\(37.8\\pm 10.9\\) | \\(38.3\\pm 12.4\\) |
Physician's global assessment of
disease activity±SD (mm) | \\(65.8\\pm 18.4\\) | \\(66.2\\pm 18.8\\) |
Patient's global assessment of disease
activity±SD (mm) | \\(64.1\\pm 24.8\\) | \\(66.4\\pm 23.7\\) |
\n\n*Data are mean±SD unless otherwise indicated.\n\nCCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.\n\nto 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.\n\nA significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).\n\n# Factors associated with the absence of radiographic progression or with clinical remission\n\nDisease activity or function baseline variables generally were associated with the absence of radiographic progression ( \\(\\Delta \\mathrm {mTSS}\\leq 0.5\\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).",
+ "document_markdown_text": "24 baseline demographics and disease characteristics. Significant ( \\(p<0.1\\) ) variables in univariate were included in multivariate models. Last, multivariate models were selected based on model fit statistics (Akaike information criterion and \\(r^2\\) ) and clinical significance. Adjusted OR and \\(95\\%\\) CIs for selected baseline variables were calculated. \n\n## RESULTS \n\nOverall, 334 patients were randomised to treatment and received adalimumab \\(+\\mathrm{MTX}\\) ( \\(n = 171\\) ) or MTX alone ( \\(n = 163\\) ), and 148 ( \\(86.5\\%\\) ) and 128 ( \\(78.5\\%\\) ) patients completed the double- blind portion of the study, respectively (figure 1). Demographics and baseline characteristics were well matched between treatment groups (table 1). The mean RA disease duration was 0.3 years, and the majority of patients had \\(\\geq 1\\) erosion at baseline and high disease activity. The mean MTX dose during the 26- week study was \\(6.2\\pm 0.8\\mathrm{mg / week}\\) in the adalimumab \\(+\\mathrm{MTX}\\) group and \\(6.6\\pm 0.6\\mathrm{mg / week}\\) in the MTX alone group ( \\(p<0.001\\) ). After 26 weeks of treatment, \\(34.5\\%\\) (59/171) of adalimumab \\(+\\mathrm{MTX}\\) patients were receiving MTX 8 mg/week versus \\(65.0\\%\\) (106/163) of MTX alone patients ( \\(p<0.001\\) ). \n\n## Radiographic progression \n\nTreatment with adalimumab \\(+\\mathrm{MTX}\\) significantly inhibited radiographic progression (figure 2A) at week 26 versus MTX alone (mean change \\(\\pm \\mathrm{SD}\\) , \\(1.5\\pm 6.1\\) vs \\(2.4\\pm 3.2\\) , respectively; \\(p<0.001\\) ). Results were confirmed by an LE analysis (figure 2A). Changes in radiographic progression during 26 weeks of treatment were also assessed by a cumulative probability plot of \\(\\Delta \\mathrm{MTSS}\\) (figure 2B). Fewer adalimumab \\(+\\mathrm{MTX}\\) patients exhibited radiographic progression ( \\(\\Delta \\mathrm{MTSS} > 0.5\\) ), with \\(62.0\\%\\) (106/171) of patients showing no radiographic progression versus \\(35.4\\%\\) (57/161) of MTX alone patients ( \\(p<0.001\\) ). Furthermore, only \\(14.0\\%\\) (24/171) of adalimumab \\(+\\mathrm{MTX}\\) patients exhibited clinically relevant radiographic progression ( \\(\\Delta \\mathrm{MTSS} > 3\\) ) versus \\(37.3\\%\\) (60/161) of MTX alone patients ( \\(p<0.001\\) ). In addition, a significantly higher percentage of adalimumab \\(+\\mathrm{MTX}\\) patients did not experience worsening ( \\(\\leq 0.5\\) ) in erosion score ( \\(73.7\\%\\) (126/171)) versus MTX alone patients ( \\(42.2\\%\\) (68/161); \\(p<0.001\\) ). In patients who lacked baseline erosive damage, the continued absence of erosions was reported in more adalimumab \\(+\\mathrm{MTX}\\) patients versus MTX alone patients (9/9 vs 2/6 patients, respectively; \\(p = 0.01\\) ). \n\n## Clinical response \n\nA significantly higher percentage of adalimumab \\(+\\mathrm{MTX}\\) patients achieved ACR responses versus MTX alone patients at each assessment (figure 3A- C). Significant differences between treatment groups, observed as early as week 2, were maintained through week 26. At week 26, a significantly larger percentage of adalimumab \\(+\\mathrm{MTX}\\) patients versus MTX alone patients achieved ACR20, ACR50 and ACR70 (figure 3A- C) and ACR90 (12.9% vs 5.5%; \\(p = 0.02\\) ) responses. Significant differences in favour of adalimumab \\(+\\mathrm{MTX}\\) were also observed from week 2 to 26 for DAS28- ESR, DAS28- CRP, SDAI and CDAI (see online supplementary figure 1A- D). A larger percentage of adalimumab \\(+\\mathrm{MTX}\\) patients than MTX alone patients demonstrated good or moderate European League Against Rheumatism responses (figure 3D) and were in states of low disease activity or remission after 26 weeks of treatment (figure 3E). Furthermore, a significantly larger percentage of adalimumab \\(+\\mathrm{MTX}\\) patients versus MTX alone patients satisfied Boolean remission criteria (19.3% vs 8.6%, \\(p = 0.007\\) ). Adalimumab \\(+\\mathrm{MTX}\\) achieved a 1.8- \n\nTable 1 Demographics and baseline characteristics \n\nNature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
",
+ "document_markdown_text": "Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | |
| | | | | | | Patterson |
",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -348,7 +400,7 @@
"raw_response_path": "sample_00022/raw_response.md",
"source_image_path": "sample_00022/source.png",
"document_with_boxes_path": "sample_00022/document_with_boxes.png",
- "document_markdown_text": "0.3-0.7 \n\nof anti- TNF- \\(\\alpha\\) and MTX combination therapy in patients with early RA and high disease activity. \n\n## Author affiliations \n\nDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan \n\nAcknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. \n\nContributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. \n\nFunding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). \n\nCompeting interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. \n\npatients other to distribute, remix, adapt, build upon this work non- commercially, \n\nand license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/ \n\n## REFERENCES \n\n1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \\(\\alpha\\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective",
+ "document_markdown_text": "0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -360,7 +412,7 @@
"raw_response_path": "sample_00023/raw_response.md",
"source_image_path": "sample_00023/source.png",
"document_with_boxes_path": "sample_00023/document_with_boxes.png",
- "document_markdown_text": "0.5cm 0cm 0cm 0cm 0cm \n\n## Adding Time Limit for Degree Completion for Students who Stop Out- \n\nS. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved",
+ "document_markdown_text": "2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2: 2.0 2.0 2.0 2.0 2.0 2.0 2.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.10 3.10 3.10 3.10 3.10 3.10 3.11 3.11 3.11 3.11 3.11 3.11 3.12 3.12 3.12 3.12 3.12 3.12 3.13 3.13 3.13 3.13 3.13 3.14 3.14 3.14 3.14 3.14 3.14 3.15 3.15 3.15 3.15 3.15 3.15 3.16 3.16 3.16 3.16 3.16 3.16 3.17 3.17 3.17 3.17 3.17 3.17 3.18 3.18 3.18 3.18 3.18 3.18 3.19 3.19 3.19 3.19 3.19 3.19 3.20 3.20 3.20 3.20 3.20 3.20 3.21 3.21 3.21 3.21 3.21 3.21 3.22 3.22 3.22 3.22 3.22 3.22 3.23 3.23 3.23 3.23 3.23 3.23 3.24 3.24 3.24 3.24 3.24 3.24 3.25 3.25 3.25 3.25 3.25 3.25 3.26 3.26 3.26 3.26 3.26 3.26 3.27 3.27 3.27 3.27 3.27 3.27 3.28 3.28 3.28 3.28 3.28 3.28 3.29 3.29 3.29 3.29 3.29 3.29 3.30 3.30 3.30 3.30 3.30 3.30 3.31 3.31 3.31 3.31 3.31 3.31 3.32 3.32 3.32 3.32 3.32 3.32 3.33 3.33 3.33 3.33 3.33 3.33 3.34 3.34 3.34 3.34 3.34 3.34 3.35 3.35 3.35 3.35 3.35 3.35 3.36 3.36 3.36 3.36 3.36 3.36 3.37 3.37 3.37 3.37 3.37 3.37 3.38 3.38 3.38 3.38 3.38 3.38 3.39 3.39 3.39 3.39 3.39 3.39 3.40 3.40 3.40 3.40 3.40 3.40 3.41 3.41 3.41 3.41 3.41 3.41 3.42 3.42 3.42 3.42 3.42 3.42 3.43 3.43 3.43 3.43 3.43 3.43 3.44 3.44 3.44 3.44 3.44 3.44 3.45 3.45 3.45 3.45 3.45 3.45 3.46 3.46 3.46 3.46 3.46 3.46 3.47 3.47 3.47 3.47 3.47 3.47 3.48 3.48 3.48 3.48 3.48 3.48 3.49 3.49 3.49 3.49 3.49 3.49 3.50 3.50 3.50 3.50 3.50 3.50 3.51 3.51 3.51 3.51 3.51 3.51 3.52 3.52 3.52 3.52 3.52 3.52 3.53 3.53 3.53 3.53 3.53 3.53 3.54 3.54 3.54 3.54 3.54 3.54 3.55 3.55 3.55 3.55 3.55 3.55 3.56 3.56 3.56 3.56 3.56 3.56 3.57 3.57 3.57 3.57 3.57 3.57 3.58 3.58 3.58 3.58 3.58 3.58 3.59 3.59 3.59 3.59 3.59 3.59 3.60 3.60 3.60 3.60 3.60 3.60 3.61 3.61 3.61 3.61 3.61 3.61 3.62 3.62 3.62 3.62 3.62 3.62 3.63 3.63 3.63 3.63 3.63 3.63 3.64 3.64 3.64 3.64 3.64 3.64 3.65 3.65 3.65 3.65 3.65 3.65 3.66 3.66 3.66 3.66 3.66 3.66 3.67 3.67 3.67 3.67 3.67 3.67 3.68 3.68 3.68 3.68 3.68 3.68 3.69 3.69 3.69 3.69 3.69 3.69 3.70 3.70 3.70 3.70 3.70 3.70 3.71 3.71 3.71 3.71 3.71 3.71 3.72 3.72 3.72 3.72 3.72 3.72 3.73 3.73 3.73 3.73 3.73 3.73 3.74 3.74 3.74 3.74 3.74 3.74 3.75 3.75 3.75 3.75 3.75 3.75 3.76 3.76 3.76 3.76 3.76 3.76 3.77 3.77 3.77 3.77 3.77 3.77 3.78 3.78 3.78 3.78 3.78 3.78 3.79 3.79 3.79 3.79 3.79 3.79 3.80 3.80 3.80 3.80 3.80 3.80 3.81 3.81 3.81 3.81 3.81 3.81 3.82 3.82 3.82 3.82 3.82 3.82 3.83 3.83 3.83 3.83 3.83 3.83 3.84 3.84 3.84 3.84 3.84 3.84 3.85 3.85 3.85 3.85 3.85 3.85 3.86 3.86 3.86 3.86 3.86 3.86 3.87 3.87 3.87 3.87 3.87 3.87 3.88 3.88 3.88 3.88 3.88 3.88 3.89 3.89 3.89 3.89 3.89 3.89 3.90 3.90 3.90 3.90 3.90 3.90 3.91 3.91 3.91 3.91 3.91 3.91 3.92 3.92 3.92 3.92 3.92 3.92 3.93 3.93 3.93 3.93 3.93 3.93 3.94 3.94 3.94 3.94 3.94 3.94 3.95 3.95 3.95 3.95 3.95 3.95 3.96 3.96 3.96 3.96 3.96 3.96 3.97 3.97 3.97 3.97 3.97 3.97 3.98 3.98 3.98 3.98 3.98 3.98 3.99 3.99 3.99 3.99 3.99 3.99 3.100 3.100 3.100 3.100 3.100 3.100 3.101 3.101 3.101 3.101 3.101 3.101 3.102 3.102 3.102 3.102 3.102 3.102 3.103 3.103 3.103 3.103 3.103 3.103 3.104 3.104 3.104 3.104 3.104 3.104 3.105 3.105 3.105 3.105 3.105 3.105 3.106 3.106 3.106 3.106 3.106 3.106 3.107 3.107 3.107 3.107 3.107 3.107 3.108 3.108 3.108 3.108 3.108 3.108 3.109 3.109 3.109 3.109 3.109 3.109 3.110 3.110 3.110 3.110 3.110 3.110 3.111 3.111 3.111 3.111 3.111 3.111 3.112 3.112 3.112 3.112 3.112 3.112 3.113 3.113 3.113 3.113 3.113 3.113 3.114 3.114 3.114 3.114 3.114 3.114 3.115 3.115 3.115 3.115 3.115 3.115 3.116 3.116 3.116 3.116 3.116 3.116 3.117 3.117 3.117 3.117 3.117 3.117 3.118 3.118 3.118 3.118 3.118 3.118 3.119 3.119 3.119 3.119 3.119 3.119 3.120 3.120 3.120 3.120 3.120 3.120 3.121 3.121 3.121 3.121 3.121 3.121 3.122 3.122 3.122 3.122 3.122 3.122 3.123 3.123 3.123 3.123 3.123 3.123 3.124 3.124 3.124 3.124 3.124 3.124 3.125 3.125 3.125 3.125 3.125 3.125 3.126 3.126 3.126 3.126 3.126 3.126 3.127 3.127 3.127 3.127 3.127 3.127 3.128 3.128 3.128 3.128 3.128 3.128 3.129 3.129 3.129 3.129 3.129 3.129 3.130 3.130 3.130 3.130 3.130 3.130 3.131 3.131 3.131 3.131 3.131 3.131 3.132 3.132 3.132 3.132 3.132 3.132 3.133 3.133 3.133 3.133 3.133 3.133 3.134 3.134 3.134 3.134 3.134 3.134 3.135 3.135 3.135 3.135 3.135 3.135 3.136 3.136 3.136 3.136 3.136 3.136 3.137 3.137 3.137 3.137 3.137 3.137 3.138 3.138 3.138 3.138 3.138 3.138 3.139 3.139 3.139 3.139 3.139 3.139 3.140 3.140 3.140 3.140 3.140 3.140 3.141 3.141 3.141 3.141 3.141 3.141 3.142 3.142 3.142 3.142 3.142 3.142 3.143 3.143 3.143 3.143 3.143 3.143 3.144 3.144 3.144 3.144 3.144 3.144 3.145 3.145 3.145 3.145 3.145 3.145 3.146 3.146 3.146 3.146 3.146 3.146 3.147 3.147 3.147 3.147 3.147 3.147 3.148 3.148 3.148 3.148 3.148 3.148 3.149 3.149 3.149 3.149 3.149 3.149 3.150 3.150 3.150 3.150 3.150 3.150 3.151 3.151 3.151 3.151 3.151 3.151 3.152 3.152 3.152 3.152 3.152 3.152 3.153 3.153 3.153 3.153 3.153 3.153 3.154 3.154 3.154 3.154 3.154 3.154 3.155 3.155 3.155 3.155 3.155 3.155 3.156 3.156 3.156 3.156 3.156 3.156 3.157 3.157 3.157 3.157 3.157 3.157 3.158 3.158 3.158 3.158 3.158 3.158 3.159 3.159 3.159 3.159 3.159 3.159 3.160 3.160 3.160 3.160 3.160 3.160 3.161 3.161 3.161 3.161 3.161 3.161 3.162 3.162 3.162 3.162 3.162 3.162 3.163 3.163 3.163 3.163 3.163 3.163 3.164 3.164 3.164 3.164 3.164 3.164 3.165 3.165 3.165 3.165 3.165 3.165 3.166 3.166 3.166 3.166 3.166 3.166 3.167 3",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -384,7 +436,7 @@
"raw_response_path": "sample_00025/raw_response.md",
"source_image_path": "sample_00025/source.png",
"document_with_boxes_path": "sample_00025/document_with_boxes.png",
- "document_markdown_text": "5B-10\n\n| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
",
+ "document_markdown_text": "2015 ASC 715 report) valuation report) \n\nService Cost (cost of benefits earned) \n\nExpense/Minimum Required Contribution \n\nProjected Benefit Obligation (PBO) \n\nAccumulated Benefit Obligation (ABO)/Funding Target \n\nAssets \n\nBalance Sheet Liability \n\nAOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment) \n\nCash into Plan \n\nCash out of Plan \n\nLiability by Group: \n\nActives \n\nRetired \n\nTerminated Vested \n\nTotal \n\nPBGC Premiums \n\nDemographics: \n\nActives \n\nRetired \n\nTerminated Vested \n\nTotal \n\nDiscount Rate/Effective Rate \n\nAccounting (based on June 30, 2015 ASC 715 report) \n\nN/A - plan frozen \n\n\\(\\)63,881\\$ \n\n\\(\\)15,498,295\\$ \n\n\\(\\)15,498,295\\$ \n\n\\(\\)11,888,246\\$ \n\n\\(\\)3,610,049\\$ \n\n\\(\\)7,690,218\\$ \n\n\\(\\)548,000 (cash basis) \n\n\\(\\)628,690+$99,236 (expenses) \n\n\\(\\)4,326,586\\$ \n\n6,791,034 \n\n4,380,675 \n\n\\(\\)15,498,295\\$ \n\n152 \n\n472 \n\n4.30% (BOY)/4.25% (EOY) \n\nFunding (based on July 1, 2015 \n\nvaluation report) \n\n\\(\\)0\\$ \n\nN/A \n\nN/A \n\n\\(\\)321,000 (accrual basis) \n\n\\(\\)628,690+$99,236 (expenses) \n\n\\(\\)3,046,932\\$ \n\n5,791,017 \n\n3,038,118 \n\n\\(\\)11,876,067\\$ \n\n152 \n\n472 \n\n6.28%",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -396,7 +448,7 @@
"raw_response_path": "sample_00026/raw_response.md",
"source_image_path": "sample_00026/source.png",
"document_with_boxes_path": "sample_00026/document_with_boxes.png",
- "document_markdown_text": "1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: \n\n## Friday \n\nCourse preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting. \n\n## Saturday \n\nCourse preparation. Course review and practice by participants. Women's race - race start time to be determined.\\* Men's race - race start time to be determined.\\* Post- competition recognition ceremony. \n\n\\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.",
+ "document_markdown_text": "1. Course preparation. 2. Course walk-through with NCAA site representative. 3. Course review and practice by participants. 4. Packet pick-up. 5. Mandatory coaches meeting. \n\n## Friday \n\nCourse preparation. Course walk-through with NCAA site representative. Course review and practice by participants. Packet pick-up. Mandatory coaches meeting. \n\n## Saturday \n\nCourse preparation. Course review and practice by participants. Women's race - race start time to be determined.* Men's race - race start time to be determined.* Post-competition recognition ceremony. \n\n*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -418,9 +470,9 @@
"image_path": "sample_00027/figures/sample_00027_fig01.png",
"document_relative_path": "figures/sample_00027_fig01.png",
"bounding_box_pixels": {
- "x1": 209,
- "y1": 348,
- "x2": 1448,
+ "x1": 211,
+ "y1": 347,
+ "x2": 1443,
"y2": 998
},
"description": ""
@@ -434,7 +486,7 @@
"raw_response_path": "sample_00028/raw_response.md",
"source_image_path": "sample_00028/source.png",
"document_with_boxes_path": "sample_00028/document_with_boxes.png",
- "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.",
+ "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\nYES NO NO with Exception \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -446,7 +498,7 @@
"raw_response_path": "sample_00029/raw_response.md",
"source_image_path": "sample_00029/source.png",
"document_with_boxes_path": "sample_00029/document_with_boxes.png",
- "document_markdown_text": "5B-15",
+ "document_markdown_text": "0.00(continued)Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases \n\n# Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program \n\n- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -458,7 +510,7 @@
"raw_response_path": "sample_00030/raw_response.md",
"source_image_path": "sample_00030/source.png",
"document_with_boxes_path": "sample_00030/document_with_boxes.png",
- "document_markdown_text": "145 (Fig. 6B), which over-express EGFR (Fig. 6C). \n\n\n \n\n| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
\n\nPrinciples of Organizations and Communities\n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
+| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14° F - 113° F (-10° C - 45° C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50° C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical - input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
+
+## AQUAVAR® IPC VARIABLE SPEED CONTROLLER
## FEATURES
-- Easier start-up and programming with Start-Up Genie
-- Wide range of standard and permanent magnet motors with power up to 600 hp
-- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)
-- Remote commissioning and monitoring with USB connectivity and software
-- Two wire multi-pump connection for faster installation
-- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation
-- System redundancy with multi-master control in case of drive failure
-- BACnet and Modbus as a standard for seamless BMS integration
-- Submersible and above ground applications
-- Wide range of voltage and enclosure options
-- True 208 V coverage
-- Dedicated single phase input
-- Remote commissioning and monitoring with USB connectivity and software
-- In-panel or handheld keypad with backlit display
-- Alarm Log for last 5 alarms and maintenance events
-- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference
+- Easier start-up and programming with Start-Up Genie
+
+- Wide range of standard and permanent magnet motors with power up to 600 hp
+
+- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)
+
+- Remote commissioning and monitoring with USB connectivity and software
+
+- Two wire multi-pump connection for faster installation
+
+- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation
+
+- System redundancy with multi-master control in case of drive failure
+
+- BACnet and Modbus as a standard for seamless BMS integration
+
+- Submersible and above ground applications
+
+- Wide range of voltage and enclosure options
+
+- True 208 V coverage
+
+- Dedicated single phase input
+
+- Remote commissioning and monitoring with USB connectivity and software
+
+- In-panel or handheld keypad with backlit display
+
+- Alarm Log for last 5 alarms and maintenance events
+
+- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference
+
- I/O expansion cards, factory installed or field configured
\ No newline at end of file
diff --git a/stage1/sample_00003/document_with_boxes.png b/stage1/sample_00003/document_with_boxes.png
index 0260fe7ed6c79f91b0926667b8ac06add8cf01a9..d77621d016668781a94847ad883b6cb291b0c11a 100644
--- a/stage1/sample_00003/document_with_boxes.png
+++ b/stage1/sample_00003/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:bdef21419bf5a9c22e68912f9a6917521b82edca235efbaf663b542e5b8a1832
-size 628816
+oid sha256:9250a3d640ff2f3f8031b4763cb061781e3b7ea90ca883e647af54ee8fe4dd8e
+size 630964
diff --git a/stage1/sample_00003/figures/sample_00003_fig01.png b/stage1/sample_00003/figures/sample_00003_fig01.png
index 919b4cda20e5da4daa67a3f36754721d4804c60d..f7ec8dc89e3499f7944cc75484e2024aa9c8d52d 100644
--- a/stage1/sample_00003/figures/sample_00003_fig01.png
+++ b/stage1/sample_00003/figures/sample_00003_fig01.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:7f77821cba3b88bcc9f4ebe560dc431e59a7f434d5fb1810e7df9356754b4103
-size 184551
+oid sha256:90d1efb926e8a272e10a44cb11508c5c090fa6f58b543a66cca4bf2647909f79
+size 184877
diff --git a/stage1/sample_00003/raw_response.md b/stage1/sample_00003/raw_response.md
index 962fedce5f9a97203dea91c1efb54b59c9a5022f..7f2996dab9ded14be6d7dd8a057adf863f006b9e 100644
--- a/stage1/sample_00003/raw_response.md
+++ b/stage1/sample_00003/raw_response.md
@@ -1,32 +1,67 @@
-0 to 70% (vs. fixed speed) while reducing installation time.
+To build and operate an efficient water system, you need both the right products and experts who know the application. Aquavar® IPC and Hydrovar® controllers have been designed by Xylem's engineers with these things in mind. The Aquavar® IPC or Hydrovar® variable speed controller provide built in pump protection controls and monitoring to help you optimize pump operations and increase energy savings up to 70% (vs. fixed speed) while reducing installation time.
-<|ref|>title<|/ref|><|det|>[[512, 309, 750, 385]]<|/det|>
-# AQUAVAR® IPC VARIABLE SPEED CONTROLLER
+<|ref|>image<|/ref|><|det|>[[54, 237, 405, 516]]<|/det|>
+
-<|ref|>sub_title<|/ref|><|det|>[[55, 528, 198, 542]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[57, 527, 202, 542]]<|/det|>
## SPECIFICATIONS
-<|ref|>table<|/ref|><|det|>[[56, 547, 486, 950]]<|/det|>
-| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
+<|ref|>table<|/ref|><|det|>[[57, 546, 488, 952]]<|/det|>
+| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14° F - 113° F (-10° C - 45° C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50° C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical - input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
-<|ref|>sub_title<|/ref|><|det|>[[512, 433, 597, 448]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[508, 307, 754, 387]]<|/det|>
+## AQUAVAR® IPC VARIABLE SPEED CONTROLLER
+
+<|ref|>sub_title<|/ref|><|det|>[[510, 432, 597, 446]]<|/det|>
## FEATURES
-<|ref|>text<|/ref|><|det|>[[512, 456, 932, 951]]<|/det|>
-- Easier start-up and programming with Start-Up Genie
-- Wide range of standard and permanent magnet motors with power up to 600 hp
-- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)
-- Remote commissioning and monitoring with USB connectivity and software
-- Two wire multi-pump connection for faster installation
-- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation
-- System redundancy with multi-master control in case of drive failure
-- BACnet and Modbus as a standard for seamless BMS integration
-- Submersible and above ground applications
-- Wide range of voltage and enclosure options
-- True 208 V coverage
-- Dedicated single phase input
-- Remote commissioning and monitoring with USB connectivity and software
-- In-panel or handheld keypad with backlit display
-- Alarm Log for last 5 alarms and maintenance events
-- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference
+<|ref|>text<|/ref|><|det|>[[510, 455, 933, 470]]<|/det|>
+- Easier start-up and programming with Start-Up Genie
+
+<|ref|>text<|/ref|><|det|>[[510, 475, 891, 506]]<|/det|>
+- Wide range of standard and permanent magnet motors with power up to 600 hp
+
+<|ref|>text<|/ref|><|det|>[[510, 511, 935, 542]]<|/det|>
+- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)
+
+<|ref|>text<|/ref|><|det|>[[510, 547, 890, 577]]<|/det|>
+- Remote commissioning and monitoring with USB connectivity and software
+
+<|ref|>text<|/ref|><|det|>[[510, 582, 930, 613]]<|/det|>
+- Two wire multi-pump connection for faster installation
+
+<|ref|>text<|/ref|><|det|>[[510, 618, 922, 648]]<|/det|>
+- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation
+
+<|ref|>text<|/ref|><|det|>[[510, 654, 942, 684]]<|/det|>
+- System redundancy with multi-master control in case of drive failure
+
+<|ref|>text<|/ref|><|det|>[[510, 690, 924, 721]]<|/det|>
+- BACnet and Modbus as a standard for seamless BMS integration
+
+<|ref|>text<|/ref|><|det|>[[510, 727, 860, 742]]<|/det|>
+- Submersible and above ground applications
+
+<|ref|>text<|/ref|><|det|>[[510, 747, 867, 763]]<|/det|>
+- Wide range of voltage and enclosure options
+
+<|ref|>text<|/ref|><|det|>[[510, 768, 684, 783]]<|/det|>
+- True 208 V coverage
+
+<|ref|>text<|/ref|><|det|>[[510, 789, 748, 805]]<|/det|>
+- Dedicated single phase input
+
+<|ref|>text<|/ref|><|det|>[[510, 810, 894, 841]]<|/det|>
+- Remote commissioning and monitoring with USB connectivity and software
+
+<|ref|>text<|/ref|><|det|>[[510, 847, 892, 862]]<|/det|>
+- In-panel or handheld keypad with backlit display
+
+<|ref|>text<|/ref|><|det|>[[510, 867, 912, 883]]<|/det|>
+- Alarm Log for last 5 alarms and maintenance events
+
+<|ref|>text<|/ref|><|det|>[[510, 888, 908, 918]]<|/det|>
+- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference
+
+<|ref|>text<|/ref|><|det|>[[510, 924, 865, 955]]<|/det|>
- I/O expansion cards, factory installed or field configured
\ No newline at end of file
diff --git a/stage1/sample_00004/document.md b/stage1/sample_00004/document.md
index 9dba446e6579175b83468a92cef9e8f9de58e179..ba6fa3054e0e43b787a6ef386af8ba14340f0e64 100644
--- a/stage1/sample_00004/document.md
+++ b/stage1/sample_00004/document.md
@@ -1,4 +1,4 @@
-2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article
+2645-9248 Journal homepage: www.jidhealth.com Open A ccess
# A case report on generalized pemphigus vulgaris treated with rituximaba
@@ -16,4 +16,6 @@ Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacc
## Background
-The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of
+
+immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
diff --git a/stage1/sample_00004/document_with_boxes.png b/stage1/sample_00004/document_with_boxes.png
index d18f7fab4c19e26775514a953df14e4818865a5d..5434164bcd885e036d36092a34d9975a712df1cc 100644
--- a/stage1/sample_00004/document_with_boxes.png
+++ b/stage1/sample_00004/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:14892c4b141d4c727969d7676d7bbbd081e6f1efb6b9cefd17870cd968a7129c
-size 574972
+oid sha256:b1261c4c89ff342f3b8da148e30e77fee9b4537ae3b5d84ffd7d306b7e5401a8
+size 581400
diff --git a/stage1/sample_00004/raw_response.md b/stage1/sample_00004/raw_response.md
index 87c38b5f371345ab624e09f19b748d1b03b65ffd..705a960eb10a336006f2f083e7a05b2322d9aeea 100644
--- a/stage1/sample_00004/raw_response.md
+++ b/stage1/sample_00004/raw_response.md
@@ -1,28 +1,31 @@
-2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article
+2645-9248 Journal homepage: www.jidhealth.com Open A ccess
-<|ref|>title<|/ref|><|det|>[[88, 215, 797, 266]]<|/det|>
+<|ref|>title<|/ref|><|det|>[[89, 215, 793, 264]]<|/det|>
# A case report on generalized pemphigus vulgaris treated with rituximaba
-<|ref|>text<|/ref|><|det|>[[89, 290, 897, 327]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[89, 291, 894, 326]]<|/det|>
J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)
<|ref|>sub_title<|/ref|><|det|>[[102, 351, 175, 364]]<|/det|>
## Abstract
-<|ref|>text<|/ref|><|det|>[[100, 366, 876, 406]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 367, 875, 404]]<|/det|>
Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris.
-<|ref|>text<|/ref|><|det|>[[100, 412, 890, 477]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 412, 887, 475]]<|/det|>
Case presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed.
-<|ref|>text<|/ref|><|det|>[[100, 486, 890, 514]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 485, 891, 512]]<|/det|>
Conclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails.
-<|ref|>text<|/ref|><|det|>[[100, 523, 814, 558]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[100, 521, 814, 556]]<|/det|>
Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India
-<|ref|>sub_title<|/ref|><|det|>[[90, 595, 193, 610]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[92, 593, 192, 607]]<|/det|>
## Background
-<|ref|>text<|/ref|><|det|>[[91, 611, 483, 834], [512, 595, 905, 902]]<|/det|>
-The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[92, 610, 483, 834]]<|/det|>
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of
+
+<|ref|>text<|/ref|><|det|>[[513, 594, 905, 903]]<|/det|>
+immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
diff --git a/stage1/sample_00005/document.md b/stage1/sample_00005/document.md
index 1328c923582f9683e6bc7dcad9aa4d521052d9b4..1c5b373d2023a8a15e95b07f748a2e2572e2bcff 100644
--- a/stage1/sample_00005/document.md
+++ b/stage1/sample_00005/document.md
@@ -2,24 +2,24 @@
Information Pertinent to Performance of the Procedure
-- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).
+- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \(\sim 1\) h for SPECT.
-Precautions and Conscious Sedation
+## Precautions and Conscious Sedation
-- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients.
+- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oxymetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients.
-Radiopharmaceutical
+## Radiopharmaceutical
-Radiopharmaceutical
+## Radiopharmaceutical
- [18F]Fluoro-2-deoxyglucose (FDG).
-- 3-\[^{123}\mathrm{I}\]Iodo-α-methyl-L-tyrosine (IMT).
-- \[ \mathrm{Methyl-}^{11}\mathrm{C} \]-L-methionine (MET).
-- \(O-(2-[^{18}\mathrm{F}]\mathrm{Fluoroethyl})-L\)-tyrosine (FET).
+- 3-\[^{123}\mathrm{I}\]Iodo-\(\alpha\) -methyl-L-tyrosine (IMT).
+- [Methyl-\(^{11}\mathrm{C}\)]-L-methionine (MET).
+- \(O-(2-[^{18}\mathrm{F}]\) Fluoroethyl)-L-tyrosine (FET).
## Recommended Dosage
-The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode.
+The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode.
- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants.
- IMT: 100-400 MBq (typically 185 MBq).
@@ -30,6 +30,6 @@ The administered dose may increase using 2D- mode and vary for other systems acc
## Radiation Dosimetry (Table 2.1)
-Radiation Dosimetry of Brain Transmission Scans
+## Radiation Dosimetry of Brain Transmission Scans
-Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \(\sim 20\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.
\ No newline at end of file
+Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 \(\mu \mathrm{Sv}\) for Germanium- based transmission, \(\sim 20 \mu \mathrm{Sv}\) for low- dose high- speed CT, and between 220 and 450 \(\mu \mathrm{Sv}\) for high- quality CT.
\ No newline at end of file
diff --git a/stage1/sample_00005/document_with_boxes.png b/stage1/sample_00005/document_with_boxes.png
index 4cf8dbd24c0bc479492e9246eb475c7721f21dbb..019ffa825fd2092a15e627a695361b6c1cf6edea 100644
--- a/stage1/sample_00005/document_with_boxes.png
+++ b/stage1/sample_00005/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:e85e5cdb4538683931f00a448e29262a5027536e2913c6c853665c8224d7552a
-size 522490
+oid sha256:1208246518a0299a32be63409fb2a6784dcbd063d4e041c5b9f83624bfd38414
+size 523348
diff --git a/stage1/sample_00005/raw_response.md b/stage1/sample_00005/raw_response.md
index fce38ecb1d99336969230556fd1096272245a16b..5aa98e8fd3fed048e708d50d4f4d6b411c324d30 100644
--- a/stage1/sample_00005/raw_response.md
+++ b/stage1/sample_00005/raw_response.md
@@ -1,49 +1,49 @@
1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine.
-<|ref|>text<|/ref|><|det|>[[115, 181, 448, 217]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[115, 181, 450, 216]]<|/det|>
Information Pertinent to Performance of the Procedure
-<|ref|>text<|/ref|><|det|>[[113, 227, 492, 473]]<|/det|>
-- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).
+<|ref|>text<|/ref|><|det|>[[113, 225, 491, 477]]<|/det|>
+- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \(\sim 1\) h for SPECT.
-<|ref|>text<|/ref|><|det|>[[115, 483, 438, 499]]<|/det|>
-Precautions and Conscious Sedation
+<|ref|>sub_title<|/ref|><|det|>[[115, 499, 439, 516]]<|/det|>
+## Precautions and Conscious Sedation
-<|ref|>text<|/ref|><|det|>[[113, 528, 492, 899]]<|/det|>
-- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients.
+<|ref|>text<|/ref|><|det|>[[113, 526, 491, 902]]<|/det|>
+- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oxymetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients.
-<|ref|>text<|/ref|><|det|>[[511, 82, 701, 99]]<|/det|>
-Radiopharmaceutical
+<|ref|>sub_title<|/ref|><|det|>[[511, 82, 699, 100]]<|/det|>
+## Radiopharmaceutical
-<|ref|>text<|/ref|><|det|>[[511, 111, 689, 126]]<|/det|>
-Radiopharmaceutical
+<|ref|>sub_title<|/ref|><|det|>[[512, 110, 688, 127]]<|/det|>
+## Radiopharmaceutical
-<|ref|>text<|/ref|><|det|>[[511, 137, 886, 227]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 136, 886, 229]]<|/det|>
- [18F]Fluoro-2-deoxyglucose (FDG).
-- 3-\[^{123}\mathrm{I}\]Iodo-α-methyl-L-tyrosine (IMT).
-- \[ \mathrm{Methyl-}^{11}\mathrm{C} \]-L-methionine (MET).
-- \(O-(2-[^{18}\mathrm{F}]\mathrm{Fluoroethyl})-L\)-tyrosine (FET).
+- 3-\[^{123}\mathrm{I}\]Iodo-\(\alpha\) -methyl-L-tyrosine (IMT).
+- [Methyl-\(^{11}\mathrm{C}\)]-L-methionine (MET).
+- \(O-(2-[^{18}\mathrm{F}]\) Fluoroethyl)-L-tyrosine (FET).
-<|ref|>sub_title<|/ref|><|det|>[[511, 259, 696, 276]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[512, 259, 695, 276]]<|/det|>
## Recommended Dosage
-<|ref|>text<|/ref|><|det|>[[510, 286, 886, 362]]<|/det|>
-The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode.
+<|ref|>text<|/ref|><|det|>[[510, 286, 887, 358]]<|/det|>
+The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode.
-<|ref|>text<|/ref|><|det|>[[510, 364, 886, 507]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 361, 887, 507]]<|/det|>
- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants.
- IMT: 100-400 MBq (typically 185 MBq).
- MET: 200-250 MBq.
- FET: 200-250 MBq.
-<|ref|>text<|/ref|><|det|>[[510, 521, 886, 691]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 520, 886, 692]]<|/det|>
The administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group.
-<|ref|>sub_title<|/ref|><|det|>[[511, 722, 775, 739]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[512, 721, 776, 738]]<|/det|>
## Radiation Dosimetry (Table 2.1)
-<|ref|>text<|/ref|><|det|>[[510, 749, 866, 783]]<|/det|>
-Radiation Dosimetry of Brain Transmission Scans
+<|ref|>sub_title<|/ref|><|det|>[[512, 748, 866, 782]]<|/det|>
+## Radiation Dosimetry of Brain Transmission Scans
-<|ref|>text<|/ref|><|det|>[[510, 793, 886, 903]]<|/det|>
-Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \(\sim 20\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[510, 792, 886, 903]]<|/det|>
+Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 \(\mu \mathrm{Sv}\) for Germanium- based transmission, \(\sim 20 \mu \mathrm{Sv}\) for low- dose high- speed CT, and between 220 and 450 \(\mu \mathrm{Sv}\) for high- quality CT.
\ No newline at end of file
diff --git a/stage1/sample_00006/document.md b/stage1/sample_00006/document.md
index fdaa937754f00a26c1606f8cdd76e1a699a42acc..282f76fda0650af5a8e6ae9892c1c872bcceb1ba 100644
--- a/stage1/sample_00006/document.md
+++ b/stage1/sample_00006/document.md
@@ -1 +1 @@
-1) (X) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 2) 1) 1) 1) 1) 1) 1) 1) 1) 1) 3) 1) 1) 1) 1) 1) 1) 1) 1) 1) 4) 1) 1) 1) 1) 1) 1) 1) 1) 1) 5) 1) 1) 1) 1) 1) 1) 1) 1) 6) 1) 1) 1) 1) 1) 1) 1) 1) 1) 7) 1) 1) 1) 1) 1) 1) 1) 1) 1) 8) 1) 1) 1) 1) 1) 1) 1) 1) 1) 9) 1) 1) 1) 1) 1) 1) 1) 1) 1) 10) 1) 1) 1) 1) 1) 1) 1) 1) 1) 11) 1) 1) 1) 1) 1) 1) 1) 1) 1) 12) 1) 1) 1) 1) 1) 1) 1) 1) 1) 13) 1) 1) 1) 1) 1) 1) 1) 1) 1) 14) 1) 1) 1) 1) 1) 1) 1) 1) 1) 15) 1) 1) 1) 1) 1) 1) 1) 1) 1) 16) 1) 1) 1) 1) 1) 1) 1) 1) 1) 17) 1) 1) 1) 1) 1) 1) 1) 1) 1) 18) 1) 1) 1) 1) 1) 1) 1) 1) 1) 19) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 20) 1) 1) 1) 1) 1) 1) 1) 1) 1) 21) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 22) 1) 1) 1) 1) 1) 1) 1) 1) 1) 23) 1) 1) 1) 1) 1) 1) 1) 1) 1) 24) 1) 1) 1) 1) 1) 1) 1) 1) 1) 25) 1) 1) 1) 1) 1) 1) 1) 1) 1) 26) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 27) 1) 1) 1) 1) 1) 1) 1) 1) 1) 28) 1) 1) 1) 1) 1) 1) 1) 1) 1) 29) 1) 1) 1) 1) 1) 1) 1) 1) 30) 1) 1) 1) 1) 1) 1) 1) 1) 1) 31) 1) 1) 1) 1) 1) 1) 1) 1) 1) 32) 1) 1) 1) 1) 1) 1) 1) 1) 1) 33) 1) 1) 1) 1) 1) 1) 1) 1) 1) 34) 1) 1) 1) 1) 1) 1) 1) 1) 1) 35) 1) 1) 1) 1) 1) 1) 1) 1) 1) 36) 1) 1) 1) 1) 1) 1) 1) 1) 1) 37) 1) 1) 1) 1) 1) 1) 1) 1) 1) 38) 1) 1) 1) 1) 1) 1) 1) 1) 1) 39) 1) 1) 1) 1) 1) 1) 1) 1) 1) 40) 1) 1) 1) 1) 1) 1) 1) 1) 1) 41) 1) 1) 1) 1) 1) 1) 1) 1) 1) 42) 1) 1) 1) 1) 1) 1) 1) 1) 1) 43) 1) 1) 1) 1) 1) 1) 1) 1) 1) 44) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 45) 1) 1) 1) 1) 1) 1) 1) 1) 1) 46) 1) 1) 1) 1) 1) 1) 1) 1) 1) 47) 1) 1) 1) 1) 1) 1) 1) 1) 1) 48) 1) 1) 1) 1) 1) 1) 1) 1) 1) 49) 1) 1) 1) 1) 1) 1) 1) 1) 1) 50) 1) 1) 1) 1) 1) 1) 1) 1) 1) 51) 1) 1) 1) 1) 1) 1) 1) 1) 1) 52) 1) 1) 1) 1) 1) 1) 1) 1) 1) 53) 1) 1) 1) 1) 1) 1) 1) 1) 1) 54) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 55) 1) 1) 1) 1) 1) 1) 1) 1) 1) 56) 1) 1) 1) 1) 1) 1) 1) 1) 1) 57) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 58) 1) 1) 1) 1) 1) 1) 1) 1) 1) 59) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 60) 1) 1) 1) 1) 1) 1) 1) 1) 1) 61) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 62) 1) 1) 1) 1) 1) 1) 1) 1) 1) 63) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 64) 1) 1) 1) 1) 1) 1) 1) 1) 1) 65) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 66) 1) 1) 1) 1) 1) 1) 1) 1) 1) 67) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 68) 1) 1) 1) 1) 1) 1) 1) 1) 1) 69) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 70) 1) 1) 1) 1) 1) 1) 1) 1) 1) 71) 1) 1) 1) 1) 1) 1) 1) 1) 1) 72) 1) 1) 1) 1) 1) 1) 1) 1) 1) 73) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 74) 1) 1) 1) 1) 1) 1) 1) 1) 1) 75) 1) 1) 1) 1) 1) 1) 1) 1) 1) 76) 1) 1) 1) 1) 1) 1) 1) 1) 1) 77) 1) 1) 1) 1) 1) 1) 1) 1) 1) 78) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 79) 1) 1) 1) 1) 1) 1) 1) 1) 1) 80) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 81) 1) 1) 1) 1) 1) 1) 1) 1) 1) 82) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 83) 1) 1) 1) 1) 1) 1) 1) 1) 1) 84) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 85) 1) 1) 1) 1) 1) 1) 1) 1) 1) 86) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 87) 1) 1) 1) 1) 1) 1) 1) 1) 1) 88) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 89) 1) 1) 1) 1) 1) 1) 1) 1) 1) 90) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 91) 1) 1) 1) 1) 1) 1) 1) 1) 92) 1) 1) 1) 1) 1) 1) 1) 1) 1) 93) 1) 1) 1) 1) 1) 1) 1) 1) 1) 94) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 95) 1) 1) 1) 1) 1) 1) 1) 1) 1) 96) 1) 1) 1) 1) 1) 1) 1) 1) 1) 97) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 98) 1) 1) 1) 1) 1) 1) 1) 1) 1) 99) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 100) 1) 1) 1) 1) 1) 1) 1) 1) 1) 101) 1) 1) 1) 1) 1) 1) 1) 1) 1) 102) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 103) 1) 1) 1) 1) 1) 1) 1) 1) 1) 104) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 105) 1) 1) 1) 1) 1) 1) 1) 1) 1) 106) 1) 1) 1) 1) 1) 1) 1) 1) 1) 107) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 108) 1) 1) 1) 1) 1) 1) 1) 1) 1) 109) 1) 1) 1) 1) 1) 1) 1) 1) 1) 110) 1) 1) 1) 1) 1) 1) 1) 1) 1) 111) 1) 1) 1) 1) 1) 1) 1) 1) 1) 112) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 113) 1) 1) 1) 1) 1) 1) 1) 1) 1) 114) 1) 1) 1) 1) 1) 1) 1) 1) 115) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 116) 1) 1) 1) 1) 1) 1) 1) 1) 1) 117) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 118) 1) 1) 1) 1) 1) 1) 1) 1) 1) 119) 1) 1) 1) 1) 1) 1) 1) 1) 120) 1) 1) 1) 1) 1) 1) 1) 1) 1) 121) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 122) 1) 1) 1) 1) 1) 1) 1) 1) 1) 123) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 124) 1) 1) 1) 1) 1) 1) 1) 1) 1) 125) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 126) 1) 1) 1) 1) 1) 1) 1) 1) 1) 127) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 128) 1) 1) 1) 1) 1) 1) 1) 1) 1) 129) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 130) 1) 1) 1) 1) 1) 1) 1) 1) 1) 131) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 132) 1) 1) 1) 1) 1) 1) 1) 1) 1) 133) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 134) 1) 1
\ No newline at end of file
+1) (X) 1) (X) 1) (X) 1) (X) 1) (X) 1) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y
\ No newline at end of file
diff --git a/stage1/sample_00006/raw_response.md b/stage1/sample_00006/raw_response.md
index fdaa937754f00a26c1606f8cdd76e1a699a42acc..282f76fda0650af5a8e6ae9892c1c872bcceb1ba 100644
--- a/stage1/sample_00006/raw_response.md
+++ b/stage1/sample_00006/raw_response.md
@@ -1 +1 @@
-1) (X) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 2) 1) 1) 1) 1) 1) 1) 1) 1) 1) 3) 1) 1) 1) 1) 1) 1) 1) 1) 1) 4) 1) 1) 1) 1) 1) 1) 1) 1) 1) 5) 1) 1) 1) 1) 1) 1) 1) 1) 6) 1) 1) 1) 1) 1) 1) 1) 1) 1) 7) 1) 1) 1) 1) 1) 1) 1) 1) 1) 8) 1) 1) 1) 1) 1) 1) 1) 1) 1) 9) 1) 1) 1) 1) 1) 1) 1) 1) 1) 10) 1) 1) 1) 1) 1) 1) 1) 1) 1) 11) 1) 1) 1) 1) 1) 1) 1) 1) 1) 12) 1) 1) 1) 1) 1) 1) 1) 1) 1) 13) 1) 1) 1) 1) 1) 1) 1) 1) 1) 14) 1) 1) 1) 1) 1) 1) 1) 1) 1) 15) 1) 1) 1) 1) 1) 1) 1) 1) 1) 16) 1) 1) 1) 1) 1) 1) 1) 1) 1) 17) 1) 1) 1) 1) 1) 1) 1) 1) 1) 18) 1) 1) 1) 1) 1) 1) 1) 1) 1) 19) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 20) 1) 1) 1) 1) 1) 1) 1) 1) 1) 21) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 22) 1) 1) 1) 1) 1) 1) 1) 1) 1) 23) 1) 1) 1) 1) 1) 1) 1) 1) 1) 24) 1) 1) 1) 1) 1) 1) 1) 1) 1) 25) 1) 1) 1) 1) 1) 1) 1) 1) 1) 26) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 27) 1) 1) 1) 1) 1) 1) 1) 1) 1) 28) 1) 1) 1) 1) 1) 1) 1) 1) 1) 29) 1) 1) 1) 1) 1) 1) 1) 1) 30) 1) 1) 1) 1) 1) 1) 1) 1) 1) 31) 1) 1) 1) 1) 1) 1) 1) 1) 1) 32) 1) 1) 1) 1) 1) 1) 1) 1) 1) 33) 1) 1) 1) 1) 1) 1) 1) 1) 1) 34) 1) 1) 1) 1) 1) 1) 1) 1) 1) 35) 1) 1) 1) 1) 1) 1) 1) 1) 1) 36) 1) 1) 1) 1) 1) 1) 1) 1) 1) 37) 1) 1) 1) 1) 1) 1) 1) 1) 1) 38) 1) 1) 1) 1) 1) 1) 1) 1) 1) 39) 1) 1) 1) 1) 1) 1) 1) 1) 1) 40) 1) 1) 1) 1) 1) 1) 1) 1) 1) 41) 1) 1) 1) 1) 1) 1) 1) 1) 1) 42) 1) 1) 1) 1) 1) 1) 1) 1) 1) 43) 1) 1) 1) 1) 1) 1) 1) 1) 1) 44) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 45) 1) 1) 1) 1) 1) 1) 1) 1) 1) 46) 1) 1) 1) 1) 1) 1) 1) 1) 1) 47) 1) 1) 1) 1) 1) 1) 1) 1) 1) 48) 1) 1) 1) 1) 1) 1) 1) 1) 1) 49) 1) 1) 1) 1) 1) 1) 1) 1) 1) 50) 1) 1) 1) 1) 1) 1) 1) 1) 1) 51) 1) 1) 1) 1) 1) 1) 1) 1) 1) 52) 1) 1) 1) 1) 1) 1) 1) 1) 1) 53) 1) 1) 1) 1) 1) 1) 1) 1) 1) 54) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 55) 1) 1) 1) 1) 1) 1) 1) 1) 1) 56) 1) 1) 1) 1) 1) 1) 1) 1) 1) 57) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 58) 1) 1) 1) 1) 1) 1) 1) 1) 1) 59) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 60) 1) 1) 1) 1) 1) 1) 1) 1) 1) 61) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 62) 1) 1) 1) 1) 1) 1) 1) 1) 1) 63) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 64) 1) 1) 1) 1) 1) 1) 1) 1) 1) 65) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 66) 1) 1) 1) 1) 1) 1) 1) 1) 1) 67) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 68) 1) 1) 1) 1) 1) 1) 1) 1) 1) 69) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 70) 1) 1) 1) 1) 1) 1) 1) 1) 1) 71) 1) 1) 1) 1) 1) 1) 1) 1) 1) 72) 1) 1) 1) 1) 1) 1) 1) 1) 1) 73) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 74) 1) 1) 1) 1) 1) 1) 1) 1) 1) 75) 1) 1) 1) 1) 1) 1) 1) 1) 1) 76) 1) 1) 1) 1) 1) 1) 1) 1) 1) 77) 1) 1) 1) 1) 1) 1) 1) 1) 1) 78) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 79) 1) 1) 1) 1) 1) 1) 1) 1) 1) 80) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 81) 1) 1) 1) 1) 1) 1) 1) 1) 1) 82) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 83) 1) 1) 1) 1) 1) 1) 1) 1) 1) 84) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 85) 1) 1) 1) 1) 1) 1) 1) 1) 1) 86) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 87) 1) 1) 1) 1) 1) 1) 1) 1) 1) 88) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 89) 1) 1) 1) 1) 1) 1) 1) 1) 1) 90) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 91) 1) 1) 1) 1) 1) 1) 1) 1) 92) 1) 1) 1) 1) 1) 1) 1) 1) 1) 93) 1) 1) 1) 1) 1) 1) 1) 1) 1) 94) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 95) 1) 1) 1) 1) 1) 1) 1) 1) 1) 96) 1) 1) 1) 1) 1) 1) 1) 1) 1) 97) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 98) 1) 1) 1) 1) 1) 1) 1) 1) 1) 99) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 100) 1) 1) 1) 1) 1) 1) 1) 1) 1) 101) 1) 1) 1) 1) 1) 1) 1) 1) 1) 102) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 103) 1) 1) 1) 1) 1) 1) 1) 1) 1) 104) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 105) 1) 1) 1) 1) 1) 1) 1) 1) 1) 106) 1) 1) 1) 1) 1) 1) 1) 1) 1) 107) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 108) 1) 1) 1) 1) 1) 1) 1) 1) 1) 109) 1) 1) 1) 1) 1) 1) 1) 1) 1) 110) 1) 1) 1) 1) 1) 1) 1) 1) 1) 111) 1) 1) 1) 1) 1) 1) 1) 1) 1) 112) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 113) 1) 1) 1) 1) 1) 1) 1) 1) 1) 114) 1) 1) 1) 1) 1) 1) 1) 1) 115) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 116) 1) 1) 1) 1) 1) 1) 1) 1) 1) 117) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 118) 1) 1) 1) 1) 1) 1) 1) 1) 1) 119) 1) 1) 1) 1) 1) 1) 1) 1) 120) 1) 1) 1) 1) 1) 1) 1) 1) 1) 121) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 122) 1) 1) 1) 1) 1) 1) 1) 1) 1) 123) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 124) 1) 1) 1) 1) 1) 1) 1) 1) 1) 125) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 126) 1) 1) 1) 1) 1) 1) 1) 1) 1) 127) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 128) 1) 1) 1) 1) 1) 1) 1) 1) 1) 129) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 130) 1) 1) 1) 1) 1) 1) 1) 1) 1) 131) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 132) 1) 1) 1) 1) 1) 1) 1) 1) 1) 133) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 134) 1) 1
\ No newline at end of file
+1) (X) 1) (X) 1) (X) 1) (X) 1) (X) 1) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y) (X) (X) (X) (X) (X) (X) (X) (X) (X) (N) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (Y
\ No newline at end of file
diff --git a/stage1/sample_00007/document.md b/stage1/sample_00007/document.md
index 0fda634d326460188addec56cdae51ffe71c3cf1..c278d1c8372cb531a6cc6df78c8f6c6f3aafec99 100644
--- a/stage1/sample_00007/document.md
+++ b/stage1/sample_00007/document.md
@@ -1 +1 @@
-2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8
\ No newline at end of file
+2011, XLVl, 394 p., Hardcover ISBN: 978-90-481-8664-8
\ No newline at end of file
diff --git a/stage1/sample_00007/raw_response.md b/stage1/sample_00007/raw_response.md
index 0fda634d326460188addec56cdae51ffe71c3cf1..c278d1c8372cb531a6cc6df78c8f6c6f3aafec99 100644
--- a/stage1/sample_00007/raw_response.md
+++ b/stage1/sample_00007/raw_response.md
@@ -1 +1 @@
-2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8
\ No newline at end of file
+2011, XLVl, 394 p., Hardcover ISBN: 978-90-481-8664-8
\ No newline at end of file
diff --git a/stage1/sample_00008/document.md b/stage1/sample_00008/document.md
index 9475e32f84528b684236b3977749eb4de949df66..b355153d8f62894a331a354ec2f2b0f807a9a1f4 100644
--- a/stage1/sample_00008/document.md
+++ b/stage1/sample_00008/document.md
@@ -1,8 +1,8 @@
The parametric equations for a projectile with constant gravity g:
-\[x = v_0 t \cos \theta + x_0\]
+\[ x = v_0 t \cos \theta + x_0 \]
-\[y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0\]
+\[ y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0 \]
ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find:
diff --git a/stage1/sample_00008/document_with_boxes.png b/stage1/sample_00008/document_with_boxes.png
index 97e7dd70ecba848249fdf79a8283c75270ca0e6e..16e7abfcd2d4053fc90b56dcc3251bee83847644 100644
--- a/stage1/sample_00008/document_with_boxes.png
+++ b/stage1/sample_00008/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:c1dd077c528bd841721a677c89ac0862640a5099441f03d93e991be0ed045823
-size 114076
+oid sha256:3aa2125192609bb14bb441a9f4ccef2d5a5ac9caf9d127629d9eb9d8cd99ad25
+size 114497
diff --git a/stage1/sample_00008/raw_response.md b/stage1/sample_00008/raw_response.md
index 78c54d3c1ea8e032575ec8eb47f8c0aab3e5432f..0a480feb6c55ec5d380b6c46d447f29a5d51d48c 100644
--- a/stage1/sample_00008/raw_response.md
+++ b/stage1/sample_00008/raw_response.md
@@ -1,26 +1,26 @@
-<|ref|>text<|/ref|><|det|>[[89, 80, 860, 107]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[90, 80, 861, 106]]<|/det|>
The parametric equations for a projectile with constant gravity g:
-<|ref|>equation<|/ref|><|det|>[[153, 108, 426, 140]]<|/det|>
-\[x = v_0 t \cos \theta + x_0\]
+<|ref|>equation<|/ref|><|det|>[[151, 108, 426, 145]]<|/det|>
+\[ x = v_0 t \cos \theta + x_0 \]
-<|ref|>equation<|/ref|><|det|>[[153, 154, 566, 227]]<|/det|>
-\[y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0\]
+<|ref|>equation<|/ref|><|det|>[[151, 155, 566, 227]]<|/det|>
+\[ y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0 \]
-<|ref|>text<|/ref|><|det|>[[89, 257, 868, 308]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[90, 255, 868, 308]]<|/det|>
ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find:
-<|ref|>text<|/ref|><|det|>[[92, 307, 183, 349]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[91, 310, 183, 352]]<|/det|>
1. \(\vec{r}(t)\)
-<|ref|>text<|/ref|><|det|>[[91, 357, 483, 381]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[91, 356, 485, 381]]<|/det|>
2. the maximum altitude attained
-<|ref|>text<|/ref|><|det|>[[91, 383, 372, 407]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[91, 384, 372, 408]]<|/det|>
3. the range of the shell
-<|ref|>text<|/ref|><|det|>[[91, 410, 361, 433]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[91, 410, 361, 434]]<|/det|>
4. the speed on impact
-<|ref|>text<|/ref|><|det|>[[91, 436, 607, 461]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[91, 437, 607, 462]]<|/det|>
5. the horizontal distance when \(y = 2240\) ft.
\ No newline at end of file
diff --git a/stage1/sample_00009/document.md b/stage1/sample_00009/document.md
index 5a255d87d39f706a0257a17219bd51f0abad8001..d8d95567f05aafb0c34715ef608239053cbd7526 100644
--- a/stage1/sample_00009/document.md
+++ b/stage1/sample_00009/document.md
@@ -1,18 +1,15 @@
-purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at 140 kV, which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is <10 s). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction.
+2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection.
-- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15–30 min aiming to collect 50–200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection.
+purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \(140\mathrm{kV}\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \(< 10\mathrm{~s}\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction.
-## IMT Single Photon Emission Tomography
+Emission scan. As semiquantitative estimates of tumor- to- background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3- D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15- 30 min aiming to collect 50- 200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection.
-- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images.
+## IMT Single Photon Emission Tomography
-- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\mathrm{I}\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2.
+- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images.
-TABLE 2.2. Acquisition parameters for IMT-SPECT
+- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\mathrm{I}\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2.
-- Rotational radius: smallest possible with appropriate patient safeguard
-- Matrix: \(128 \times 128\)
-- Angular sampling: \(\leq 3^\circ\) (360° rotation)
-- Zoom: acquisition pixel size should be \(1/3-1/2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size
-- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort
-- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30–50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)
\ No newline at end of file
+# TABLE 2.2. Acquisition parameters for IMT-SPECT
+
+- Rotational radius: smallest possible with appropriate patient safeguard- Matrix: \(128 \times 128\) - Angular sampling: \(\leq 3^{\circ}\) (360° rotation)- Zoom: acquisition pixel size should be \(1 / 3 - 1 / 2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30-50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)
\ No newline at end of file
diff --git a/stage1/sample_00009/document_with_boxes.png b/stage1/sample_00009/document_with_boxes.png
index 7dfd8234a3c4d378350b38138a22fb09a8c0e749..9c6350893f5192b04632d3e56a416368e801ba5b 100644
--- a/stage1/sample_00009/document_with_boxes.png
+++ b/stage1/sample_00009/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:7217f2e7b907eb33ee7d3541a3d08b6fd965b4d6e8d13a8260dc321b04346449
-size 573017
+oid sha256:e687bbedc61e25c3fae1bb705801750c50fd0c620f9bcbc5dfb804393328af32
+size 576408
diff --git a/stage1/sample_00009/raw_response.md b/stage1/sample_00009/raw_response.md
index fa352adc80de9d670115229420fe05d05094b258..4dceb1acdd720b8fd115d0810d756ed9c761f5ce 100644
--- a/stage1/sample_00009/raw_response.md
+++ b/stage1/sample_00009/raw_response.md
@@ -1,25 +1,22 @@
-<|ref|>text<|/ref|><|det|>[[135, 87, 492, 441]]<|/det|>
-purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at 140 kV, which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is <10 s). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction.
+2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection.
-<|ref|>text<|/ref|><|det|>[[115, 444, 492, 896]]<|/det|>
-- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15–30 min aiming to collect 50–200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection.
+<|ref|>text<|/ref|><|det|>[[122, 86, 494, 440]]<|/det|>
+purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \(140\mathrm{kV}\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \(< 10\mathrm{~s}\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction.
-<|ref|>sub_title<|/ref|><|det|>[[511, 82, 826, 98]]<|/det|>
-## IMT Single Photon Emission Tomography
+<|ref|>text<|/ref|><|det|>[[116, 444, 492, 896]]<|/det|>
+Emission scan. As semiquantitative estimates of tumor- to- background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3- D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15- 30 min aiming to collect 50- 200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection.
-<|ref|>text<|/ref|><|det|>[[511, 107, 886, 299]]<|/det|>
-- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images.
+<|ref|>sub_title<|/ref|><|det|>[[510, 81, 825, 98]]<|/det|>
+## IMT Single Photon Emission Tomography
-<|ref|>text<|/ref|><|det|>[[511, 300, 887, 619]]<|/det|>
-- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\mathrm{I}\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2.
+<|ref|>text<|/ref|><|det|>[[510, 109, 885, 299]]<|/det|>
+- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images.
-<|ref|>table_caption<|/ref|><|det|>[[511, 686, 854, 701]]<|/det|>
-TABLE 2.2. Acquisition parameters for IMT-SPECT
+<|ref|>text<|/ref|><|det|>[[510, 300, 885, 619]]<|/det|>
+- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\mathrm{I}\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2.
-<|ref|>text<|/ref|><|det|>[[511, 707, 879, 890]]<|/det|>
-- Rotational radius: smallest possible with appropriate patient safeguard
-- Matrix: \(128 \times 128\)
-- Angular sampling: \(\leq 3^\circ\) (360° rotation)
-- Zoom: acquisition pixel size should be \(1/3-1/2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size
-- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort
-- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30–50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)
\ No newline at end of file
+<|ref|>title<|/ref|><|det|>[[510, 685, 854, 700]]<|/det|>
+# TABLE 2.2. Acquisition parameters for IMT-SPECT
+
+<|ref|>text<|/ref|><|det|>[[509, 706, 881, 893]]<|/det|>
+- Rotational radius: smallest possible with appropriate patient safeguard- Matrix: \(128 \times 128\) - Angular sampling: \(\leq 3^{\circ}\) (360° rotation)- Zoom: acquisition pixel size should be \(1 / 3 - 1 / 2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30-50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)
\ No newline at end of file
diff --git a/stage1/sample_00010/document.md b/stage1/sample_00010/document.md
index 273a00d6bba84bd21eaaad6788f2a95e16062178..5f3ff59c6e827934a8c4afa934839abebc525fdf 100644
--- a/stage1/sample_00010/document.md
+++ b/stage1/sample_00010/document.md
@@ -1,3 +1,3 @@
Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \(10^{6}\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used?
-a. \(y = -4.9t^2\) b. \(y = -4.9t^2 - 5x10^6t\) c. \(5x10^6t = 4\) d. \(5x10^6t = 40\)
\ No newline at end of file
+a. \(y = -4.9t^2\) b. \(y = -4.9t^2 - 5\times 10^6 t\) c. \(5\times 10^6 t = 4\) d. \(5\times 10^6 t = 40\)
\ No newline at end of file
diff --git a/stage1/sample_00010/document_with_boxes.png b/stage1/sample_00010/document_with_boxes.png
index a3fccbb2ba420f3f2c91bb598ed654e8b95fd4c4..e3abfa9c93d66e6ac40fbb30b63d9132ebeba4b5 100644
--- a/stage1/sample_00010/document_with_boxes.png
+++ b/stage1/sample_00010/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:2a707c6fde40c9d79740a69e550028608df2e90f0a546a65aa2f123b039cd541
-size 84900
+oid sha256:0dfbf2e0afae5587dc926b2ced15429b74d65645d25e905acf9d0ccbf5dfe172
+size 85211
diff --git a/stage1/sample_00010/raw_response.md b/stage1/sample_00010/raw_response.md
index 993adf130609a762044496c9ee2bc8dc56e5b0f2..5ce4182b64ab54eb2ea52e9411f76368e64846b0 100644
--- a/stage1/sample_00010/raw_response.md
+++ b/stage1/sample_00010/raw_response.md
@@ -1,5 +1,5 @@
-<|ref|>text<|/ref|><|det|>[[88, 81, 901, 181]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[89, 82, 902, 180]]<|/det|>
Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \(10^{6}\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used?
-<|ref|>text<|/ref|><|det|>[[88, 212, 421, 356]]<|/det|>
-a. \(y = -4.9t^2\) b. \(y = -4.9t^2 - 5x10^6t\) c. \(5x10^6t = 4\) d. \(5x10^6t = 40\)
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[88, 213, 420, 357]]<|/det|>
+a. \(y = -4.9t^2\) b. \(y = -4.9t^2 - 5\times 10^6 t\) c. \(5\times 10^6 t = 4\) d. \(5\times 10^6 t = 40\)
\ No newline at end of file
diff --git a/stage1/sample_00011/document.md b/stage1/sample_00011/document.md
index f145cfb46970bd747ac3bb4c4dbfcecbf8137f87..5fb902a82f4a7d8893beff9c3e7f708ef3b4cdab 100644
--- a/stage1/sample_00011/document.md
+++ b/stage1/sample_00011/document.md
@@ -1,45 +1 @@
-0
-
-
-
-# Bio
-
-**Bio**
-
-Brett received his B.S. in Chemical Engineering from the University of Massachusetts Amherst in 2009. There he worked in the lab of Dr. Neil Forbes developing microfluidic devices to study the interactions between bacteria and in vitro tumor models. He earned his Ph.D. in Chemical Engineering from the California Institute of Technology in 2016 where he worked with Dr. Dave Tirrell and Dr. Dianne Newman. His thesis focused on the development and application of a method for time- and cell-selective proteomic analysis in bacteria. He used this approach to study protein synthesis by the opportunistic pathogen Pseudomonas aeruginosa under dormancy and biofilm growth conditions. Brett joined the Bogyo lab at Stanford in the fall of 2016. His current focus is on the roles of serine hydrolases in the physiology of pathogenic bacteria.
-
-# HONORS AND AWARDS
-
-• A. P. Giannini Postdoctoral Fellowship, A. P. Giannini Foundation (2018)
-
-• Microbiology and Immunology Postdoctoral Fellowship, Stanford School of Medicine (2018)
-
-• Dean's Fellowship, Stanford School of Medicine (2017)
-
-# PROFESSIONAL EDUCATION
-
-• Bachelor of Science, University of Massachusetts Amherst (2009)
-
-• Doctor of Philosophy, California Institute of Technology (2016)
-
-# STANFORD ADVISORS
-
-• Matthew Bogyo, Postdoctoral Faculty Sponsor
-
-# Research & Scholarship
-
-**LAB AFFILIATIONS**
-
-• Matthew Bogyo, Bogyo Lab (9/1/2016)
-
-# Publications
-
-## PUBLICATIONS
-
-• Activity-based protein profiling in bacteria: Applications for identification of therapeutic targets and characterization of microbial communities. Current opinion in chemical biology
-
-Keller, L. J., Babin, B. M., Lakemeyer, M., Bogyo, M.
-
-2019; 54: 45-53
-
-• Leveraging Peptide Substrate Libraries to Design Inhibitors of Bacterial L Proteinase ACS CHEMICAL BIOLOGY
\ No newline at end of file
+0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 12.9 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 13.9 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 14.9 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 15.9 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 16.9 17.0 17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8 17.9 18.0 18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9 19.0 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 21.0 21.1 21.2 21.3 21.4 21.5 21.6 21.7 21.8 21.9 22.0 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 23.0 23.1 23.2 23.3 23.4 23.5 23.6 23.7 23.8 23.9 24.0 24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 24.9 25.0 25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8 25.9 26.0 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8 26.9 27.0 27.1 27.2 27.3 27.4 27.5 27.6 27.7 27.8 27.9 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 28.9 29.0 29.1 29.2 29.3 29.4 29.5 29.6 29.7 29.8 29.9 30.0 30.1 30.2 30.3 30.4 30.5 30.6 30.7 30.8 30.9 31.0 31.1 31.2 31.3 31.4 31.5 31.6 31.7 31.8 31.9 32.0 32.1 32.2 32.3 32.4 32.5 32.6 32.7 32.8 32.9 33.0 33.1 33.2 33.3 33.4 33.5 33.6 33.7 33.8 33.9 34.0 34.1 34.2 34.3 34.4 34.5 34.6 34.7 34.8 34.9 35.0 35.1 35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 36.0 36.1 36.2 36.3 36.4 36.5 36.6 36.7 36.8 36.9 37.0 37.1 37.2 37.3 37.4 37.5 37.6 37.7 37.8 37.9 38.0 38.1 38.2 38.3 38.4 38.5 38.6 38.7 38.8 38.9 39.0 39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 39.9 40.0 40.1 40.2 40.3 40.4 40.5 40.6 40.7 40.8 40.9 41.0 41.1 41.2 41.3 41.4 41.5 41.6 41.7 41.8 41.9 42.0 42.1 42.2 42.3 42.4 42.5 42.6 42.7 42.8 42.9 43.0 43.1 43.2 43.3 43.4 43.5 43.6 43.7 43.8 43.9 44.0 44.1 44.2 44.3 44.4 44.5 44.6 44.7 44.8 44.9 45.0 45.1 45.2 45.3 45.4 45.5 45.6 45.7 45.8 45.9 46.0 46.1 46.2 46.3 46.4 46.5 46.6 46.7 46.8 46.9 47.0 47.1 47.2 47.3 47.4 47.5 47.6 47.7 47.8 47.9 48.0 48.1 48.2 48.3 48.4 48.5 48.6 48.7 48.8 48.9 49.0 49.1 49.2 49.3 49.4 49.5 49.6 49.7 49.8 49.9 50.0 50.1 50.2 50.3 50.4 50.5 50.6 50.7 50.8 50.9 51.0 51.1 51.2 51.3 51.4 51.5 51.6 51.7 51.8 51.9 52.0 52.1 52.2 52.3 52.4 52.5 52.6 52.7 52.8 52.9 53.0 53.1 53.2 53.3 53.4 53.5 53.6 53.7 53.8 53.9 54.0 54.1 54.2 54.3 54.4 54.5 54.6 54.7 54.8 54.9 55.0 55.1 55.2 55.3 55.4 55.5 55.6 55.7 55.8 55.9 56.0 56.1 56.2 56.3 56.4 56.5 56.6 56.7 56.8 56.9 57.0 57.1 57.2 57.3 57.4 57.5 57.6 57.7 57.8 57.9 58.0 58.1 58.2 58.3 58.4 58.5 58.6 58.7 58.8 58.9 59.0 59.1 59.2 59.3 59.4 59.5 59.6 59.7 59.8 59.9 60.0 60.1 60.2 60.3 60.4 60.5 60.6 60.7 60.8 60.9 61.0 61.1 61.2 61.3 61.4 61.5 61.6 61.7 61.8 61.9 62.0 62.1 62.2 62.3 62.4 62.5 62.6 62.7 62.8 62.9 63.0 63.1 63.2 63.3 63.4 63.5 63.6 63.7 63.8 63.9 64.0 64.1 64.2 64.3 64.4 64.5 64.6 64.7 64.8 64.9 65.0 65.1 65.2 65.3 65.4 65.5 65.6 65.7 65.8 65.9 66.0 66.1 66.2 66.3 66.4 66.5 66.6 66.7 66.8 66.9 67.0 67.1 67.2 67.3 67.4 67.5 67.6 67.7 67.8 67.9 68.0 68.1 68.2 68.3 68.4 68.5 68.6 68.7 68.8 68.9 69.0 69.1 69.2 69.3 69.4 69.5 69.6 69.7 69.8 69.9 70.0 70.1 70.2 70.3 70.4 70.5 70.6 70.7 70.8 70.9 71.0 71.1 71.2 71.3 71.4 71.5 71.6 71.7 71.8 71.9 72.0 72.1 72.2 72.3 72.4 72.5 72.6 72.7 72.8 72.9 73.0 73.1 73.2 73.3 73.4 73.5 73.6 73.7 73.8 73.9 74.0 74.1 74.2 74.3 74.4 74.5 74.6 74.7 74.8 74.9 75.0 75.1 75.2 75.3 75.4 75.5 75.6 75.7 75.8 75.9 76.0 76.1 76.2 76.3 76.4 76.5 76.6 76.7 76.8 76.9 77.0 77.1 77.2 77.3 77.4 77.5 77.6 77.7 77.8 77.9 78.0 78.1 78.2 78.3 78.4 78.5 78.6 78.7 78.8 78.9 79.0 79.1 79.2 79.3 79.4 79.5 79.6 79.7 79.8 79.9 80.0 80.1 80.2 80.3 80.4 80.5 80.6 80.7 80.8 80.9 81.0 81.1 81.2 81.3 81.4 81.5 81.6 81.7 81.8 81.9 82.0 82.1 82.2 82.3 82.4 82.5 82.6 82.7 82.8 82.9 83.0 83.1 83.2 83.3 83.4 83.5 83.6 83.7 83.8 83.9 84.0 84.1 84.2 84.3 84.4 84.5 84.6 84.7 84.8 84.9 85.0 85.1 85.2 85.3 85.4 85.5 85.6 85.7 85.8 85.9 86.0 86.1 86.2 86.3 86.4 86.5 86.6 86.7 86.8 86.9 87.0 87.1 87.2 87.3 87.4 87.5 87.6 87.7 87.8 87.9 88.0 88.1 88.2 88.3 88.4 88.5 88.6 88.7 88.8 88.9 89.0 89.1 89.2 89.3 89.4 89.5 89.6 89.7 89.8 89.9 90.0 90.1 90.2 90.3 90.4 90.5 90.6 90.7 90.8 90.9 91.0 91.1 91.2 91.3 91.4 91.5 91.6 91.7 91.8 91.9 92.0 92.1 92.2 92.3 92.4 92.5 92.6 92.7 92.8 92.9 93.0 93.1 93.2 93.3 93.4 93.5 93.6 93.7 93.8 93.9 94.0 94.1 94.2 94.3 94.4 94.5 94.6 94.7 94.8 94.9 95.0 95.1 95.2 95.3 95.4 95.5 95.6 95.7 95.8 95.9 96.0 96.1 96.2 96.3 96.4 96.5 96.6 96.7 96.8 96.9 97.0 97.1 97.2 97.3 97.4 97.5 97.6 97.7 97.8 97.9 98.0 98.1 98.2 98.3 98.4 98.5 98.6 98.7 98.8 98.9 99.0 99.1 99.2 99.3 99.4 99.5 99.6 99.7 99.8 99.9 100.0 100.1 100.2 100.3 100.4 100.5 100.6 100.7 100.8 100.9 101.0 101.1 101.2 101.3 101.4 101.5 101.6 101.7 101.8 101.9 102.0 102.1 102.2 102.3 102.4 102.5 102.6
\ No newline at end of file
diff --git a/stage1/sample_00011/document_with_boxes.png b/stage1/sample_00011/document_with_boxes.png
index 9b37ce1c11aa9420f0d1e6013170d470c951671e..d8a707ee29cf8cf7277460a502ab33f7550cd569 100644
--- a/stage1/sample_00011/document_with_boxes.png
+++ b/stage1/sample_00011/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:402c821fca1ed979c419a5d5d78157219dce96b683459280b07c496163ce9d7c
-size 295163
+oid sha256:d44e1ccf27f44362129167fed3b7c4aea295519563b6dfa3cb4bcd74cb2ef2d0
+size 281506
diff --git a/stage1/sample_00011/raw_response.md b/stage1/sample_00011/raw_response.md
index b0fc6dcbdb5c5cc0aff627bca53c92d1374b9764..5fb902a82f4a7d8893beff9c3e7f708ef3b4cdab 100644
--- a/stage1/sample_00011/raw_response.md
+++ b/stage1/sample_00011/raw_response.md
@@ -1,66 +1 @@
-0
-
-<|ref|>image<|/ref|><|det|>[[57, 138, 217, 260]]<|/det|>
-
-<|ref|>title<|/ref|><|det|>[[57, 297, 90, 310]]<|/det|>
-# Bio
-
-<|ref|>text<|/ref|><|det|>[[57, 326, 92, 340]]<|/det|>
-**Bio**
-
-<|ref|>text<|/ref|><|det|>[[57, 348, 936, 460]]<|/det|>
-Brett received his B.S. in Chemical Engineering from the University of Massachusetts Amherst in 2009. There he worked in the lab of Dr. Neil Forbes developing microfluidic devices to study the interactions between bacteria and in vitro tumor models. He earned his Ph.D. in Chemical Engineering from the California Institute of Technology in 2016 where he worked with Dr. Dave Tirrell and Dr. Dianne Newman. His thesis focused on the development and application of a method for time- and cell-selective proteomic analysis in bacteria. He used this approach to study protein synthesis by the opportunistic pathogen Pseudomonas aeruginosa under dormancy and biofilm growth conditions. Brett joined the Bogyo lab at Stanford in the fall of 2016. His current focus is on the roles of serine hydrolases in the physiology of pathogenic bacteria.
-
-<|ref|>title<|/ref|><|det|>[[57, 476, 248, 490]]<|/det|>
-# HONORS AND AWARDS
-
-<|ref|>text<|/ref|><|det|>[[57, 495, 519, 509]]<|/det|>
-• A. P. Giannini Postdoctoral Fellowship, A. P. Giannini Foundation (2018)
-
-<|ref|>text<|/ref|><|det|>[[57, 516, 567, 529]]<|/det|>
-• Microbiology and Immunology Postdoctoral Fellowship, Stanford School of Medicine (2018)
-
-<|ref|>text<|/ref|><|det|>[[57, 538, 369, 550]]<|/det|>
-• Dean's Fellowship, Stanford School of Medicine (2017)
-
-<|ref|>title<|/ref|><|det|>[[57, 566, 293, 580]]<|/det|>
-# PROFESSIONAL EDUCATION
-
-<|ref|>text<|/ref|><|det|>[[57, 587, 421, 600]]<|/det|>
-• Bachelor of Science, University of Massachusetts Amherst (2009)
-
-<|ref|>text<|/ref|><|det|>[[57, 607, 411, 621]]<|/det|>
-• Doctor of Philosophy, California Institute of Technology (2016)
-
-<|ref|>title<|/ref|><|det|>[[57, 637, 239, 650]]<|/det|>
-# STANFORD ADVISORS
-
-<|ref|>text<|/ref|><|det|>[[57, 657, 322, 669]]<|/det|>
-• Matthew Bogyo, Postdoctoral Faculty Sponsor
-
-<|ref|>title<|/ref|><|det|>[[57, 686, 263, 702]]<|/det|>
-# Research & Scholarship
-
-<|ref|>text<|/ref|><|det|>[[57, 718, 218, 730]]<|/det|>
-**LAB AFFILIATIONS**
-
-<|ref|>text<|/ref|><|det|>[[57, 737, 284, 750]]<|/det|>
-• Matthew Bogyo, Bogyo Lab (9/1/2016)
-
-<|ref|>title<|/ref|><|det|>[[57, 767, 164, 781]]<|/det|>
-# Publications
-
-<|ref|>sub_title<|/ref|><|det|>[[57, 797, 186, 810]]<|/det|>
-## PUBLICATIONS
-
-<|ref|>text<|/ref|><|det|>[[57, 820, 927, 844]]<|/det|>
-• Activity-based protein profiling in bacteria: Applications for identification of therapeutic targets and characterization of microbial communities. Current opinion in chemical biology
-
-<|ref|>text<|/ref|><|det|>[[69, 847, 360, 858]]<|/det|>
-Keller, L. J., Babin, B. M., Lakemeyer, M., Bogyo, M.
-
-<|ref|>text<|/ref|><|det|>[[69, 862, 160, 873]]<|/det|>
-2019; 54: 45-53
-
-<|ref|>text<|/ref|><|det|>[[57, 891, 710, 904]]<|/det|>
-• Leveraging Peptide Substrate Libraries to Design Inhibitors of Bacterial L Proteinase ACS CHEMICAL BIOLOGY
\ No newline at end of file
+0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 12.9 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 13.9 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 14.9 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 15.9 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 16.9 17.0 17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8 17.9 18.0 18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9 19.0 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 21.0 21.1 21.2 21.3 21.4 21.5 21.6 21.7 21.8 21.9 22.0 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 23.0 23.1 23.2 23.3 23.4 23.5 23.6 23.7 23.8 23.9 24.0 24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 24.9 25.0 25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8 25.9 26.0 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8 26.9 27.0 27.1 27.2 27.3 27.4 27.5 27.6 27.7 27.8 27.9 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 28.9 29.0 29.1 29.2 29.3 29.4 29.5 29.6 29.7 29.8 29.9 30.0 30.1 30.2 30.3 30.4 30.5 30.6 30.7 30.8 30.9 31.0 31.1 31.2 31.3 31.4 31.5 31.6 31.7 31.8 31.9 32.0 32.1 32.2 32.3 32.4 32.5 32.6 32.7 32.8 32.9 33.0 33.1 33.2 33.3 33.4 33.5 33.6 33.7 33.8 33.9 34.0 34.1 34.2 34.3 34.4 34.5 34.6 34.7 34.8 34.9 35.0 35.1 35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 36.0 36.1 36.2 36.3 36.4 36.5 36.6 36.7 36.8 36.9 37.0 37.1 37.2 37.3 37.4 37.5 37.6 37.7 37.8 37.9 38.0 38.1 38.2 38.3 38.4 38.5 38.6 38.7 38.8 38.9 39.0 39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 39.9 40.0 40.1 40.2 40.3 40.4 40.5 40.6 40.7 40.8 40.9 41.0 41.1 41.2 41.3 41.4 41.5 41.6 41.7 41.8 41.9 42.0 42.1 42.2 42.3 42.4 42.5 42.6 42.7 42.8 42.9 43.0 43.1 43.2 43.3 43.4 43.5 43.6 43.7 43.8 43.9 44.0 44.1 44.2 44.3 44.4 44.5 44.6 44.7 44.8 44.9 45.0 45.1 45.2 45.3 45.4 45.5 45.6 45.7 45.8 45.9 46.0 46.1 46.2 46.3 46.4 46.5 46.6 46.7 46.8 46.9 47.0 47.1 47.2 47.3 47.4 47.5 47.6 47.7 47.8 47.9 48.0 48.1 48.2 48.3 48.4 48.5 48.6 48.7 48.8 48.9 49.0 49.1 49.2 49.3 49.4 49.5 49.6 49.7 49.8 49.9 50.0 50.1 50.2 50.3 50.4 50.5 50.6 50.7 50.8 50.9 51.0 51.1 51.2 51.3 51.4 51.5 51.6 51.7 51.8 51.9 52.0 52.1 52.2 52.3 52.4 52.5 52.6 52.7 52.8 52.9 53.0 53.1 53.2 53.3 53.4 53.5 53.6 53.7 53.8 53.9 54.0 54.1 54.2 54.3 54.4 54.5 54.6 54.7 54.8 54.9 55.0 55.1 55.2 55.3 55.4 55.5 55.6 55.7 55.8 55.9 56.0 56.1 56.2 56.3 56.4 56.5 56.6 56.7 56.8 56.9 57.0 57.1 57.2 57.3 57.4 57.5 57.6 57.7 57.8 57.9 58.0 58.1 58.2 58.3 58.4 58.5 58.6 58.7 58.8 58.9 59.0 59.1 59.2 59.3 59.4 59.5 59.6 59.7 59.8 59.9 60.0 60.1 60.2 60.3 60.4 60.5 60.6 60.7 60.8 60.9 61.0 61.1 61.2 61.3 61.4 61.5 61.6 61.7 61.8 61.9 62.0 62.1 62.2 62.3 62.4 62.5 62.6 62.7 62.8 62.9 63.0 63.1 63.2 63.3 63.4 63.5 63.6 63.7 63.8 63.9 64.0 64.1 64.2 64.3 64.4 64.5 64.6 64.7 64.8 64.9 65.0 65.1 65.2 65.3 65.4 65.5 65.6 65.7 65.8 65.9 66.0 66.1 66.2 66.3 66.4 66.5 66.6 66.7 66.8 66.9 67.0 67.1 67.2 67.3 67.4 67.5 67.6 67.7 67.8 67.9 68.0 68.1 68.2 68.3 68.4 68.5 68.6 68.7 68.8 68.9 69.0 69.1 69.2 69.3 69.4 69.5 69.6 69.7 69.8 69.9 70.0 70.1 70.2 70.3 70.4 70.5 70.6 70.7 70.8 70.9 71.0 71.1 71.2 71.3 71.4 71.5 71.6 71.7 71.8 71.9 72.0 72.1 72.2 72.3 72.4 72.5 72.6 72.7 72.8 72.9 73.0 73.1 73.2 73.3 73.4 73.5 73.6 73.7 73.8 73.9 74.0 74.1 74.2 74.3 74.4 74.5 74.6 74.7 74.8 74.9 75.0 75.1 75.2 75.3 75.4 75.5 75.6 75.7 75.8 75.9 76.0 76.1 76.2 76.3 76.4 76.5 76.6 76.7 76.8 76.9 77.0 77.1 77.2 77.3 77.4 77.5 77.6 77.7 77.8 77.9 78.0 78.1 78.2 78.3 78.4 78.5 78.6 78.7 78.8 78.9 79.0 79.1 79.2 79.3 79.4 79.5 79.6 79.7 79.8 79.9 80.0 80.1 80.2 80.3 80.4 80.5 80.6 80.7 80.8 80.9 81.0 81.1 81.2 81.3 81.4 81.5 81.6 81.7 81.8 81.9 82.0 82.1 82.2 82.3 82.4 82.5 82.6 82.7 82.8 82.9 83.0 83.1 83.2 83.3 83.4 83.5 83.6 83.7 83.8 83.9 84.0 84.1 84.2 84.3 84.4 84.5 84.6 84.7 84.8 84.9 85.0 85.1 85.2 85.3 85.4 85.5 85.6 85.7 85.8 85.9 86.0 86.1 86.2 86.3 86.4 86.5 86.6 86.7 86.8 86.9 87.0 87.1 87.2 87.3 87.4 87.5 87.6 87.7 87.8 87.9 88.0 88.1 88.2 88.3 88.4 88.5 88.6 88.7 88.8 88.9 89.0 89.1 89.2 89.3 89.4 89.5 89.6 89.7 89.8 89.9 90.0 90.1 90.2 90.3 90.4 90.5 90.6 90.7 90.8 90.9 91.0 91.1 91.2 91.3 91.4 91.5 91.6 91.7 91.8 91.9 92.0 92.1 92.2 92.3 92.4 92.5 92.6 92.7 92.8 92.9 93.0 93.1 93.2 93.3 93.4 93.5 93.6 93.7 93.8 93.9 94.0 94.1 94.2 94.3 94.4 94.5 94.6 94.7 94.8 94.9 95.0 95.1 95.2 95.3 95.4 95.5 95.6 95.7 95.8 95.9 96.0 96.1 96.2 96.3 96.4 96.5 96.6 96.7 96.8 96.9 97.0 97.1 97.2 97.3 97.4 97.5 97.6 97.7 97.8 97.9 98.0 98.1 98.2 98.3 98.4 98.5 98.6 98.7 98.8 98.9 99.0 99.1 99.2 99.3 99.4 99.5 99.6 99.7 99.8 99.9 100.0 100.1 100.2 100.3 100.4 100.5 100.6 100.7 100.8 100.9 101.0 101.1 101.2 101.3 101.4 101.5 101.6 101.7 101.8 101.9 102.0 102.1 102.2 102.3 102.4 102.5 102.6
\ No newline at end of file
diff --git a/stage1/sample_00012/document.md b/stage1/sample_00012/document.md
index cf3b0d48314b76f92237e06494ec9e93be1de5c1..bfec1d3bd5347bec80573ca056fcff145492db10 100644
--- a/stage1/sample_00012/document.md
+++ b/stage1/sample_00012/document.md
@@ -1,3 +1 @@
-4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4:
-
-
\ No newline at end of file
+4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.8.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.9.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.12.1.1.1.1.1.1.1.1.1.1.1.1.1.1.13.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.14.1.1.1.1.1.1.1.1.1.1.1.1.1.1.15.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.16.1.1.1.1.1.1.1.1.1.1.1.1.1.1.17.1.1.1.1.1.1.1.1.1.1.1.1.1.1.18.1.1.1.1.1.1.1.1.1.1.1.1.1.1.19.1.1.1.1.1.1.1.1.1.1.1.1.1.20.1.1.1.1.1.1.1.1.1.1.1.1.1.21.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.22.1.1.1.1.1.1.1.1.1.1.1.1.1.1.23.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.24.1.1.1.1.1.1.1.1.1.1.1.1.1.1.25.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.26.1.1.1.1.1.1.1.1.1.1.1.1.1.1.27.1.1.1.1.1.1.1.1.1.1.1.1.1.1.28.1.1.1.1.1.1.1.1.1.1.1.1.1.1.29.1.1.1.1.1.1.1.1.1.1.1.1.1.1.30.1.1.1.1.1.1.1.1.1.1.1.1.1.1.31.1.1.1.1.1.1.1.1.1.1.1.1.1.32.1.1.1.1.1.1.1.1.1.1.1.1.1.1.33.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.34.1.1.1.1.1.1.1.1.1.1.1.1.1.1.35.1.1.1.1.1.1.1.1.1.1.1.1.1.1.36.1.1.1.1.1.1.1.1.1.1.1.1.1.1.37.1.1.1.1.1.1.1.1.1.1.1.1.1.1.38.1.1.1.1.1.1.1.1.1.1.1.1.1.1.39.1.1.1.1.1.1.1.1.1.1.1.1.1.1.40.1.1.1.1.1.1.1.1.1.1.1.1.1.1.41.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.42.1.1.1.1.1.1.1.1.1.1.1.1.1.1.43.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.45.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.46.1.1.1.1.1.1.1.1.1.1.1.1.1.1.47.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.48.1.1.1.1.1.1.1.1.1.1.1.1.1.1.49.1.1.1.1.1.1.1.1.1.1.1.1.1.1.50.1.1.1.1.1.1.1.1.1.1.1.1.1.1.51.1.1.1.1.1.1.1.1.1.1.1.1.1.1.52.1.1.1.1.1.1.1.1.1.1.1.1.1.1.53.1.1.1.1.1.1.1.1.1.1.1.1.1.1.54.1.1.1.1.1.1.1.1.1.1.1.1.1.1.55.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.56.1.1.1.1.1.1.1.1.1.1.1.1.1.1.57.1.1.1.1.1.1.1.1.1.1.1.1.1.1.58.1.1.1.1.1.1.1.1.1.1.1.1.1.1.59.1.1.1.1.1.1.1.1.1.1.1.1.1.1.60.1.1.1.1.1.1.1.1.1.1.1.1.1.1.61.1.1.1.1.1.1.1.1.1.1.1.1.1.1.62.1.1.1.1.1.1.1.1.1.1.1.1.1.1.63.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.64.1.1.1.1.1.1.1.1.1.1.1.1.1.1.65.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.66.1.1.1.1.1.1.1.1.1.1.1.1.1.1.67.1.1.1.1.1.1.1.1.1.1.1.1.1.1.68.1.1.1.1.1.1.1.1.1.1.1.1.1.1.69.1.1.1.1.1.1.1.1.1.1.1.1.1.1.70.1.1.1.1.1.1.1.1.1.1.1.1.1.1.71.1.1.1.1.1.1.1.1.1.1.1.1.1.1.72.1.1.1.1.1.1.1.1.1.1.1.1.1.1.73.1.1.1.1.1.1.1.1.1.1.1.1.1.1.74.1.1.1.1.1.1.1.1.1.1.1.1.1.1.75.1.1.1.1.1.1.1.1.1.1.1.1.1.1.76.1.1.1.1.1.1.1.1.1.1.1.1.1.1.77.1.1.1.1.1.1.1.1.1.1.1.1.1.1.78.1.1.1.1.1.1.1.1.1.1.1.1.1.1.79.1.1.1.1.1.1.1.1.1.1.1.1.1.1.80.1.1.1.1.1.1.1.1.1.1.1.1.1.1.81.1.1.1.1.1.1.1.1.1.1.1.1.1.1.82.1.1.1.1.1.1.1.1.1.1.1.1.1.1.83.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.84.1.1.1.1.1.1.1.1.1.1.1.1.1.1.85.1.1.1.1.1.1.1.1.1.1.1.1.1.1.86.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.87.1.1.1.1.1.1.1.1.1.1.1.1.1.1.88.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.89.1.1.1.1.1.1.1.1.1.1.1.1.1.1.90.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.91.1.1.1.1.1.1.1.1.1.1.1.1.1.1.92.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.93.1.1.1.1.1.1.1.1.1.1.1.1.1.1.94.1.1.1.1.1.1.1.1.1.1.1.1.1.1.95.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.96.1.1.1.1.1.1.1.1.1.1.1.1.1.1.97.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.98.1.1.1.1.1.1.1.1.1.1.1.1.1.1.99.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.100.1.1.1.1.1.1.1.1.1.1.1.1.1.1.101.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.102.1.1.1.1.1.1.1.1.1.1.1.1.1.1.103.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.104.1.1.1.1.1.1.1.1.1.1.1.1.1.1.105.1.1.1.1.1.1.1.1.1.1.1.1.1.1.106.1.1.1.1.1.1.1.1.1.1.1.1.1.1.107.1.1.1.1.1.1.1.1.1.1.1.1.1.1.108.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.109.1.1.1.1.1.1.1.1.1.1.1.1.1.1.110.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.111.1.1.1.1.1.1.1.1.1.1.1.1.1.1.112.1.1.1.1.1.1.1.1.1.1.1.1.1.1.113.1.1.1.1.1.1.1.1.1.1.1.1.1.1.114.1.1.1.1.1.1.1.1.1.1.1.1.1.1.115.1.1.1.1.1.1.1.1.1.1.1.1.1.1.116.1.1.1.1.1.1.1.1.1.1.1.1.1.1.117.1.1.1.1.1.1.1.1.1.1.1.1.1.1.118.1.1.1.1.1.1.1.1.1.1.1.1.1.1.119.1.1.1.1.1.1.1.1.1.1.1.1.1.1.120.1.1.1.1.1.1.1.1.1.1.1.1.1.1.121.1.1.1.1.1.1.1.1.1.1.1.1.1.1.122.1.1.1.1.1.1.1.1.1.1.1.1.1.1.123.1.1.1.1.1.1.1.1.1.1.1.1.1.1.124.1.1.1.1.1.1.1.1.1.1.1.1.1.1.125.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.126.1.1.1.1.1.1.1.1.1.1.1.1.1.1.127.1.1.1.1.1.1.1.1.1.1.1.1.1.1.128.1.1.1.1.1.1.1.1.1.1.1.1.1.1.129.1.1.1.1.1.1.1.1.1.1.1.1.1.1.130.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.131.1.1.1.1.1.
\ No newline at end of file
diff --git a/stage1/sample_00012/document_with_boxes.png b/stage1/sample_00012/document_with_boxes.png
index f1de2240ee0ddcb00c0509064cd002c7380fbd49..909a726839004aad67a787b0ef82e947ef04ea62 100644
--- a/stage1/sample_00012/document_with_boxes.png
+++ b/stage1/sample_00012/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:4740b950ea040052b2aa858bb9f792036ff1d8d86e50c5e99320b8de35e20f10
-size 359166
+oid sha256:2cd4ea5cf564a827d25191d3e1a6281f4447afd1265ec4d31eb2d81f52b33fcf
+size 357908
diff --git a/stage1/sample_00012/raw_response.md b/stage1/sample_00012/raw_response.md
index b197c2fd921941dd2a11fe71cdb136e30537d46f..bfec1d3bd5347bec80573ca056fcff145492db10 100644
--- a/stage1/sample_00012/raw_response.md
+++ b/stage1/sample_00012/raw_response.md
@@ -1,3 +1 @@
-4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4:
-
-<|ref|>image<|/ref|><|det|>[[361, 205, 760, 844]]<|/det|>
\ No newline at end of file
+4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.8.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.9.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.12.1.1.1.1.1.1.1.1.1.1.1.1.1.1.13.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.14.1.1.1.1.1.1.1.1.1.1.1.1.1.1.15.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.16.1.1.1.1.1.1.1.1.1.1.1.1.1.1.17.1.1.1.1.1.1.1.1.1.1.1.1.1.1.18.1.1.1.1.1.1.1.1.1.1.1.1.1.1.19.1.1.1.1.1.1.1.1.1.1.1.1.1.20.1.1.1.1.1.1.1.1.1.1.1.1.1.21.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.22.1.1.1.1.1.1.1.1.1.1.1.1.1.1.23.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.24.1.1.1.1.1.1.1.1.1.1.1.1.1.1.25.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.26.1.1.1.1.1.1.1.1.1.1.1.1.1.1.27.1.1.1.1.1.1.1.1.1.1.1.1.1.1.28.1.1.1.1.1.1.1.1.1.1.1.1.1.1.29.1.1.1.1.1.1.1.1.1.1.1.1.1.1.30.1.1.1.1.1.1.1.1.1.1.1.1.1.1.31.1.1.1.1.1.1.1.1.1.1.1.1.1.32.1.1.1.1.1.1.1.1.1.1.1.1.1.1.33.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.34.1.1.1.1.1.1.1.1.1.1.1.1.1.1.35.1.1.1.1.1.1.1.1.1.1.1.1.1.1.36.1.1.1.1.1.1.1.1.1.1.1.1.1.1.37.1.1.1.1.1.1.1.1.1.1.1.1.1.1.38.1.1.1.1.1.1.1.1.1.1.1.1.1.1.39.1.1.1.1.1.1.1.1.1.1.1.1.1.1.40.1.1.1.1.1.1.1.1.1.1.1.1.1.1.41.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.42.1.1.1.1.1.1.1.1.1.1.1.1.1.1.43.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.45.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.46.1.1.1.1.1.1.1.1.1.1.1.1.1.1.47.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.48.1.1.1.1.1.1.1.1.1.1.1.1.1.1.49.1.1.1.1.1.1.1.1.1.1.1.1.1.1.50.1.1.1.1.1.1.1.1.1.1.1.1.1.1.51.1.1.1.1.1.1.1.1.1.1.1.1.1.1.52.1.1.1.1.1.1.1.1.1.1.1.1.1.1.53.1.1.1.1.1.1.1.1.1.1.1.1.1.1.54.1.1.1.1.1.1.1.1.1.1.1.1.1.1.55.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.56.1.1.1.1.1.1.1.1.1.1.1.1.1.1.57.1.1.1.1.1.1.1.1.1.1.1.1.1.1.58.1.1.1.1.1.1.1.1.1.1.1.1.1.1.59.1.1.1.1.1.1.1.1.1.1.1.1.1.1.60.1.1.1.1.1.1.1.1.1.1.1.1.1.1.61.1.1.1.1.1.1.1.1.1.1.1.1.1.1.62.1.1.1.1.1.1.1.1.1.1.1.1.1.1.63.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.64.1.1.1.1.1.1.1.1.1.1.1.1.1.1.65.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.66.1.1.1.1.1.1.1.1.1.1.1.1.1.1.67.1.1.1.1.1.1.1.1.1.1.1.1.1.1.68.1.1.1.1.1.1.1.1.1.1.1.1.1.1.69.1.1.1.1.1.1.1.1.1.1.1.1.1.1.70.1.1.1.1.1.1.1.1.1.1.1.1.1.1.71.1.1.1.1.1.1.1.1.1.1.1.1.1.1.72.1.1.1.1.1.1.1.1.1.1.1.1.1.1.73.1.1.1.1.1.1.1.1.1.1.1.1.1.1.74.1.1.1.1.1.1.1.1.1.1.1.1.1.1.75.1.1.1.1.1.1.1.1.1.1.1.1.1.1.76.1.1.1.1.1.1.1.1.1.1.1.1.1.1.77.1.1.1.1.1.1.1.1.1.1.1.1.1.1.78.1.1.1.1.1.1.1.1.1.1.1.1.1.1.79.1.1.1.1.1.1.1.1.1.1.1.1.1.1.80.1.1.1.1.1.1.1.1.1.1.1.1.1.1.81.1.1.1.1.1.1.1.1.1.1.1.1.1.1.82.1.1.1.1.1.1.1.1.1.1.1.1.1.1.83.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.84.1.1.1.1.1.1.1.1.1.1.1.1.1.1.85.1.1.1.1.1.1.1.1.1.1.1.1.1.1.86.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.87.1.1.1.1.1.1.1.1.1.1.1.1.1.1.88.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.89.1.1.1.1.1.1.1.1.1.1.1.1.1.1.90.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.91.1.1.1.1.1.1.1.1.1.1.1.1.1.1.92.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.93.1.1.1.1.1.1.1.1.1.1.1.1.1.1.94.1.1.1.1.1.1.1.1.1.1.1.1.1.1.95.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.96.1.1.1.1.1.1.1.1.1.1.1.1.1.1.97.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.98.1.1.1.1.1.1.1.1.1.1.1.1.1.1.99.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.100.1.1.1.1.1.1.1.1.1.1.1.1.1.1.101.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.102.1.1.1.1.1.1.1.1.1.1.1.1.1.1.103.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.104.1.1.1.1.1.1.1.1.1.1.1.1.1.1.105.1.1.1.1.1.1.1.1.1.1.1.1.1.1.106.1.1.1.1.1.1.1.1.1.1.1.1.1.1.107.1.1.1.1.1.1.1.1.1.1.1.1.1.1.108.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.109.1.1.1.1.1.1.1.1.1.1.1.1.1.1.110.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.111.1.1.1.1.1.1.1.1.1.1.1.1.1.1.112.1.1.1.1.1.1.1.1.1.1.1.1.1.1.113.1.1.1.1.1.1.1.1.1.1.1.1.1.1.114.1.1.1.1.1.1.1.1.1.1.1.1.1.1.115.1.1.1.1.1.1.1.1.1.1.1.1.1.1.116.1.1.1.1.1.1.1.1.1.1.1.1.1.1.117.1.1.1.1.1.1.1.1.1.1.1.1.1.1.118.1.1.1.1.1.1.1.1.1.1.1.1.1.1.119.1.1.1.1.1.1.1.1.1.1.1.1.1.1.120.1.1.1.1.1.1.1.1.1.1.1.1.1.1.121.1.1.1.1.1.1.1.1.1.1.1.1.1.1.122.1.1.1.1.1.1.1.1.1.1.1.1.1.1.123.1.1.1.1.1.1.1.1.1.1.1.1.1.1.124.1.1.1.1.1.1.1.1.1.1.1.1.1.1.125.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.126.1.1.1.1.1.1.1.1.1.1.1.1.1.1.127.1.1.1.1.1.1.1.1.1.1.1.1.1.1.128.1.1.1.1.1.1.1.1.1.1.1.1.1.1.129.1.1.1.1.1.1.1.1.1.1.1.1.1.1.130.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.131.1.1.1.1.1.
\ No newline at end of file
diff --git a/stage1/sample_00013/document.md b/stage1/sample_00013/document.md
index 5e32916d567888678bee7e128c1c99736339aead..b737299902efce8203454e263d4f41078c4d6220 100644
--- a/stage1/sample_00013/document.md
+++ b/stage1/sample_00013/document.md
@@ -1,17 +1,45 @@
2019; 14 (11): 2453-62
-• The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology Bergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019
+- The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology
-• Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY Garland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M. 2019; 14 (1): 76-87
+Bergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019
-• Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio Babin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5)
+- Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY
-• SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Babin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A. 2016; 113 (5): E597-E605
+Garland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M.
-• In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY Hatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J. 2014; 16 (8): 2568-2590
+2019; 14 (1): 76- 87
-• State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY Ngo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A. 2012; 7 (8): 1326-1330
+- Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio
-• Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE Solorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A. 2010; 143 (2): 183-190
+Babin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5)
-• A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP Walsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S. 2009; 9 (4): 545-554
\ No newline at end of file
+- SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
+
+Babin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A.
+
+2016; 113 (5): E597- E605
+
+- In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY
+
+Hatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J.
+
+2014; 16 (8): 2568- 2590
+
+- State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY
+
+Ngo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A.
+
+2012; 7 (8): 1326- 1330
+
+- Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE
+
+Solorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A.
+
+2010; 143 (2): 183- 190
+
+- A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP
+
+Walsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S.
+
+2009; 9 (4): 545- 554
\ No newline at end of file
diff --git a/stage1/sample_00013/document_with_boxes.png b/stage1/sample_00013/document_with_boxes.png
index 173484bd6aece2fc08b40fc200fe2b40bc5da193..664b9082baa18b4d04628e4df4c140171826caf7 100644
--- a/stage1/sample_00013/document_with_boxes.png
+++ b/stage1/sample_00013/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:cadb2f39d19cef444e55652d5ee5d6d93b5b9712a7b28cafd512b7a7cf57084a
-size 227942
+oid sha256:221e1c07aa88a11d61297679ee65cfe8f6b2cef3cf14103ccf2eb473008a270f
+size 228353
diff --git a/stage1/sample_00013/raw_response.md b/stage1/sample_00013/raw_response.md
index 05935edf01db7c4ef6eadf9c1c1034256a97b895..9c773f9c20c71a5bb9e0d7eb1e802de7d6fa91e6 100644
--- a/stage1/sample_00013/raw_response.md
+++ b/stage1/sample_00013/raw_response.md
@@ -1,25 +1,67 @@
2019; 14 (11): 2453-62
-<|ref|>text<|/ref|><|det|>[[56, 125, 927, 169]]<|/det|>
-• The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology Bergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019
+<|ref|>text<|/ref|><|det|>[[57, 127, 925, 179]]<|/det|>
+- The dormancy-specific regulator, SutA, is intrinsically disordered and modulates transcription initiation in Pseudomonas aeruginosa. Molecular microbiology
-<|ref|>text<|/ref|><|det|>[[57, 189, 649, 217]]<|/det|>
-• Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY Garland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M. 2019; 14 (1): 76-87
+<|ref|>text<|/ref|><|det|>[[60, 172, 922, 183]]<|/det|>
+Bergkessel, M., Babin, B. M., VanderVelde, D., Sweredoski, M. J., Moradian, A., Eggleston-Rangel, R., Hess, S., Tirrell, D. A., Artsimovitch, I., Newman, D. K. 2019
-<|ref|>text<|/ref|><|det|>[[57, 248, 809, 290]]<|/det|>
-• Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio Babin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5)
+<|ref|>text<|/ref|><|det|>[[57, 191, 654, 205]]<|/det|>
+- Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence ACS CHEMICAL BIOLOGY
-<|ref|>text<|/ref|><|det|>[[57, 299, 909, 341]]<|/det|>
-• SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Babin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A. 2016; 113 (5): E597-E605
+<|ref|>text<|/ref|><|det|>[[60, 206, 525, 220]]<|/det|>
+Garland, M., Babin, B. M., Miyashita, S., Loscher, S., Shen, Y., Dong, M., Bogyo, M.
-<|ref|>text<|/ref|><|det|>[[57, 363, 869, 405]]<|/det|>
-• In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY Hatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J. 2014; 16 (8): 2568-2590
+<|ref|>text<|/ref|><|det|>[[60, 222, 178, 233]]<|/det|>
+2019; 14 (1): 76- 87
-<|ref|>text<|/ref|><|det|>[[57, 428, 532, 471]]<|/det|>
-• State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY Ngo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A. 2012; 7 (8): 1326-1330
+<|ref|>text<|/ref|><|det|>[[57, 245, 807, 259]]<|/det|>
+- Selective Proteomic Analysis of Antibiotic-Tolerant Cellular Subpopulations in Pseudomonas aeruginosa Biofilms. mBio
-<|ref|>text<|/ref|><|det|>[[57, 482, 771, 526]]<|/det|>
-• Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE Solorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A. 2010; 143 (2): 183-190
+<|ref|>text<|/ref|><|det|>[[60, 260, 808, 288]]<|/det|>
+Babin, B. M., Atangcho, L., van Eldijk, M. B., Sweredoski, M. J., Moradian, A., Hess, S., Tolker-Nielsen, T., Newman, D. K., Tirrell, D. A. 2017; 8 (5)
-<|ref|>text<|/ref|><|det|>[[57, 535, 865, 579]]<|/det|>
-• A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP Walsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S. 2009; 9 (4): 545-554
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[57, 298, 908, 327]]<|/det|>
+- SutA is a bacterial transcription factor expressed during slow growth in Pseudomonas aeruginosa PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
+
+<|ref|>text<|/ref|><|det|>[[60, 328, 618, 342]]<|/det|>
+Babin, B. M., Bergkessel, M., Sweredoski, M. J., Moradian, A., Hess, S., Newman, D. K., Tirrell, D. A.
+
+<|ref|>text<|/ref|><|det|>[[60, 342, 212, 355]]<|/det|>
+2016; 113 (5): E597- E605
+
+<|ref|>text<|/ref|><|det|>[[57, 365, 866, 392]]<|/det|>
+- In situ visualization of newly synthesized proteins in environmental microbes using amino acid tagging and click chemistry ENVIRONMENTAL MICROBIOLOGY
+
+<|ref|>text<|/ref|><|det|>[[60, 393, 552, 408]]<|/det|>
+Hatzenpichler, R., Scheller, S., Tavormina, P. L., Babin, B. M., Tirrell, D. A., Orphan, V. J.
+
+<|ref|>text<|/ref|><|det|>[[60, 408, 196, 421]]<|/det|>
+2014; 16 (8): 2568- 2590
+
+<|ref|>text<|/ref|><|det|>[[57, 431, 532, 445]]<|/det|>
+- State-selective Metabolic Labeling of Cellular Proteins ACS CHEMICAL BIOLOGY
+
+<|ref|>text<|/ref|><|det|>[[60, 446, 459, 460]]<|/det|>
+Ngo, J. T., Babin, B. M., Champion, J. A., Schuman, E. M., Tirrell, D. A.
+
+<|ref|>text<|/ref|><|det|>[[60, 461, 192, 474]]<|/det|>
+2012; 7 (8): 1326- 1330
+
+<|ref|>text<|/ref|><|det|>[[57, 484, 772, 498]]<|/det|>
+- Noninvasive characterization of in situ forming implants using diagnostic ultrasound JOURNAL OF CONTROLLED RELEASE
+
+<|ref|>text<|/ref|><|det|>[[60, 500, 444, 513]]<|/det|>
+Solorio, L., Babin, B. M., Patel, R. B., Mach, J., Azar, N., Exner, A. A.
+
+<|ref|>text<|/ref|><|det|>[[60, 515, 192, 528]]<|/det|>
+2010; 143 (2): 183- 190
+
+<|ref|>text<|/ref|><|det|>[[57, 538, 866, 551]]<|/det|>
+- A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics LAB ON A CHIP
+
+<|ref|>text<|/ref|><|det|>[[60, 552, 544, 565]]<|/det|>
+Walsh, C. L., Babin, B. M., Kasinskas, R. W., Foster, J. A., McGarry, M. J., Forbes, N. S.
+
+<|ref|>text<|/ref|><|det|>[[60, 566, 178, 579]]<|/det|>
+2009; 9 (4): 545- 554
\ No newline at end of file
diff --git a/stage1/sample_00014/document.md b/stage1/sample_00014/document.md
index afe5af055ec9cb901c49819e73450ad89dc0c478..c97913cef40610fd2cc3d03ac45f6507fa7e53fd 100644
--- a/stage1/sample_00014/document.md
+++ b/stage1/sample_00014/document.md
@@ -1,4 +1,4 @@
-18
+4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.
Software functionality: SepINRIA has different functionality which can be loaded from a single main window:
@@ -16,10 +16,10 @@ This section describes concisely dependencies of the software and also its struc
#### 4.2.1 Software dependencies
-SepINRIA is based on several C++ libraries (C.f. Figure 4.2). ITK \(^2\) and MIPS \(^3\) contain both image processing tools. The first one can be downloaded on Internet and is especially used for image conversion. Whereas the second one is inner to the Asclepios team (algorithms presented in chapter 3 can be found in this library).
+SepINRIA is based on several C++ libraries (C.f. Figure 4.2). ITK \(^{2}\) and MIPS \(^{3}\) contain both image processing tools. The first one can be downloaded on Internet and is especially used for image conversion. Whereas the second one is inner to the Asclepios team (algorithms presented in chapter 3 can be found in this library).
| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \(Age\pm \mathrm {SD}\)(year) | \(54.0\pm 13.1\) | \(54.0\pm 13.2\) |
| Females (n \((\%)\) | \(144\)(84.2) | \(128\)(78.5) |
| RA duration±SD (year) | \(0.3\pm 0.4\) | \(0.3\pm 0.4\) |
| Weight±SD (kg) | \(54.4\pm 9.7\) | \(56.1\pm 12.3\) |
| Previous DMARD use (n \((\%)\) | \(74\)(43.3) | \(87\)(53.4) |
| 1 DMARD | \(57\)(33.3) | \(69\)(42.3) |
| 2 DMARDs | \(17\)(9.9) | \(18\)(11.0) |
| Corticosteroid use at baseline (n \((\%)\) | \(58\)(33.9) | \(49\)(30.1) |
| RF positive (n \((\%)\) | \(146\)(85.4) | \(136\)(83.4) |
| Mean titre±SD (IU/ml) | \(154.5\pm 202.3\) | \(163.7\pm 362.8\) |
| Anti-CCP positive (n \((\%)\) | \(145\)(84.8) | \(136\)(83.4) |
| Mean titre±SD (U/ml) | \(386.2\pm 694.2\) | \(241.3\pm 367.2\) |
| ESR (mm/h) | \(59.9\pm 30.1\) | \(61.8\pm 29.0\) |
| CRP (mg/dl) | \(2.9\pm 3.0\) | \(3.1\pm 3.3\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \(11.5\pm 4.7\) | \(11.8\pm 5.3\) |
| 0-66 | \(16.5\pm 6.2\) | \(17.3\pm 7.7\) |
| Tender joint count (n±SD) | | |
| 0-28 | \(13.2\pm 5.8\) | \(13.2\pm 6.1\) |
| 0-68 | \(20.7\pm 9.4\) | \(21.1\pm 10.2\) |
| mTSS | \(13.6\pm 22.3\) | \(13.6\pm 17.4\) |
| Erosion score | \(7.5\pm 11.6\) | \(7.3\pm 9.2\) |
| Joint space narrowing score | \(6.2\pm 11.4\) | \(6.2\pm 9.4\) |
| DAS28-ESR | \(6.6\pm 0.9\) | \(6.6\pm 1.0\) |
| DAS28-CRP | \(5.8\pm 1.0\) | \(5.9\pm 1.0\) |
| HAQ-DI score | \(1.1\pm 0.7\) | \(1.3\pm 0.8\) |
| SDAI score | \(40.7\pm 12.0\) | \(41.4\pm 13.8\) |
| CDAI score | \(37.8\pm 10.9\) | \(38.3\pm 12.4\) |
Physician's global assessment of
disease activity±SD (mm) | \(65.8\pm 18.4\) | \(66.2\pm 18.8\) |
Patient's global assessment of disease
activity±SD (mm) | \(64.1\pm 24.8\) | \(66.4\pm 23.7\) |
+| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \(Age\pm \mathrm {SD}\)(year) | \(54.0\pm 13.1\) | \(54.0\pm 13.2\) |
| Females (n \((\%)\) | \(144\)(84.2) | \(128\)(78.5) |
| RA duration±SD (year) | \(0.3\pm 0.4\) | \(0.3\pm 0.4\) |
| Weight±SD (kg) | \(54.4\pm 9.7\) | \(56.1\pm 12.3\) |
| Previous DMARD use (n \((\%)\) | \(74\)(43.3) | \(87\)(53.4) |
| 1 DMARD | \(57\)(33.3) | \(69\)(42.3) |
| 2 DMARDs | \(17\)(9.9) | \(18\)(11.0) |
| Corticosteroid use at baseline (n \((\%)\) | \(58\)(33.9) | \(49\)(30.1) |
| RF positive (n \((\%)\) | \(146\)(85.4) | \(136\)(83.4) |
| Mean titre±SD (IU/ml) | \(154.5\pm 202.3\) | \(163.7\pm 362.8\) |
| Anti-CCP positive (n \((\%)\) | \(145\)(84.8) | \(136\)(83.4) |
| Mean titre±SD (U/ml) | \(386.2\pm 694.2\) | \(241.3\pm 367.2\) |
| ESR (mm/h) | \(59.9\pm 30.1\) | \(61.8\pm 29.0\) |
| CRP (mg/dl) | \(2.9\pm 3.0\) | \(3.1\pm 3.3\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \(11.5\pm 4.7\) | \(11.8\pm 5.3\) |
| 0-66 | \(16.5\pm 6.2\) | \(17.3\pm 7.7\) |
| Tender joint count (n±SD) | | |
| 0-28 | \(13.2\pm 5.8\) | \(13.2\pm 6.1\) |
| 0-68 | \(20.7\pm 9.4\) | \(21.1\pm 10.2\) |
| mTSS | \(13.6\pm 22.3\) | \(13.6\pm 17.4\) |
| Erosion score | \(7.5\pm 11.6\) | \(7.3\pm 9.2\) |
| Joint space narrowing score | \(6.2\pm 11.4\) | \(6.2\pm 9.4\) |
| DAS28-ESR | \(6.6\pm 0.9\) | \(6.6\pm 1.0\) |
| DAS28-CRP | \(5.8\pm 1.0\) | \(5.9\pm 1.0\) |
| HAQ-DI score | \(1.1\pm 0.7\) | \(1.3\pm 0.8\) |
| SDAI score | \(40.7\pm 12.0\) | \(41.4\pm 13.8\) |
| CDAI score | \(37.8\pm 10.9\) | \(38.3\pm 12.4\) |
Physician's global assessment of
disease activity±SD (mm) | \(65.8\pm 18.4\) | \(66.2\pm 18.8\) |
Patient's global assessment of disease
activity±SD (mm) | \(64.1\pm 24.8\) | \(66.4\pm 23.7\) |
+<|ref|>table_footnote<|/ref|><|det|>[[527, 567, 918, 652]]<|/det|>
+\\*Data are mean±SD unless otherwise indicated. CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
-<|ref|>text<|/ref|><|det|>[[519, 569, 742, 579]]<|/det|>
-*Data are mean±SD unless otherwise indicated.
+<|ref|>text<|/ref|><|det|>[[518, 679, 927, 721]]<|/det|>
+to 2.2- fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
-<|ref|>text<|/ref|><|det|>[[519, 580, 919, 654]]<|/det|>
-CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
+<|ref|>text<|/ref|><|det|>[[518, 722, 927, 827]]<|/det|>
+A significantly larger decrease from baseline in mean HAQ- DI score, indicative of an improvement in physical function, was observed for adalimumab \(+\mathrm{MTX}\) patients versus MTX alone patients at week 26 ( \(- 0.6\pm 0.6\) vs \(- 0.4\pm 0.6\) ; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ- DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab \(+\mathrm{MTX}\) (figure 3F).
-<|ref|>text<|/ref|><|det|>[[512, 679, 929, 721]]<|/det|>
-to 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
+<|ref|>sub_title<|/ref|><|det|>[[518, 858, 862, 886]]<|/det|>
+## Factors associated with the absence of radiographic progression or with clinical remission
-<|ref|>text<|/ref|><|det|>[[512, 723, 929, 828]]<|/det|>
-A significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).
-
-<|ref|>title<|/ref|><|det|>[[512, 856, 862, 883]]<|/det|>
-# Factors associated with the absence of radiographic progression or with clinical remission
-
-<|ref|>text<|/ref|><|det|>[[512, 885, 929, 952]]<|/det|>
-Disease activity or function baseline variables generally were associated with the absence of radiographic progression ( \(\Delta \mathrm {mTSS}\leq 0.5\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[518, 887, 927, 951]]<|/det|>
+Disease activity or function baseline variables generally were associated with the absence of radiographic progression ( \(\Delta \mathrm{MTSS} \leq 0.5\) ) and with clinical remission (DAS28- ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).
\ No newline at end of file
diff --git a/stage1/sample_00019/document.md b/stage1/sample_00019/document.md
index d8aa5d9c240b7e8e1f95d1d124f5f4f1791df2ef..5fef5473819ec63d9c888a6947175563aa06bce1 100644
--- a/stage1/sample_00019/document.md
+++ b/stage1/sample_00019/document.md
@@ -1,68 +1,59 @@
1 unit
-**CPE 101. Fundamentals of Computer Science. 4 units**
-Term Typically Offered: F, W, SP
-Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
+CPE 101. Fundamentals of Computer Science. 4 unitsTerm Typically Offered: F, W, SPPrerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
-Basic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
+Basic principles of algorithmic problem solving and programming using methods of top- down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/ output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
-**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.**
+CPE 105. Fundamentals of Computer Science I Supplemental Instruction.
-1 unit
+1 unitCR/NC
-Term Typically Offered: TBD
-Concurrent: CPE/CSC 101.
+Term Typically Offered: TBDConcurrent: CPE/CSC 101.
Facilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105.
-CPE 108. Accelerated Introduction to Computer Science. 4 units
+CPE 108. Accelerated Introduction to Computer Science. 4 unitsTerm Typically Offered: TBDPrerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
-Term Typically Offered: TBD
-Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
+Accelerated introduction to basic principles of algorithmic and object- oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
-Accelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
+## CPE 123. Introduction to Computing. 4 units
-CPE 123. Introduction to Computing. 4 units
-Term Typically Offered: F
-Prerequisite: Basic computer literacy.
+Term Typically Offered: FPrerequisite: Basic computer literacy.
Use of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123.
-CPE 133. Digital Design. 4 units
-Term Typically Offered: F, W, SP
-Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
+## CPE 133. Digital Design. 4 units
-Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
+Term Typically Offered: F,W, SP,SUPrerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
-CPE 200. Special Problems for Undergraduates. 1- 2 units
-Term Typically Offered: F, W, SP
-Prerequisite: Consent of instructor.
+Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom- based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
+
+## CPE 200. Special Problems for Undergraduates. 1-2 units
+
+Term Typically Offered: F, W, SP, SUPrerequisite: Consent of instructor.
Individual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter.
-CPE 202. Data Structures. 4 units
+## CPE 202. Data Structures. 4 units
-Term Typically Offered: F, W, SP
-Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
+Term Typically Offered: F, W, SPPrerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
Introduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103.
-CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
+## CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
+
+Term Typically Offered: F, W, SPPrerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
-Term Typically Offered: F, W, SP
-Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
+Object- oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
-Object-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
+## CPE 233. Computer Design and Assembly Language Programming. 4 units
-CPE 233. Computer Design and Assembly Language Programming. 4 units
+Term Typically Offered: F, W, SPPrerequisite: CPE/EE 133.
-Term Typically Offered: F, W, SP
-Prerequisite: CPE/EE 133.
+Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off- the- shelf RISC- based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
-Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
+## CPE 290. Selected Topics. 1-4 units
-CPE 290. Selected Topics. 1- 4 units
-Term Typically Offered: TBD
-Prerequisite: Open to undergraduate students and consent of instructor.
+Term Typically Offered: TBDPrerequisite: Open to undergraduate students and consent of instructor.
Directed group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.
\ No newline at end of file
diff --git a/stage1/sample_00019/document_with_boxes.png b/stage1/sample_00019/document_with_boxes.png
index b12a3fa14866cc8b329e350290951472600760e7..33285b3f945a777df9957d57e33ee47dd8b271de 100644
--- a/stage1/sample_00019/document_with_boxes.png
+++ b/stage1/sample_00019/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:edb71029fc214303af8d56c1e97d11570fc84eff29d4ff7acbcfaa8896fa8563
-size 581477
+oid sha256:bd68ab4a14ef1a5a6a1f5d0566231f5edeb510cdfff675d4fa97e09ed6dfe0b5
+size 583381
diff --git a/stage1/sample_00019/raw_response.md b/stage1/sample_00019/raw_response.md
index 92f637b4a543f06ddda6b3c442a3a485f6ad3471..a76db29e39e045e21dbc2d53b266b124687505f5 100644
--- a/stage1/sample_00019/raw_response.md
+++ b/stage1/sample_00019/raw_response.md
@@ -1,94 +1,88 @@
1 unit
-<|ref|>text<|/ref|><|det|>[[56, 90, 488, 156]]<|/det|>
-**CPE 101. Fundamentals of Computer Science. 4 units**
-Term Typically Offered: F, W, SP
-Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
+<|ref|>text<|/ref|><|det|>[[56, 97, 491, 156]]<|/det|>
+CPE 101. Fundamentals of Computer Science. 4 unitsTerm Typically Offered: F, W, SPPrerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
-<|ref|>text<|/ref|><|det|>[[56, 168, 490, 275]]<|/det|>
-Basic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
+<|ref|>text<|/ref|><|det|>[[56, 168, 488, 275]]<|/det|>
+Basic principles of algorithmic problem solving and programming using methods of top- down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/ output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
-<|ref|>text<|/ref|><|det|>[[56, 289, 488, 313]]<|/det|>
-**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.**
+<|ref|>text<|/ref|><|det|>[[56, 287, 488, 311]]<|/det|>
+CPE 105. Fundamentals of Computer Science I Supplemental Instruction.
-<|ref|>text<|/ref|><|det|>[[56, 315, 99, 339]]<|/det|>
-1 unit
+<|ref|>text<|/ref|><|det|>[[56, 314, 117, 338]]<|/det|>
+1 unitCR/NC
-<|ref|>text<|/ref|><|det|>[[56, 341, 222, 366]]<|/det|>
-Term Typically Offered: TBD
-Concurrent: CPE/CSC 101.
+<|ref|>text<|/ref|><|det|>[[56, 333, 224, 359]]<|/det|>
+Term Typically Offered: TBDConcurrent: CPE/CSC 101.
-<|ref|>text<|/ref|><|det|>[[56, 373, 476, 414]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[56, 370, 476, 411]]<|/det|>
Facilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105.
-<|ref|>text<|/ref|><|det|>[[56, 423, 435, 438]]<|/det|>
-CPE 108. Accelerated Introduction to Computer Science. 4 units
+<|ref|>text<|/ref|><|det|>[[56, 421, 433, 481]]<|/det|>
+CPE 108. Accelerated Introduction to Computer Science. 4 unitsTerm Typically Offered: TBDPrerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
-<|ref|>text<|/ref|><|det|>[[56, 439, 447, 492]]<|/det|>
-Term Typically Offered: TBD
-Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
+<|ref|>text<|/ref|><|det|>[[56, 498, 489, 636]]<|/det|>
+Accelerated introduction to basic principles of algorithmic and object- oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
-<|ref|>text<|/ref|><|det|>[[56, 502, 490, 638]]<|/det|>
-Accelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
+<|ref|>sub_title<|/ref|><|det|>[[56, 649, 316, 661]]<|/det|>
+## CPE 123. Introduction to Computing. 4 units
-<|ref|>text<|/ref|><|det|>[[56, 651, 320, 691]]<|/det|>
-CPE 123. Introduction to Computing. 4 units
-Term Typically Offered: F
-Prerequisite: Basic computer literacy.
+<|ref|>text<|/ref|><|det|>[[56, 663, 277, 689]]<|/det|>
+Term Typically Offered: FPrerequisite: Basic computer literacy.
-<|ref|>text<|/ref|><|det|>[[56, 703, 473, 796]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[56, 701, 474, 797]]<|/det|>
Use of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123.
-<|ref|>text<|/ref|><|det|>[[506, 91, 926, 144]]<|/det|>
-CPE 133. Digital Design. 4 units
-Term Typically Offered: F, W, SP
-Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
+<|ref|>sub_title<|/ref|><|det|>[[506, 94, 693, 106]]<|/det|>
+## CPE 133. Digital Design. 4 units
-<|ref|>text<|/ref|><|det|>[[506, 156, 937, 250]]<|/det|>
-Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
+<|ref|>text<|/ref|><|det|>[[506, 108, 922, 134]]<|/det|>
+Term Typically Offered: F,W, SP,SUPrerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
-<|ref|>text<|/ref|><|det|>[[506, 262, 847, 301]]<|/det|>
-CPE 200. Special Problems for Undergraduates. 1- 2 units
-Term Typically Offered: F, W, SP
-Prerequisite: Consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 152, 934, 249]]<|/det|>
+Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom- based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
-<|ref|>text<|/ref|><|det|>[[506, 313, 927, 355]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[506, 261, 845, 273]]<|/det|>
+## CPE 200. Special Problems for Undergraduates. 1-2 units
+
+<|ref|>text<|/ref|><|det|>[[506, 275, 715, 301]]<|/det|>
+Term Typically Offered: F, W, SP, SUPrerequisite: Consent of instructor.
+
+<|ref|>text<|/ref|><|det|>[[506, 313, 924, 353]]<|/det|>
Individual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter.
-<|ref|>text<|/ref|><|det|>[[506, 368, 706, 381]]<|/det|>
-CPE 202. Data Structures. 4 units
+<|ref|>sub_title<|/ref|><|det|>[[506, 366, 705, 377]]<|/det|>
+## CPE 202. Data Structures. 4 units
-<|ref|>text<|/ref|><|det|>[[506, 383, 908, 422]]<|/det|>
-Term Typically Offered: F, W, SP
-Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 380, 910, 420]]<|/det|>
+Term Typically Offered: F, W, SPPrerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 434, 936, 514]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[506, 431, 937, 512]]<|/det|>
Introduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103.
-<|ref|>text<|/ref|><|det|>[[506, 526, 912, 550]]<|/det|>
-CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
+<|ref|>sub_title<|/ref|><|det|>[[506, 525, 913, 549]]<|/det|>
+## CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
+
+<|ref|>text<|/ref|><|det|>[[506, 551, 905, 590]]<|/det|>
+Term Typically Offered: F, W, SPPrerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 552, 908, 593]]<|/det|>
-Term Typically Offered: F, W, SP
-Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 603, 912, 655]]<|/det|>
+Object- oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
-<|ref|>text<|/ref|><|det|>[[506, 605, 913, 659]]<|/det|>
-Object-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
+<|ref|>sub_title<|/ref|><|det|>[[506, 668, 911, 694]]<|/det|>
+## CPE 233. Computer Design and Assembly Language Programming. 4 units
-<|ref|>text<|/ref|><|det|>[[506, 671, 911, 683]]<|/det|>
-CPE 233. Computer Design and Assembly Language Programming. 4 units
+<|ref|>text<|/ref|><|det|>[[506, 697, 695, 724]]<|/det|>
+Term Typically Offered: F, W, SPPrerequisite: CPE/EE 133.
-<|ref|>text<|/ref|><|det|>[[506, 687, 695, 730]]<|/det|>
-Term Typically Offered: F, W, SP
-Prerequisite: CPE/EE 133.
+<|ref|>text<|/ref|><|det|>[[506, 737, 929, 817]]<|/det|>
+Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off- the- shelf RISC- based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
-<|ref|>text<|/ref|><|det|>[[506, 742, 932, 814]]<|/det|>
-Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
+<|ref|>sub_title<|/ref|><|det|>[[506, 829, 718, 841]]<|/det|>
+## CPE 290. Selected Topics. 1-4 units
-<|ref|>text<|/ref|><|det|>[[506, 827, 933, 853]]<|/det|>
-CPE 290. Selected Topics. 1- 4 units
-Term Typically Offered: TBD
-Prerequisite: Open to undergraduate students and consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 844, 932, 871]]<|/det|>
+Term Typically Offered: TBDPrerequisite: Open to undergraduate students and consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 876, 933, 904]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[506, 883, 933, 909]]<|/det|>
Directed group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.
\ No newline at end of file
diff --git a/stage1/sample_00020/document.md b/stage1/sample_00020/document.md
index b35c5896c57d50d5d3af3ae754b876ec3ccde758..220f29f337d20d0ba401772dc2bc3d8ef21578fe 100644
--- a/stage1/sample_00020/document.md
+++ b/stage1/sample_00020/document.md
@@ -1 +1 @@
-1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.
\ No newline at end of file
+1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1996;39:34-40. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.
\ No newline at end of file
diff --git a/stage1/sample_00020/raw_response.md b/stage1/sample_00020/raw_response.md
index b35c5896c57d50d5d3af3ae754b876ec3ccde758..220f29f337d20d0ba401772dc2bc3d8ef21578fe 100644
--- a/stage1/sample_00020/raw_response.md
+++ b/stage1/sample_00020/raw_response.md
@@ -1 +1 @@
-1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.
\ No newline at end of file
+1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1996;39:34-40. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.
\ No newline at end of file
diff --git a/stage1/sample_00021/document.md b/stage1/sample_00021/document.md
index 7a6c15ad5951a3853782a5e1eea5c8db8d4cbed7..080ddb20b0b3fd6ce89cadddd4bc5e12d6499724 100644
--- a/stage1/sample_00021/document.md
+++ b/stage1/sample_00021/document.md
@@ -1 +1 @@
-Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
\ No newline at end of file
+Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | |
| | | | | | | Patterson |
\ No newline at end of file
diff --git a/stage1/sample_00021/document_with_boxes.png b/stage1/sample_00021/document_with_boxes.png
index f443e0ee548ad5d2993e8d0b885d7f9d069863fb..b878a83d6da8223214249a56b8bc0a959405d636 100644
--- a/stage1/sample_00021/document_with_boxes.png
+++ b/stage1/sample_00021/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:a6ca57cb7cb8bb5bfea1bb3837df609ca6b8832336ccf40151b9c6bc019e76ea
-size 270620
+oid sha256:673aa95c8990a17b9ff272f230d6066316fae225aebfc7f37b628b79f54789b2
+size 271906
diff --git a/stage1/sample_00021/raw_response.md b/stage1/sample_00021/raw_response.md
index ee4b10f00220e9cb930349dadfeedb2d9c26bdc6..0a963f443a606ff78edfad028be8a036eb0cf112 100644
--- a/stage1/sample_00021/raw_response.md
+++ b/stage1/sample_00021/raw_response.md
@@ -1,3 +1,3 @@
-<|ref|>table<|/ref|><|det|>[[78, 71, 920, 787]]<|/det|>
+<|ref|>table<|/ref|><|det|>[[80, 71, 920, 787]]<|/det|>
-Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
\ No newline at end of file
+Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | |
| | | | | | | Patterson |
\ No newline at end of file
diff --git a/stage1/sample_00022/document.md b/stage1/sample_00022/document.md
index e50d099da0c9c9b85e3b5965e0981364e9273e81..de7af4300c690a3d6262dec32530f9254c1a0d16 100644
--- a/stage1/sample_00022/document.md
+++ b/stage1/sample_00022/document.md
@@ -1,23 +1 @@
-0.3-0.7
-
-of anti- TNF- \(\alpha\) and MTX combination therapy in patients with early RA and high disease activity.
-
-## Author affiliations
-
-Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan
-
-Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott.
-
-Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version.
-
-Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan).
-
-Competing interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K.
-
-patients other to distribute, remix, adapt, build upon this work non- commercially,
-
-and license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/
-
-## REFERENCES
-
-1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \(\alpha\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective
\ No newline at end of file
+0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.
\ No newline at end of file
diff --git a/stage1/sample_00022/document_with_boxes.png b/stage1/sample_00022/document_with_boxes.png
index 368a3464523be4628880725548870bf88f304074..6feaeadbaa40d0f9bcd33e74a24c8648e6131e5f 100644
--- a/stage1/sample_00022/document_with_boxes.png
+++ b/stage1/sample_00022/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:b2ddb219db8ee7fb8f04dde679d1a474710ba3b66fa05bd23ae90be6e2e11b8f
-size 894773
+oid sha256:2bb57301a3d3b80224539cac2dbb97a72fb212d76ca7e5a6c6fec4dbe46aee51
+size 827448
diff --git a/stage1/sample_00022/raw_response.md b/stage1/sample_00022/raw_response.md
index 417f0a4d0f11064c22e4c6f50d0e67c4e226dbc9..de7af4300c690a3d6262dec32530f9254c1a0d16 100644
--- a/stage1/sample_00022/raw_response.md
+++ b/stage1/sample_00022/raw_response.md
@@ -1,34 +1 @@
-0.3-0.7
-
-<|ref|>text<|/ref|><|det|>[[67, 73, 488, 100]]<|/det|>
-of anti- TNF- \(\alpha\) and MTX combination therapy in patients with early RA and high disease activity.
-
-<|ref|>sub_title<|/ref|><|det|>[[68, 114, 169, 125]]<|/det|>
-## Author affiliations
-
-<|ref|>text<|/ref|><|det|>[[67, 124, 488, 315]]<|/det|>
-Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan
-
-<|ref|>text<|/ref|><|det|>[[67, 317, 479, 370]]<|/det|>
-Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott.
-
-<|ref|>text<|/ref|><|det|>[[66, 375, 478, 410]]<|/det|>
-Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version.
-
-<|ref|>text<|/ref|><|det|>[[66, 413, 486, 438]]<|/det|>
-Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan).
-
-<|ref|>text<|/ref|><|det|>[[66, 444, 487, 930]]<|/det|>
-Competing interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K.
-
-<|ref|>text<|/ref|><|det|>[[65, 934, 472, 954]]<|/det|>
-patients other to distribute, remix, adapt, build upon this work non- commercially,
-
-<|ref|>text<|/ref|><|det|>[[512, 72, 923, 105]]<|/det|>
-and license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/
-
-<|ref|>sub_title<|/ref|><|det|>[[514, 139, 599, 151]]<|/det|>
-## REFERENCES
-
-<|ref|>text<|/ref|><|det|>[[512, 152, 926, 944]]<|/det|>
-1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \(\alpha\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective
\ No newline at end of file
+0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.
\ No newline at end of file
diff --git a/stage1/sample_00023/document.md b/stage1/sample_00023/document.md
index 7a3d241be1c24e2afb5b213f0a3f52af0302a6c4..0a9cfc874bba531880c7ed1218a385b6aa2ed99c 100644
--- a/stage1/sample_00023/document.md
+++ b/stage1/sample_00023/document.md
@@ -1,5 +1 @@
-0.5cm 0cm 0cm 0cm 0cm
-
-## Adding Time Limit for Degree Completion for Students who Stop Out-
-
-S. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved
\ No newline at end of file
+2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2: 2.0 2.0 2.0 2.0 2.0 2.0 2.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.10 3.10 3.10 3.10 3.10 3.10 3.11 3.11 3.11 3.11 3.11 3.11 3.12 3.12 3.12 3.12 3.12 3.12 3.13 3.13 3.13 3.13 3.13 3.14 3.14 3.14 3.14 3.14 3.14 3.15 3.15 3.15 3.15 3.15 3.15 3.16 3.16 3.16 3.16 3.16 3.16 3.17 3.17 3.17 3.17 3.17 3.17 3.18 3.18 3.18 3.18 3.18 3.18 3.19 3.19 3.19 3.19 3.19 3.19 3.20 3.20 3.20 3.20 3.20 3.20 3.21 3.21 3.21 3.21 3.21 3.21 3.22 3.22 3.22 3.22 3.22 3.22 3.23 3.23 3.23 3.23 3.23 3.23 3.24 3.24 3.24 3.24 3.24 3.24 3.25 3.25 3.25 3.25 3.25 3.25 3.26 3.26 3.26 3.26 3.26 3.26 3.27 3.27 3.27 3.27 3.27 3.27 3.28 3.28 3.28 3.28 3.28 3.28 3.29 3.29 3.29 3.29 3.29 3.29 3.30 3.30 3.30 3.30 3.30 3.30 3.31 3.31 3.31 3.31 3.31 3.31 3.32 3.32 3.32 3.32 3.32 3.32 3.33 3.33 3.33 3.33 3.33 3.33 3.34 3.34 3.34 3.34 3.34 3.34 3.35 3.35 3.35 3.35 3.35 3.35 3.36 3.36 3.36 3.36 3.36 3.36 3.37 3.37 3.37 3.37 3.37 3.37 3.38 3.38 3.38 3.38 3.38 3.38 3.39 3.39 3.39 3.39 3.39 3.39 3.40 3.40 3.40 3.40 3.40 3.40 3.41 3.41 3.41 3.41 3.41 3.41 3.42 3.42 3.42 3.42 3.42 3.42 3.43 3.43 3.43 3.43 3.43 3.43 3.44 3.44 3.44 3.44 3.44 3.44 3.45 3.45 3.45 3.45 3.45 3.45 3.46 3.46 3.46 3.46 3.46 3.46 3.47 3.47 3.47 3.47 3.47 3.47 3.48 3.48 3.48 3.48 3.48 3.48 3.49 3.49 3.49 3.49 3.49 3.49 3.50 3.50 3.50 3.50 3.50 3.50 3.51 3.51 3.51 3.51 3.51 3.51 3.52 3.52 3.52 3.52 3.52 3.52 3.53 3.53 3.53 3.53 3.53 3.53 3.54 3.54 3.54 3.54 3.54 3.54 3.55 3.55 3.55 3.55 3.55 3.55 3.56 3.56 3.56 3.56 3.56 3.56 3.57 3.57 3.57 3.57 3.57 3.57 3.58 3.58 3.58 3.58 3.58 3.58 3.59 3.59 3.59 3.59 3.59 3.59 3.60 3.60 3.60 3.60 3.60 3.60 3.61 3.61 3.61 3.61 3.61 3.61 3.62 3.62 3.62 3.62 3.62 3.62 3.63 3.63 3.63 3.63 3.63 3.63 3.64 3.64 3.64 3.64 3.64 3.64 3.65 3.65 3.65 3.65 3.65 3.65 3.66 3.66 3.66 3.66 3.66 3.66 3.67 3.67 3.67 3.67 3.67 3.67 3.68 3.68 3.68 3.68 3.68 3.68 3.69 3.69 3.69 3.69 3.69 3.69 3.70 3.70 3.70 3.70 3.70 3.70 3.71 3.71 3.71 3.71 3.71 3.71 3.72 3.72 3.72 3.72 3.72 3.72 3.73 3.73 3.73 3.73 3.73 3.73 3.74 3.74 3.74 3.74 3.74 3.74 3.75 3.75 3.75 3.75 3.75 3.75 3.76 3.76 3.76 3.76 3.76 3.76 3.77 3.77 3.77 3.77 3.77 3.77 3.78 3.78 3.78 3.78 3.78 3.78 3.79 3.79 3.79 3.79 3.79 3.79 3.80 3.80 3.80 3.80 3.80 3.80 3.81 3.81 3.81 3.81 3.81 3.81 3.82 3.82 3.82 3.82 3.82 3.82 3.83 3.83 3.83 3.83 3.83 3.83 3.84 3.84 3.84 3.84 3.84 3.84 3.85 3.85 3.85 3.85 3.85 3.85 3.86 3.86 3.86 3.86 3.86 3.86 3.87 3.87 3.87 3.87 3.87 3.87 3.88 3.88 3.88 3.88 3.88 3.88 3.89 3.89 3.89 3.89 3.89 3.89 3.90 3.90 3.90 3.90 3.90 3.90 3.91 3.91 3.91 3.91 3.91 3.91 3.92 3.92 3.92 3.92 3.92 3.92 3.93 3.93 3.93 3.93 3.93 3.93 3.94 3.94 3.94 3.94 3.94 3.94 3.95 3.95 3.95 3.95 3.95 3.95 3.96 3.96 3.96 3.96 3.96 3.96 3.97 3.97 3.97 3.97 3.97 3.97 3.98 3.98 3.98 3.98 3.98 3.98 3.99 3.99 3.99 3.99 3.99 3.99 3.100 3.100 3.100 3.100 3.100 3.100 3.101 3.101 3.101 3.101 3.101 3.101 3.102 3.102 3.102 3.102 3.102 3.102 3.103 3.103 3.103 3.103 3.103 3.103 3.104 3.104 3.104 3.104 3.104 3.104 3.105 3.105 3.105 3.105 3.105 3.105 3.106 3.106 3.106 3.106 3.106 3.106 3.107 3.107 3.107 3.107 3.107 3.107 3.108 3.108 3.108 3.108 3.108 3.108 3.109 3.109 3.109 3.109 3.109 3.109 3.110 3.110 3.110 3.110 3.110 3.110 3.111 3.111 3.111 3.111 3.111 3.111 3.112 3.112 3.112 3.112 3.112 3.112 3.113 3.113 3.113 3.113 3.113 3.113 3.114 3.114 3.114 3.114 3.114 3.114 3.115 3.115 3.115 3.115 3.115 3.115 3.116 3.116 3.116 3.116 3.116 3.116 3.117 3.117 3.117 3.117 3.117 3.117 3.118 3.118 3.118 3.118 3.118 3.118 3.119 3.119 3.119 3.119 3.119 3.119 3.120 3.120 3.120 3.120 3.120 3.120 3.121 3.121 3.121 3.121 3.121 3.121 3.122 3.122 3.122 3.122 3.122 3.122 3.123 3.123 3.123 3.123 3.123 3.123 3.124 3.124 3.124 3.124 3.124 3.124 3.125 3.125 3.125 3.125 3.125 3.125 3.126 3.126 3.126 3.126 3.126 3.126 3.127 3.127 3.127 3.127 3.127 3.127 3.128 3.128 3.128 3.128 3.128 3.128 3.129 3.129 3.129 3.129 3.129 3.129 3.130 3.130 3.130 3.130 3.130 3.130 3.131 3.131 3.131 3.131 3.131 3.131 3.132 3.132 3.132 3.132 3.132 3.132 3.133 3.133 3.133 3.133 3.133 3.133 3.134 3.134 3.134 3.134 3.134 3.134 3.135 3.135 3.135 3.135 3.135 3.135 3.136 3.136 3.136 3.136 3.136 3.136 3.137 3.137 3.137 3.137 3.137 3.137 3.138 3.138 3.138 3.138 3.138 3.138 3.139 3.139 3.139 3.139 3.139 3.139 3.140 3.140 3.140 3.140 3.140 3.140 3.141 3.141 3.141 3.141 3.141 3.141 3.142 3.142 3.142 3.142 3.142 3.142 3.143 3.143 3.143 3.143 3.143 3.143 3.144 3.144 3.144 3.144 3.144 3.144 3.145 3.145 3.145 3.145 3.145 3.145 3.146 3.146 3.146 3.146 3.146 3.146 3.147 3.147 3.147 3.147 3.147 3.147 3.148 3.148 3.148 3.148 3.148 3.148 3.149 3.149 3.149 3.149 3.149 3.149 3.150 3.150 3.150 3.150 3.150 3.150 3.151 3.151 3.151 3.151 3.151 3.151 3.152 3.152 3.152 3.152 3.152 3.152 3.153 3.153 3.153 3.153 3.153 3.153 3.154 3.154 3.154 3.154 3.154 3.154 3.155 3.155 3.155 3.155 3.155 3.155 3.156 3.156 3.156 3.156 3.156 3.156 3.157 3.157 3.157 3.157 3.157 3.157 3.158 3.158 3.158 3.158 3.158 3.158 3.159 3.159 3.159 3.159 3.159 3.159 3.160 3.160 3.160 3.160 3.160 3.160 3.161 3.161 3.161 3.161 3.161 3.161 3.162 3.162 3.162 3.162 3.162 3.162 3.163 3.163 3.163 3.163 3.163 3.163 3.164 3.164 3.164 3.164 3.164 3.164 3.165 3.165 3.165 3.165 3.165 3.165 3.166 3.166 3.166 3.166 3.166 3.166 3.167 3
\ No newline at end of file
diff --git a/stage1/sample_00023/document_with_boxes.png b/stage1/sample_00023/document_with_boxes.png
index 48f04efeb6708564b29e9d5436e0b63f24e58918..bbe32ae417250409a828fd083fa09d8e3ac61bf7 100644
--- a/stage1/sample_00023/document_with_boxes.png
+++ b/stage1/sample_00023/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:1ee409217b0ad6bad6899cf8b31f11b7a0665b455a38d6408ee217c79e6587e8
-size 113872
+oid sha256:17b4fb35de06027d7fbd454cb91b3e4dd38e09107e9cf08dea8cc0d491822ccb
+size 107229
diff --git a/stage1/sample_00023/raw_response.md b/stage1/sample_00023/raw_response.md
index 14d3148f4c096e319c7f3ce8885170bb2dac2ab6..0a9cfc874bba531880c7ed1218a385b6aa2ed99c 100644
--- a/stage1/sample_00023/raw_response.md
+++ b/stage1/sample_00023/raw_response.md
@@ -1,7 +1 @@
-0.5cm 0cm 0cm 0cm 0cm
-
-<|ref|>sub_title<|/ref|><|det|>[[115, 206, 710, 227]]<|/det|>
-## Adding Time Limit for Degree Completion for Students who Stop Out-
-
-<|ref|>text<|/ref|><|det|>[[115, 243, 832, 350]]<|/det|>
-S. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved
\ No newline at end of file
+2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2: 2.0 2.0 2.0 2.0 2.0 2.0 2.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.10 3.10 3.10 3.10 3.10 3.10 3.11 3.11 3.11 3.11 3.11 3.11 3.12 3.12 3.12 3.12 3.12 3.12 3.13 3.13 3.13 3.13 3.13 3.14 3.14 3.14 3.14 3.14 3.14 3.15 3.15 3.15 3.15 3.15 3.15 3.16 3.16 3.16 3.16 3.16 3.16 3.17 3.17 3.17 3.17 3.17 3.17 3.18 3.18 3.18 3.18 3.18 3.18 3.19 3.19 3.19 3.19 3.19 3.19 3.20 3.20 3.20 3.20 3.20 3.20 3.21 3.21 3.21 3.21 3.21 3.21 3.22 3.22 3.22 3.22 3.22 3.22 3.23 3.23 3.23 3.23 3.23 3.23 3.24 3.24 3.24 3.24 3.24 3.24 3.25 3.25 3.25 3.25 3.25 3.25 3.26 3.26 3.26 3.26 3.26 3.26 3.27 3.27 3.27 3.27 3.27 3.27 3.28 3.28 3.28 3.28 3.28 3.28 3.29 3.29 3.29 3.29 3.29 3.29 3.30 3.30 3.30 3.30 3.30 3.30 3.31 3.31 3.31 3.31 3.31 3.31 3.32 3.32 3.32 3.32 3.32 3.32 3.33 3.33 3.33 3.33 3.33 3.33 3.34 3.34 3.34 3.34 3.34 3.34 3.35 3.35 3.35 3.35 3.35 3.35 3.36 3.36 3.36 3.36 3.36 3.36 3.37 3.37 3.37 3.37 3.37 3.37 3.38 3.38 3.38 3.38 3.38 3.38 3.39 3.39 3.39 3.39 3.39 3.39 3.40 3.40 3.40 3.40 3.40 3.40 3.41 3.41 3.41 3.41 3.41 3.41 3.42 3.42 3.42 3.42 3.42 3.42 3.43 3.43 3.43 3.43 3.43 3.43 3.44 3.44 3.44 3.44 3.44 3.44 3.45 3.45 3.45 3.45 3.45 3.45 3.46 3.46 3.46 3.46 3.46 3.46 3.47 3.47 3.47 3.47 3.47 3.47 3.48 3.48 3.48 3.48 3.48 3.48 3.49 3.49 3.49 3.49 3.49 3.49 3.50 3.50 3.50 3.50 3.50 3.50 3.51 3.51 3.51 3.51 3.51 3.51 3.52 3.52 3.52 3.52 3.52 3.52 3.53 3.53 3.53 3.53 3.53 3.53 3.54 3.54 3.54 3.54 3.54 3.54 3.55 3.55 3.55 3.55 3.55 3.55 3.56 3.56 3.56 3.56 3.56 3.56 3.57 3.57 3.57 3.57 3.57 3.57 3.58 3.58 3.58 3.58 3.58 3.58 3.59 3.59 3.59 3.59 3.59 3.59 3.60 3.60 3.60 3.60 3.60 3.60 3.61 3.61 3.61 3.61 3.61 3.61 3.62 3.62 3.62 3.62 3.62 3.62 3.63 3.63 3.63 3.63 3.63 3.63 3.64 3.64 3.64 3.64 3.64 3.64 3.65 3.65 3.65 3.65 3.65 3.65 3.66 3.66 3.66 3.66 3.66 3.66 3.67 3.67 3.67 3.67 3.67 3.67 3.68 3.68 3.68 3.68 3.68 3.68 3.69 3.69 3.69 3.69 3.69 3.69 3.70 3.70 3.70 3.70 3.70 3.70 3.71 3.71 3.71 3.71 3.71 3.71 3.72 3.72 3.72 3.72 3.72 3.72 3.73 3.73 3.73 3.73 3.73 3.73 3.74 3.74 3.74 3.74 3.74 3.74 3.75 3.75 3.75 3.75 3.75 3.75 3.76 3.76 3.76 3.76 3.76 3.76 3.77 3.77 3.77 3.77 3.77 3.77 3.78 3.78 3.78 3.78 3.78 3.78 3.79 3.79 3.79 3.79 3.79 3.79 3.80 3.80 3.80 3.80 3.80 3.80 3.81 3.81 3.81 3.81 3.81 3.81 3.82 3.82 3.82 3.82 3.82 3.82 3.83 3.83 3.83 3.83 3.83 3.83 3.84 3.84 3.84 3.84 3.84 3.84 3.85 3.85 3.85 3.85 3.85 3.85 3.86 3.86 3.86 3.86 3.86 3.86 3.87 3.87 3.87 3.87 3.87 3.87 3.88 3.88 3.88 3.88 3.88 3.88 3.89 3.89 3.89 3.89 3.89 3.89 3.90 3.90 3.90 3.90 3.90 3.90 3.91 3.91 3.91 3.91 3.91 3.91 3.92 3.92 3.92 3.92 3.92 3.92 3.93 3.93 3.93 3.93 3.93 3.93 3.94 3.94 3.94 3.94 3.94 3.94 3.95 3.95 3.95 3.95 3.95 3.95 3.96 3.96 3.96 3.96 3.96 3.96 3.97 3.97 3.97 3.97 3.97 3.97 3.98 3.98 3.98 3.98 3.98 3.98 3.99 3.99 3.99 3.99 3.99 3.99 3.100 3.100 3.100 3.100 3.100 3.100 3.101 3.101 3.101 3.101 3.101 3.101 3.102 3.102 3.102 3.102 3.102 3.102 3.103 3.103 3.103 3.103 3.103 3.103 3.104 3.104 3.104 3.104 3.104 3.104 3.105 3.105 3.105 3.105 3.105 3.105 3.106 3.106 3.106 3.106 3.106 3.106 3.107 3.107 3.107 3.107 3.107 3.107 3.108 3.108 3.108 3.108 3.108 3.108 3.109 3.109 3.109 3.109 3.109 3.109 3.110 3.110 3.110 3.110 3.110 3.110 3.111 3.111 3.111 3.111 3.111 3.111 3.112 3.112 3.112 3.112 3.112 3.112 3.113 3.113 3.113 3.113 3.113 3.113 3.114 3.114 3.114 3.114 3.114 3.114 3.115 3.115 3.115 3.115 3.115 3.115 3.116 3.116 3.116 3.116 3.116 3.116 3.117 3.117 3.117 3.117 3.117 3.117 3.118 3.118 3.118 3.118 3.118 3.118 3.119 3.119 3.119 3.119 3.119 3.119 3.120 3.120 3.120 3.120 3.120 3.120 3.121 3.121 3.121 3.121 3.121 3.121 3.122 3.122 3.122 3.122 3.122 3.122 3.123 3.123 3.123 3.123 3.123 3.123 3.124 3.124 3.124 3.124 3.124 3.124 3.125 3.125 3.125 3.125 3.125 3.125 3.126 3.126 3.126 3.126 3.126 3.126 3.127 3.127 3.127 3.127 3.127 3.127 3.128 3.128 3.128 3.128 3.128 3.128 3.129 3.129 3.129 3.129 3.129 3.129 3.130 3.130 3.130 3.130 3.130 3.130 3.131 3.131 3.131 3.131 3.131 3.131 3.132 3.132 3.132 3.132 3.132 3.132 3.133 3.133 3.133 3.133 3.133 3.133 3.134 3.134 3.134 3.134 3.134 3.134 3.135 3.135 3.135 3.135 3.135 3.135 3.136 3.136 3.136 3.136 3.136 3.136 3.137 3.137 3.137 3.137 3.137 3.137 3.138 3.138 3.138 3.138 3.138 3.138 3.139 3.139 3.139 3.139 3.139 3.139 3.140 3.140 3.140 3.140 3.140 3.140 3.141 3.141 3.141 3.141 3.141 3.141 3.142 3.142 3.142 3.142 3.142 3.142 3.143 3.143 3.143 3.143 3.143 3.143 3.144 3.144 3.144 3.144 3.144 3.144 3.145 3.145 3.145 3.145 3.145 3.145 3.146 3.146 3.146 3.146 3.146 3.146 3.147 3.147 3.147 3.147 3.147 3.147 3.148 3.148 3.148 3.148 3.148 3.148 3.149 3.149 3.149 3.149 3.149 3.149 3.150 3.150 3.150 3.150 3.150 3.150 3.151 3.151 3.151 3.151 3.151 3.151 3.152 3.152 3.152 3.152 3.152 3.152 3.153 3.153 3.153 3.153 3.153 3.153 3.154 3.154 3.154 3.154 3.154 3.154 3.155 3.155 3.155 3.155 3.155 3.155 3.156 3.156 3.156 3.156 3.156 3.156 3.157 3.157 3.157 3.157 3.157 3.157 3.158 3.158 3.158 3.158 3.158 3.158 3.159 3.159 3.159 3.159 3.159 3.159 3.160 3.160 3.160 3.160 3.160 3.160 3.161 3.161 3.161 3.161 3.161 3.161 3.162 3.162 3.162 3.162 3.162 3.162 3.163 3.163 3.163 3.163 3.163 3.163 3.164 3.164 3.164 3.164 3.164 3.164 3.165 3.165 3.165 3.165 3.165 3.165 3.166 3.166 3.166 3.166 3.166 3.166 3.167 3
\ No newline at end of file
diff --git a/stage1/sample_00025/document.md b/stage1/sample_00025/document.md
index 422b3d2db7d4d31ebc8e4aa439059103f2d0c9ba..ed13d45b65ef91f6af7bf9112ed3d92583d89fc8 100644
--- a/stage1/sample_00025/document.md
+++ b/stage1/sample_00025/document.md
@@ -1,3 +1,105 @@
-5B-10
+2015 ASC 715 report) valuation report)
-| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
\ No newline at end of file
+Service Cost (cost of benefits earned)
+
+Expense/Minimum Required Contribution
+
+Projected Benefit Obligation (PBO)
+
+Accumulated Benefit Obligation (ABO)/Funding Target
+
+Assets
+
+Balance Sheet Liability
+
+AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment)
+
+Cash into Plan
+
+Cash out of Plan
+
+Liability by Group:
+
+Actives
+
+Retired
+
+Terminated Vested
+
+Total
+
+PBGC Premiums
+
+Demographics:
+
+Actives
+
+Retired
+
+Terminated Vested
+
+Total
+
+Discount Rate/Effective Rate
+
+Accounting (based on June 30, 2015 ASC 715 report)
+
+N/A - plan frozen
+
+\(\)63,881\$
+
+\(\)15,498,295\$
+
+\(\)15,498,295\$
+
+\(\)11,888,246\$
+
+\(\)3,610,049\$
+
+\(\)7,690,218\$
+
+\(\)548,000 (cash basis)
+
+\(\)628,690+$99,236 (expenses)
+
+\(\)4,326,586\$
+
+6,791,034
+
+4,380,675
+
+\(\)15,498,295\$
+
+152
+
+472
+
+4.30% (BOY)/4.25% (EOY)
+
+Funding (based on July 1, 2015
+
+valuation report)
+
+\(\)0\$
+
+N/A
+
+N/A
+
+\(\)321,000 (accrual basis)
+
+\(\)628,690+$99,236 (expenses)
+
+\(\)3,046,932\$
+
+5,791,017
+
+3,038,118
+
+\(\)11,876,067\$
+
+152
+
+472
+
+6.28%
\ No newline at end of file
diff --git a/stage1/sample_00025/document_with_boxes.png b/stage1/sample_00025/document_with_boxes.png
index 72f1fb4517bf18bd75e6e769b2ae211e8ef082ff..35fda3b7d8a1d7d3035d09bf03c122bec8f1ace7 100644
--- a/stage1/sample_00025/document_with_boxes.png
+++ b/stage1/sample_00025/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:20bfcb9b187b6c78adaa4706206c83542ccd568977fe770e9f5522a042466918
-size 249715
+oid sha256:402e25bdadcff2e4d37475a6daf6c6f343db96a9a4202789338267a8578d521f
+size 248547
diff --git a/stage1/sample_00025/raw_response.md b/stage1/sample_00025/raw_response.md
index 45ed6ef31b87512747659bc987da0504b6e5e69e..6d4b79aad3f116f6e7798f9b65c0babd77d8bc98 100644
--- a/stage1/sample_00025/raw_response.md
+++ b/stage1/sample_00025/raw_response.md
@@ -1,5 +1,157 @@
-5B-10
+2015 ASC 715 report) valuation report)
-<|ref|>table<|/ref|><|det|>[[183, 271, 814, 844]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[191, 323, 360, 340]]<|/det|>
+Service Cost (cost of benefits earned)
-| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[191, 350, 381, 367]]<|/det|>
+Expense/Minimum Required Contribution
+
+<|ref|>text<|/ref|><|det|>[[191, 378, 358, 394]]<|/det|>
+Projected Benefit Obligation (PBO)
+
+<|ref|>text<|/ref|><|det|>[[191, 397, 438, 413]]<|/det|>
+Accumulated Benefit Obligation (ABO)/Funding Target
+
+<|ref|>text<|/ref|><|det|>[[191, 415, 237, 430]]<|/det|>
+Assets
+
+<|ref|>text<|/ref|><|det|>[[191, 432, 296, 448]]<|/det|>
+Balance Sheet Liability
+
+<|ref|>text<|/ref|><|det|>[[191, 458, 457, 529]]<|/det|>
+AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment)
+
+<|ref|>text<|/ref|><|det|>[[191, 540, 267, 556]]<|/det|>
+Cash into Plan
+
+<|ref|>text<|/ref|><|det|>[[191, 558, 269, 573]]<|/det|>
+Cash out of Plan
+
+<|ref|>text<|/ref|><|det|>[[191, 585, 280, 601]]<|/det|>
+Liability by Group:
+
+<|ref|>text<|/ref|><|det|>[[191, 604, 229, 619]]<|/det|>
+Actives
+
+<|ref|>text<|/ref|><|det|>[[191, 622, 229, 637]]<|/det|>
+Retired
+
+<|ref|>text<|/ref|><|det|>[[191, 639, 286, 655]]<|/det|>
+Terminated Vested
+
+<|ref|>text<|/ref|><|det|>[[191, 656, 219, 672]]<|/det|>
+Total
+
+<|ref|>text<|/ref|><|det|>[[191, 693, 273, 709]]<|/det|>
+PBGC Premiums
+
+<|ref|>text<|/ref|><|det|>[[191, 721, 260, 737]]<|/det|>
+Demographics:
+
+<|ref|>text<|/ref|><|det|>[[191, 739, 229, 754]]<|/det|>
+Actives
+
+<|ref|>text<|/ref|><|det|>[[191, 757, 229, 772]]<|/det|>
+Retired
+
+<|ref|>text<|/ref|><|det|>[[191, 775, 286, 790]]<|/det|>
+Terminated Vested
+
+<|ref|>text<|/ref|><|det|>[[191, 792, 219, 807]]<|/det|>
+Total
+
+<|ref|>text<|/ref|><|det|>[[191, 817, 324, 833]]<|/det|>
+Discount Rate/Effective Rate
+
+<|ref|>text<|/ref|><|det|>[[476, 323, 619, 340]]<|/det|>
+Accounting (based on June 30, 2015 ASC 715 report)
+
+<|ref|>text<|/ref|><|det|>[[476, 350, 561, 366]]<|/det|>
+N/A - plan frozen
+
+<|ref|>text<|/ref|><|det|>[[476, 378, 514, 394]]<|/det|>
+\(\)63,881\$
+
+<|ref|>text<|/ref|><|det|>[[476, 398, 537, 413]]<|/det|>
+\(\)15,498,295\$
+
+<|ref|>text<|/ref|><|det|>[[476, 415, 537, 431]]<|/det|>
+\(\)15,498,295\$
+
+<|ref|>text<|/ref|><|det|>[[476, 432, 537, 448]]<|/det|>
+\(\)11,888,246\$
+
+<|ref|>text<|/ref|><|det|>[[476, 451, 534, 466]]<|/det|>
+\(\)3,610,049\$
+
+<|ref|>text<|/ref|><|det|>[[476, 478, 534, 494]]<|/det|>
+\(\)7,690,218\$
+
+<|ref|>text<|/ref|><|det|>[[476, 540, 609, 556]]<|/det|>
+\(\)548,000 (cash basis)
+
+<|ref|>text<|/ref|><|det|>[[476, 558, 616, 573]]<|/det|>
+\(\)628,690+$99,236 (expenses)
+
+<|ref|>text<|/ref|><|det|>[[476, 585, 537, 601]]<|/det|>
+\(\)4,326,586\$
+
+<|ref|>text<|/ref|><|det|>[[486, 604, 537, 619]]<|/det|>
+6,791,034
+
+<|ref|>text<|/ref|><|det|>[[486, 622, 537, 637]]<|/det|>
+4,380,675
+
+<|ref|>text<|/ref|><|det|>[[476, 639, 537, 655]]<|/det|>
+\(\)15,498,295\$
+
+<|ref|>text<|/ref|><|det|>[[476, 693, 514, 709]]<|/det|>
+152
+
+<|ref|>text<|/ref|><|det|>[[476, 757, 514, 772]]<|/det|>
+472
+
+<|ref|>text<|/ref|><|det|>[[476, 817, 592, 833]]<|/det|>
+4.30% (BOY)/4.25% (EOY)
+
+<|ref|>text<|/ref|><|det|>[[636, 323, 778, 340]]<|/det|>
+Funding (based on July 1, 2015
+
+<|ref|>text<|/ref|><|det|>[[636, 350, 722, 366]]<|/det|>
+valuation report)
+
+<|ref|>text<|/ref|><|det|>[[636, 378, 715, 394]]<|/det|>
+\(\)0\$
+
+<|ref|>text<|/ref|><|det|>[[636, 398, 666, 413]]<|/det|>
+N/A
+
+<|ref|>text<|/ref|><|det|>[[636, 451, 664, 466]]<|/det|>
+N/A
+
+<|ref|>text<|/ref|><|det|>[[636, 540, 764, 556]]<|/det|>
+\(\)321,000 (accrual basis)
+
+<|ref|>text<|/ref|><|det|>[[636, 558, 784, 573]]<|/det|>
+\(\)628,690+$99,236 (expenses)
+
+<|ref|>text<|/ref|><|det|>[[636, 585, 700, 601]]<|/det|>
+\(\)3,046,932\$
+
+<|ref|>text<|/ref|><|det|>[[646, 604, 696, 619]]<|/det|>
+5,791,017
+
+<|ref|>text<|/ref|><|det|>[[646, 622, 696, 637]]<|/det|>
+3,038,118
+
+<|ref|>text<|/ref|><|det|>[[636, 639, 696, 655]]<|/det|>
+\(\)11,876,067\$
+
+<|ref|>text<|/ref|><|det|>[[636, 693, 674, 709]]<|/det|>
+152
+
+<|ref|>text<|/ref|><|det|>[[636, 757, 666, 772]]<|/det|>
+472
+
+<|ref|>text<|/ref|><|det|>[[636, 817, 668, 833]]<|/det|>
+6.28%
\ No newline at end of file
diff --git a/stage1/sample_00026/document.md b/stage1/sample_00026/document.md
index 4fd789f8666c7dda0b27843d1accdcadcf79342c..8dd6f963e2d832778b192c438de4f2f3f908dbb0 100644
--- a/stage1/sample_00026/document.md
+++ b/stage1/sample_00026/document.md
@@ -1,11 +1,11 @@
-1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:
+1. Course preparation. 2. Course walk-through with NCAA site representative. 3. Course review and practice by participants. 4. Packet pick-up. 5. Mandatory coaches meeting.
-## Friday
+## Friday
-Course preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting.
+Course preparation. Course walk-through with NCAA site representative. Course review and practice by participants. Packet pick-up. Mandatory coaches meeting.
-## Saturday
+## Saturday
-Course preparation. Course review and practice by participants. Women's race - race start time to be determined.\* Men's race - race start time to be determined.\* Post- competition recognition ceremony.
+Course preparation. Course review and practice by participants. Women's race - race start time to be determined.* Men's race - race start time to be determined.* Post-competition recognition ceremony.
-\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
+*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
diff --git a/stage1/sample_00026/document_with_boxes.png b/stage1/sample_00026/document_with_boxes.png
index dff0e697c98a11324a34bcf27db9bc5412eceaf0..7773402f251da6dbae8a8706c7fe40eaa5d0196d 100644
--- a/stage1/sample_00026/document_with_boxes.png
+++ b/stage1/sample_00026/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:89ecff4d716b875ba3957b5d603934202f022e6078c52b1ea2c1a67ad83013c0
-size 366570
+oid sha256:969dd4b22ed047c3b0f699071d5efbaf89a712a420a20a0af276ba5a07803412
+size 366240
diff --git a/stage1/sample_00026/raw_response.md b/stage1/sample_00026/raw_response.md
index afe9bf59ac2f4736cfc1c046bb6674512b817cb0..5dc1854b038cb4f8afb6b5609d5fe05ce76c3908 100644
--- a/stage1/sample_00026/raw_response.md
+++ b/stage1/sample_00026/raw_response.md
@@ -1,16 +1,16 @@
-1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:
+1. Course preparation. 2. Course walk-through with NCAA site representative. 3. Course review and practice by participants. 4. Packet pick-up. 5. Mandatory coaches meeting.
-<|ref|>sub_title<|/ref|><|det|>[[119, 251, 169, 265]]<|/det|>
-## Friday
+<|ref|>sub_title<|/ref|><|det|>[[122, 258, 171, 273]]<|/det|>
+## Friday
-<|ref|>text<|/ref|><|det|>[[120, 268, 464, 346]]<|/det|>
-Course preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting.
+<|ref|>text<|/ref|><|det|>[[122, 276, 466, 345]]<|/det|>
+Course preparation. Course walk-through with NCAA site representative. Course review and practice by participants. Packet pick-up. Mandatory coaches meeting.
-<|ref|>sub_title<|/ref|><|det|>[[120, 363, 188, 377]]<|/det|>
-## Saturday
+<|ref|>sub_title<|/ref|><|det|>[[122, 363, 189, 377]]<|/det|>
+## Saturday
-<|ref|>text<|/ref|><|det|>[[120, 379, 454, 457]]<|/det|>
-Course preparation. Course review and practice by participants. Women's race - race start time to be determined.\* Men's race - race start time to be determined.\* Post- competition recognition ceremony.
+<|ref|>text<|/ref|><|det|>[[122, 380, 452, 458]]<|/det|>
+Course preparation. Course review and practice by participants. Women's race - race start time to be determined.* Men's race - race start time to be determined.* Post-competition recognition ceremony.
-<|ref|>text<|/ref|><|det|>[[122, 473, 875, 505]]<|/det|>
-\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[122, 474, 873, 505]]<|/det|>
+*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
diff --git a/stage1/sample_00027/document_with_boxes.png b/stage1/sample_00027/document_with_boxes.png
index e050035e8961948aa96a4de0393f595bdee21a68..ae175297ca89ce896d7c48b2adf83d4ce97a0e8e 100644
--- a/stage1/sample_00027/document_with_boxes.png
+++ b/stage1/sample_00027/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:1636406bdb82f2a00d05e589f5336590c03fabd5e2690230a1e83dba862dcc5b
-size 256740
+oid sha256:78540df02ab2ee346fc247c989c6365c44a0bb887ba466fdcf5fd1b4c26ef859
+size 256692
diff --git a/stage1/sample_00027/figures/sample_00027_fig01.png b/stage1/sample_00027/figures/sample_00027_fig01.png
index d3423ba078df5374ad8ef059cebfb559c9d20a63..52810abc70ca00fe77cb65e427d4c64218a17668 100644
--- a/stage1/sample_00027/figures/sample_00027_fig01.png
+++ b/stage1/sample_00027/figures/sample_00027_fig01.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:1d9732d6776712b68425320fdc6977611c0eabe8478f933eef9caf18413627bc
-size 182538
+oid sha256:f594784aef88185600a98a65874343667189db1da3f7c6ffb0a4a8e74d1c5258
+size 182458
diff --git a/stage1/sample_00027/raw_response.md b/stage1/sample_00027/raw_response.md
index 0926fa256d553b4314fbeb17826426454092920d..0ad0a5403433d46139de798d6d4b95104b568c3d 100644
--- a/stage1/sample_00027/raw_response.md
+++ b/stage1/sample_00027/raw_response.md
@@ -1,6 +1,6 @@
5B-6
-<|ref|>image<|/ref|><|det|>[[127, 273, 877, 782]]<|/det|>
+<|ref|>image<|/ref|><|det|>[[128, 272, 874, 782]]<|/det|>
-<|ref|>text<|/ref|><|det|>[[162, 796, 841, 842]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[163, 795, 842, 840]]<|/det|>
* As of July 9, 2015, IRS Notice 2015-49 prohibits sponsors from adopting lump sum windows for participants who currently receive annuity payments.
\ No newline at end of file
diff --git a/stage1/sample_00028/document.md b/stage1/sample_00028/document.md
index e592bc01d7e070cd11528c7c2534d201f61c59ff..11716cac901552f20fed924604260cfaca755ebf 100644
--- a/stage1/sample_00028/document.md
+++ b/stage1/sample_00028/document.md
@@ -2,4 +2,6 @@
The prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting "Yes" below.
+YES NO NO with Exception
+
Prospective hosts who do not agree with all requirements in this document shall select either "No" or "No with Exception" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.
\ No newline at end of file
diff --git a/stage1/sample_00028/document_with_boxes.png b/stage1/sample_00028/document_with_boxes.png
index ce944344493d5de4f9dc2185107d5f279bcf8021..70f66c539d6ea9301f288190b656da817b00a69a 100644
--- a/stage1/sample_00028/document_with_boxes.png
+++ b/stage1/sample_00028/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:1615a568849563fab2b8b41cb73fe1ddaf26293aa06ed5e5e89c33740e7567d0
-size 401581
+oid sha256:e4e632682d2f799dd61b4a26d266569c969d3d481ef0afe2348df2e6d677533f
+size 402401
diff --git a/stage1/sample_00028/raw_response.md b/stage1/sample_00028/raw_response.md
index a50abc6feefb62ee8e68154f2a7712c5509d5ea7..e18388fd8b60076f870ad0ecb8c9522aa89a7cbb 100644
--- a/stage1/sample_00028/raw_response.md
+++ b/stage1/sample_00028/raw_response.md
@@ -1,7 +1,10 @@
75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales.
-<|ref|>text<|/ref|><|det|>[[125, 620, 885, 698]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[126, 619, 882, 699]]<|/det|>
The prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting "Yes" below.
-<|ref|>text<|/ref|><|det|>[[129, 747, 884, 810]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[314, 710, 696, 730]]<|/det|>
+YES NO NO with Exception
+
+<|ref|>text<|/ref|><|det|>[[129, 744, 883, 809]]<|/det|>
Prospective hosts who do not agree with all requirements in this document shall select either "No" or "No with Exception" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.
\ No newline at end of file
diff --git a/stage1/sample_00029/document.md b/stage1/sample_00029/document.md
index 9d3ba0306aee1b27e6f2a3b869d97483b6a8810a..45277975170d7cfa8792b3c1509bf9004a1a7792 100644
--- a/stage1/sample_00029/document.md
+++ b/stage1/sample_00029/document.md
@@ -1 +1,5 @@
-5B-15
\ No newline at end of file
+0.00(continued)Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases
+
+# Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program
+
+- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases
\ No newline at end of file
diff --git a/stage1/sample_00029/document_with_boxes.png b/stage1/sample_00029/document_with_boxes.png
index 7e63b9ddf37fb02608e9f99d46edc85eb1445bf9..290ddbbd726230a7ed31d85e5dacb0cb28ed6cc0 100644
--- a/stage1/sample_00029/document_with_boxes.png
+++ b/stage1/sample_00029/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:d3b821761e288fea7799175c058242fbb93a341b719fd40c7e61418ca15a0b1d
-size 111129
+oid sha256:9a5c5ece886dc5303f59a67164bb7affcd57b187246838c66b929108659a2944
+size 117327
diff --git a/stage1/sample_00029/raw_response.md b/stage1/sample_00029/raw_response.md
index 9d3ba0306aee1b27e6f2a3b869d97483b6a8810a..43d42a0147c1536560fa3fba307835ac813c8e01 100644
--- a/stage1/sample_00029/raw_response.md
+++ b/stage1/sample_00029/raw_response.md
@@ -1 +1,7 @@
-5B-15
\ No newline at end of file
+0.00(continued)Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases
+
+<|ref|>title<|/ref|><|det|>[[97, 290, 762, 366]]<|/det|>
+# Plan Sponsors Have Many Factors to Consider When Implementing a Lump Sum Program
+
+<|ref|>text<|/ref|><|det|>[[98, 377, 568, 805]]<|/det|>
+- Plan funded status- Pension expense- Settlement accounting- Administration- Communication challenges- Participant reaction- Paternalism- Mortality tables (known through 2016)- PBGC premium increases
\ No newline at end of file
diff --git a/stage1/sample_00030/document.md b/stage1/sample_00030/document.md
index 49752222f2288043f38db5b2f99db5c58d27d99b..1d6b4fbb2cc2005ec0a9f058d00bd17276fd1797 100644
--- a/stage1/sample_00030/document.md
+++ b/stage1/sample_00030/document.md
@@ -1,14 +1,11 @@
-145 (Fig. 6B), which over-express EGFR (Fig. 6C).
+145 (Fig. 6B), which over-express EGFR (Fig. 6C).
-
-| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
+## Principles of Organizations and Communities
-Principles of Organizations and Communities
+| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
+<|ref|>sub_title<|/ref|><|det|>[[129, 499, 466, 515]]<|/det|>
+## Principles of Organizations and Communities
-<|ref|>table_caption<|/ref|><|det|>[[132, 499, 468, 515]]<|/det|>
-Principles of Organizations and Communities
+<|ref|>table<|/ref|><|det|>[[115, 532, 848, 767]]<|/det|>
+